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Résumé (en français) : 
Pour augmenter l’affinité des anticorps sécrétés en réponse à un antigène, les gènes 
d’immunoglobulines subissent l’hypermutation somatique, une mutagénèse adaptative initiée 
par l’action de l’activation-induced cytidine deaminase (AID). L’uracile provenant de la 
désamination des cytosines par cette enzyme est réparé de façon erronée par la suite : si il est 
pris en charge par l’uracile N-glycosylase (UNG), enzyme à l’origine d’une réparation 
poursuivie habituellement par des composantes de la voie du "base-excision repair", il reste à 
sa place un site abasique franchissable par les ADN polymérases translésionnelles avec un 
taux d’erreur très élevé. Si le mésappariement U:G est reconnu par la voie du « mismatch 
repair », le brin d’ADN entourant le U est dégradé puis néo-synthétisé par une autre ADN 
polymérase translésionnelle particulièrement mutagène en face des bases T et A, la 
polymérase eta.  
Nous avons proposé que le choix entre ces deux voies de réparation mutagènes puisse 
être régulé en fonction du cycle cellulaire: les mutations des paires A:T seraient introduites 
dans les gènes d’immunoglobulines par la voie du mismatch repair en phase G1 alors que la 
voie erronée d’UN introduirait les autres mutations lors de la phase S. Nous sommes parvenus 
à restreindre l’activité de l’AID à deux parties distinctes du cycle, la phase G1 ou les phases 
S/G2/M, et nous avons établi le fonctionnement de ce système dans le modèle murin. De 
façon surprenante, nous avons détecté un taux de mutation proche du bruit de fond chez toutes 
les souris dont l’AID opérait uniquement dans les phases S/G2/M. Par contre, les souris dont 
l’AID a été restreinte en G1 présentaient un spectre de mutation diversifié sur les quatre bases 
et similaire au normal. A la lumière de ces résultats, nous proposons que les lésions 
introduites tout au long du cycle par l’AID soient diversifiées par les acteurs de 
l’hypermutation somatique pendant la phase G1, alors que les lésions seraient soit réparées de 
façon fidèle en dehors de cette phase-là, soit de faible impact.  
Afin d’expliquer le biais de brin dans l’hypermutation somatique observé pour les 
mutations sur les bases A :T, nous proposons pour l’ADN polymérase eta un rôle inhabituel 
de réparation du brin portant la « lésion », et non de synthèse translésionnelle classique en 
face de cette lésion. Nous avons analysé le profil, le taux et la distribution des mutations 
introduites par Pol eta sur un oligonucléotide cible pour l’hypermutation, qui a été inséré au 
locus des immunoglobulines et utilisé pour l’établissement des souris knock-in avec un fond 
génétique déficient ou non en UNG. Nos résultats, selon lesquels Pol eta continue de cibler le 
brin codant indépendamment de la localisation des « points d’entrée » en forme d’uraciles, 
contredisent les rapports déjà publiés sur ce sujet. De façon inattendue, nos résultats mettent 
en évidence une coopération entre les voies UNG et et les activités endonucléasique du 
mismatch repair, fournissant la cassure simple brin qui va permettre d'initier la resynthèse à 
fort taux d'erreur à l'origine de la mutagénèse A/T. Ces résultats résolvent aussi le paradoxe 
de la non-participation apparente du complexe effecteur du mismatch repair (Mlh1/Pms2) 
dans le processus d'hypermutation, en proposant qu'il fonctionne en redondance avec UNG, 
dans une distribution des tâches qui dépend du contexte de la séquence ciblée et de la densité 
du processus de deamination.
Mots clés (français) : lymphocyte B, hypermutation somatique, gènes des 
immunoglobulines, maturation d’affinité, AID, polymérases translesionnelles, cycle 
cellulaire, dégrons 
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Abstract:
Somatic hypermutation is a localized mutagenesis, essentially targeted to the 
immunoglobulin V region, and occurring during the immune response. This process is 
triggered by AID (activation-induced cytidine deaminase) that deaminates cytosines into 
uracils at the Ig locus. This lesion is further processed by Ung or the Msh2-Msh6 complex, 
with an abnormal outcome for both pathways that results in an increased mutation load. The 
Msh2-Msh6 complex recruits Pol eta to generate a short patch DNA synthesis with mostly 
mutations at A and T bases. 
To get further insight into this error-prone repair process, we have generated 
hypermutation substrates consisting in an A/T oligonucleotide of 100 bases with or without 3 
cytidines in its core region, inserted by knock-in at the heavy chain Ig locus. Our aim was to 
compare the mutation frequency, distribution and mutation profile of substrates with C on 
either the coding or the non-coding strand on WT or Ung-deficient background, taking into 
account that Pol eta is a preferred A to G mutator. Our results suggest that Pol eta resynthesis 
may proceed on the coding strand, whatever the strand localization of the uracil, thus 
contradicting previous reports. Unexpectedly, our results revealed a cooperation between the 
Ung pathway and the endonuclease activity of the mismatch repair, with both of them 
providing the single-strand nick that allows initiation of the error-prone process that generates 
mutations at A and T bases.  These results resolve the apparent paradox of the non-
involvement of the mismatch repair effector complex (Mlh1-Pms2) in hypermutation, by 
proposing that it works  redundantly with UNG, in a distribution of tasks that will depend 
upon the sequence context and the intensity of deamination activity.  
We have also constructed cell cycle restricted mutants of AID, to study in which phase 
of the cell cycle this atypical, mismatch repair driven, error-prone synthesis is taking place. 
Using the Fucci restriction system (degrons based on Cdt1 or Geminin peptides), we have 
generated AID constructs with proper restriction in either G1 or S/G2/M phases. These 
retroviral constructs have been used to transduce mouse hematopoietic stem cells from either 
AID -deficient mice and to restore immunodeficient animals, in order to analyze their immune 
response. We report that restriction of AID expression in S/G2/M part of the cycle yielded 
only background mutation frequency, while AID operating in the G1 phase is able to generate 
an equal proportion of A/T and G/C mutations at the Ig loci, thus demonstrating that uracils 
generated in G1 are substrates for both Ung- and mismatch repair pathways. 
Keywords : B lymphocytes, somatic hypermutation, immunoglobulin genes, affinity 
maturation, activation-induced deaminase, translesional polymerases, cell cycle, degrons 

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Avant-propos 
“It takes all the running you can do to keep in the same place”
These are the words the Red Queen used to explain to Alice how Wonderland runs; 
indeed, one cannot help the feeling of being in Wonderland once they enter into the intricacies 
of vertebrate adaptive immune system. Immunity “Wonderland” is built on the constant arms 
race between the innovative mechanisms of pathogen infection and the host
recognition/reaction system. Both sides multiply their arms by using the one key parameter: 
diversity. If one side succeeds in evading the other by means of diversified attack or 
dissimulation mechanisms, this means only one thing for the winner: keep in the same place, 
or in more biological terms, survive.   
Keeping in the same place means as well that a pathogen cannot support diversity by 
entirely changing all parts of its molecular machinery that already proved to work well in the 
course of evolution. Some parts of the pathogen will inevitably remain the same and hence 
even resemble among pathogen species. The immune system knows how to take advantage of 
these invariable components, termed PAMPs (pathogen-associated molecular pattern). 
Innate immune response, one arm of the vertebrate immune system that proved to be 
extremely efficient in recognizing these generalized patterns, engages a set of effector 
molecules and cells to quickly eradicate the invading pathogen.  Therefore, the innate 
component of the immune system is the first defense line when pathogen gains access through 
the organism entry points, like skin, respiratory and digestive ways, or blood.
On the other hand, extremely short generation time allows the pathogen to quickly 
overwhelm the innate response and, more importantly, change rapidly its tactics for the attack 
and escape the immune defense. In some cases pathogens can dissimulate their PAMPs or 
resist the destruction mechanism deployed on them by the innate immune system. Therefore, 
a more targeted action is required to recognize the pathogen separately from the standard 
surface characters and elicit highly specific combating tactics. This is the moment where 
adaptive immune system comes in and helps the organism not only clear the pathogen, but 
also perpetuate  a memory of it and mount a defensive response up to several times faster in 
case of a repeated infection.  
Here, the demand of the Red Queen seems unfeasible for a vertebrate adaptive 
immune system. How to stay in the run when running means to cope with the infinite 
diversity of all pathogen moieties (antigens), by recognizing each of them with extreme 
specificity? Immunoglobulin and T-cell receptor genes, encoding the molecular effectors of 
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the adaptive immune system had only one thing left to do: diversify as fast as the ever 
changing pathogen in hope that they are innovative enough to win the arms race. 
Characteristics of the adaptive immune response 
An adaptive immune response takes place through two phases: recognition phase 
allows specialized antigen-presenting cells (APC) to take up, process and present the antigen 
to the adequate mediator cells, T and B cells; an effector phase will allow the mediator cells 
that had specifically recognized the antigen to differentiate into effector cells and fight for 
antigen elimination. In the way we have just described it, an immune response implicate both 
arms of an individual’s immune system: the innate system comprising macrophages, 
granulocytes, NK cells and dendritic cells which play the role of APCs, and the adaptive 
immune system, including the humoral and the cellular type of adaptive responses that will 
launch the effector phase.  
Humoral immunity provides for combative molecular complexes, antibodies or 
immunoglobulins which specifically bind and counteract the harmful effect of non-self 
molecules or microbes. Antibodies can exist as  cell surface proteins in the membrane of the 
B lymphocyte that produces them, and recognize specific antigens as B-cell antigen-
receptors. Once a B-cell has bound a specific antigen and receives help from other mediator 
cells, it becomes activated and differentiates into an effector plasma cell that will secrete the 
antibody in body fluids and blood. Once the antibody binds to the antigen, this immune 
complex can be either eliminated by complement factors, or phagocyted by macrophages and 
granulocytes more efficiently than bare pathogens thanks to the recognition of the antibody 
portion of the immune complex through special FcR receptors on the surface of the 
macrophage’s membrane.
The cellular component of the adaptive immune system comprises T-cells, which can 
adopt a regulatory, suppressor or effector role. T-cells can detect and bind antigen through 
their membrane bound T-cell receptor (TCR). However, TCR can recognize antigen only if 
it is presented to the T-cell by an APC, like a motile dendritic cells that has encountered the 
antigen while sampling for them in peripheral tissues. Once they recognize the specific 
antigen, T-cells will undergo the differentiation from mediator to effector cells and become 
either helper T-cells or cytotoxic T-cells.  Cytotoxic T-cells specifically target somatic cells 
that got already infected or transformed by the antigen-bearing pathogen and eliminate them 
by enzyme-mediated lysis. Helper T-cell play a part in activating B-cells, helping them to 
become antibody producers and directing the best suited antibodies according to the 
previously estimated nature of the invading antigen (parasites, viruses or bacteria).
Unlike innate immune responses, adaptive immune reactions display the following 
properties: 
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x they take time to establish (up to 5 days to detect antibodies in the blood after the 
exposure to the infectious agent); x they are by far more specific than innate reactions;x they have memory: they recognize better the infectious agent from repeated infections 
and maintain faster responses against it through time.
Since the B-cell antigen receptor (or antibody) and T-cell receptor are the molecular 
entities supposed to specifically bind a portion of the antigen (termed epitope or antigenic 
determinant), genes that code for these proteins are the units of molecular evolution at the 
somatic level that takes place in B and T cells. A variety of diversification mechanisms act on 
these genes. Both categories undergo V(D)J recombination that generates a repertoire of pre-
formed BCR and TCR specificities before encountering the antigen. This pre-formed 
primary repertoire of BCRs can specifically bind an antigen, but weakly and with low 
affinity. Only antibody genes are subjects for further diversification processes: class switch 
recombination that enhances antibody effector function, gene conversion and somatic 
hypermutation that further diversify the antigen-binding portion of the BCR/antibody. An 
antigen-governed selection process, termed affinity maturation, is carried out to keep alive 
and amplify the BCR-bearing cells that show enhanced antigen recognition and binding upon 
the diversification of the antibody genes. Therefore, with each pathogen invasion, we assist to 
a true Darwinian evolution at the micro-scale of the B cell: BCR/antibody-coding genes are 
induced to accumulate mutations, whose effect is further subjected to selective evolutionary 
pressure.
A bit of history on origins of antibody diversification 
Origins of molecular immunology emerged with the proposition of Ehrlich that 
antibodies, already studied at the chemical level, exist as side chains combined in a preformed 
receptor on the cell surface (Ganesh and Neuberger, 2011). If a fortuitous encounter of a 
preformed antibody and an antigen that fits extremely well its binding sites takes place, the 
individual is protected by counteracting the noxious effects of the antigen-bearing entity.  The 
protective effect of this encounter was questioned once Landsteiner showed that antibodies 
can be raised against any antigen, existing in nature as well as against chemically synthesized 
compound without any toxic effect. However, Landsteiner’s discovery was a very first 
glimpse into the vertiginous diversity of the antibody repertoire, perfectly adapted to cope not 
only with nature versatility but everything different from a self, be it natural or artificial. For a 
while, the scientific community concentrated on the enigma of how antibodies as proteins are 
capable of yielding this variety. Pauling (Pauling, 1940) and Haurowitz (Haurowitz F. and 
Breinl F., 1930) proposed an antigen induced-fit, suggesting that antibody changes its binding 
site at the contact with the antigen to fit it better, as an inducible enzyme will do with the 
cognate substrate. On the other hand, Jerne had a different theory in mind: paralleling the 
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survival of an individual with a selective choice of an antibody fitting the best the antigen, he 
hypothesized that antibodies with preformed specificities are subject to a natural selection 
governed by the antigen; the best fitting antibody would be reproduced within a cell and 
secreted in large quantities (Jerne N. K., 1955). The part on protein replication seemed to 
undermine the more or less accepted Jerne’s idea of natural selection operating in antibody 
production and expansion. Actually, It was already known at Jerne’s time that antibodies were 
produced by plasma cells, as experimentally proven by Fagraeus (Fagreus A., 1948). In 1950s 
Burnet modified Jerne’s theory by shifting the natural selection focus from antibodies to 
antibody-producing cells, turning it into clonal selection: therefore, one preformed antibody 
specificity corresponded to a single and unique antibody-producing cell; if the antigen-
antibody fit was good, the corresponding antibody-producing cell was selected and further 
expanded, as Burnet suggested, in perinatal period (Burnet F. M., 1957). Nossal and 
Lederberg brought experimental confirmation to Burnet’s theory by showing that there is not 
a single plasma B cell bearing two antibody specificities; furthermore, Lederberg adjusted 
Burnet’s theory in 1959 by proposing this clonal selection to be maintained through life-long 
encounters with the given antigen, by having DNA constantly mutating genome-wide in the 
selected antibody producer cell and bringing about for the first time the term of somatic 
mutations in B-cells (Lederberg, 1959).
The origin of pre-formed antibody diversity became the major debate in the scientific 
community; ones claimed that each antibody’s specificity is encoded by a gene in total B-cell 
DNA, defending the so-called germinal theory, while the others argued against this enormous 
number of genes required to cover the antigen diversity in the naive B cell and supported the 
idea of modifications in somatic B cell DNA, generating antibody diversity. Talmage showed 
that the number of antibody coding genes is not necessarily of the same order of magnitude as 
antigen diversity (Talmage D. W., 1959); if one remembers Ehrllich’s theory of combined 
chains making a for an antibody, different chain combinations account for different 
specificities. Tonegawa and Hozumi further contributed to unveiling the diversity-generating 
mechanism by showing that V and C genes are located on the same chromosome but are 
physically separated in mouse embryo cells; in hybridoma cells V and C genes are joined 
together in a primary diversification process termed V(D)J recombination (Hozumi and 
Tonegawa, 2004). Therefore, defenders of both germinal and somatic theory were right. 
Further genetic screening characterized differential gene expression of recombination-
activating genes (RAG), which led to the discovery of the recombinases specific for this 
diversification process (Schatz et al., 1989).
Body of evidence soon showed that V(D)J recombination cannot account for the 
increasing antibody diversity during subsequent encounters with antigen. Lederberg had 
already offered his somatic mutation theory, and Brenner and Milstein developed it further in 
1966 by limiting it to the V- coding region of immunoglobulin genes (Brenner and Milstein, 
1966). Restriction enzymes were emerging at the time, so they provided a mechanism for a 
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local entry in immunoglobulin DNA by a DNA-cleaving enzyme that would leave a break, 
allowing for the further entry of an error-prone polymerase that is capable of introducing 
errors at all four bases while copying the undamaged strand. In 1970 Weigert and Cohn 
backed up this somatic theory descendant with experimental evidence of extremely localized 
amino acid variations within the variable region of antibodies coming from the hybridomas 
established after different immunizations with the same antigen (Weigert et al., 1970). These 
amino acid variations translated into point mutations at the DNA level of Ig genes. This last 
finding marked the turning point where the focus of studies on somatic hypermutation 
definitively shifted from protein to DNA sequence; hypermutating Ig gene sequence became 
thoroughly dissected, either in the endogenous locus by Gearhart and colleagues or by using 
the immunoglobulin transgenes as in the Storb group. With the appearance of immortalized 
and transformed B-cell lines, research on somatic hypermutation became increasingly 
accessible, eventually leading to the landmark discovery of AID, the initiating enzyme of 
somatic hypermutation predicted by Brenner and Milstein 30 years before.  
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Figure 1. Multiple views of antibody structure.  
A) Tridimensional structure of an antibody with the color code 
corresponding to the schematic view. B) Two-dimensional 
structure of an secreted antibody (left panel) and B-cell 
receptor (BCR) tethered in the B-cell membrane (right panel), 
accompanied with signaling invariant ĐŚĂŝŶƐ /Őɲ ĂŶĚ /Őɴ͘ Ϳ
Close view on variable region of IgH and IgL: boxes outlined 
with dotted line indicate positions of CDR1, CDR2 and CDR3 
(the last one located at the VDJ and VJ junction of IgH and IgL, 
respectively). CH – heavy chain constant region, CL – light 
chain constant region, VH – heavy chain variable region, VL – 
light chain variable region. 
Adapted from following sources:   (Abbas, Abul K et al., 2010; 
Murphy et al., 2012 ) 
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Part One : General Introduction 
Chapter I : Introduction to B cell biology 
I .1 BCR receptors/Antibodies 
B-cell fulfills the role of humoral immunity mediator through the molecular structure 
unique for this cell type – antibody or immunoglobulin (Murphy et al., 2012). These specific 
molecules can be anchored in the B cell membrane with their transmembrane domain, 
followed by a cytoplasmic tail usually involved in further signaling steps. The contact with 
antigen determinants takes place at the extreme end of their free extracellular half. This form 
is expressed through the major part of B-cell ontogenesis and it is termed B-cell antigen 
receptor (BCR). However, in the final differentiation of B-cell towards their effector function, 
the expression of BCR is modified in terms of losing their transmembrane domain but 
keeping the same specificity and affinity for the eliciting antigen. Terminally differentiated B-
cells, termed plasma cells, can finally secrete antibodies in the bloodstream following the loss 
of transmembrane domain. This way, the former “extracellular” half keeps browsing for the 
cognate antigen and binds it tightly once found, while the former membrane-orientated 
domain instructs other participants in the immune response towards the most appropriate way 
of antigen elimination.
The antibody protein is composed of four polypeptide chains in total, two of them 
called heavy chains (IgH) and two light chains (IgL). Four polypeptide chains are linked 
with disulfide bonds in a way presented on the Figure 1B.: two heavy chains are linked 
between them, and each heavy chain is linked to only one light chain. Disulfide bonds exist 
even within a single polypeptide chain, allowing the maintenance of a specific 
immunoglobulin protein domain, the specific structure that can be recognized in many other 
proteins: TCR receptors, co-BCR invariant chains, cytokine receptors, Fc receptors and 
adhesion molecules. When assembled, antibody molecule resembles the Figure 1A. C-termini 
of both chain types, IgH and IgL, are facing each other, as well as N-termini. The tips of the 
antibody’s arms, composed of aligned N-termini of a heavy and a light chains, come in direct 
contact with the antigenic determinant. This means one antibody molecule can bind two 
identical epitopes simultaneously. The “stalk” region of an antibody is anchored in the 
membrane if it contains an additional transmembrane domain. The presence of two more 
immunoglobulin-like invariant chain, IgĮ and Igȕ that assemble in the proximity of this 
surface immunoglobulin is necessary for a full B-cell receptor function because these 
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accessory molecules act as signal transmitters to the tyrosine kinases of the BCR signaling 
cascade through their cytoplasmic tails (Figure 1B). When the immunoglobulin is in the 
soluble form, the stalk region is the one that communicates with the precise set of receptors 
on the surface of other immune cells and mediates the clearance of this antibody-antigen 
complex, termed immune complex.
When comparing the amino-acid sequence of two IgM antibodies found in the same 
organism, as well as comparing IgM antibodies between individuals, striking differences at 
the level of intra-species amino acid variability are found only at the level of the N-terminal 
region, therefore termed variable (V-) region. This is to be expected, since N-termini of all 
antibodies must accommodate a huge versatility of antigens, existing in nature as well as 
synthetic. For a given antibody class, a term that will be discussed soon, the rest of the 
antibody sequence is identical, and named constant (C-) region (Figure 1B).
The C-region of the heavy chain is composed of three to four immunoglobulin 
domains (depending on the antibody class), and the C-region of the light chain contains only 
one immunoglobulin domain. As mentioned, in all organisms of the same species, there are 
different classes of antibodies that one can think of as different “flavors” of an antibody’s 
constant region. Each antibody class triggers a very specific response for antigen evacuation 
or destruction, so that a precise antibody class is produced at a site where this type of 
clearance is the most appropriate. 
If the amino-acid sequence of variable regions of different B-cell clones are compared, 
one can establish histograms of amino-acid residue variability for the given position within 
the V-region of both polypeptide chains (variability plots, Chapter II, Figure 18.A). Three 
regions of extreme variability within a polypeptide V-region can be discerned; these are 
termed hyper-variable regions 1-3 (HV1, HV2, HV3). Surrounding amino-acid sequences 
with more conserved content are considered as framework regions (from the beginning of the 
N-terminus: FR1, FR2, FR3 and FR4). When the three-dimensional structure of the antibody 
became available, hyper-variable region could finally be mapped: they corresponded to six 
flexible loops (three from IgH, three from IgL) protruding away from the compact tertiary 
structure. When antigen-antibody V-region complex was examined by X-ray crystallography, 
one could see that these were the major antibody contact points with the specific epitope, 
whose shape perfectly accommodated the one of the antigenic determinant (accounting for the 
other names as complementarity-determining regions, or CDRs). The secondary structure of 
the framework regions serves to shape and rigidify the V-region spatial organization, and does 
not withstand any radical amino-acid replacement that may result in improper folding of the 
V-region immunoglobulin domain (Figure 1C).
  
Figure 2. The structure of mouse IgH and Igʃ genes. For more details, see text. Eµ : intronic enhancer, 
3’RR: 3’ regulatory region. Adapted from:  (Murphy et al., 2012; Schatz and Ji, 2011) 
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I.1.1. Mouse immunoglobulin gene organization 
The heavy chain polypeptide is coded by the heavy chain locus (IgH) on the 
chromosome 12 (Figure 2). This locus contains coding sequences (exons) interspersed with 
pseudogenes and intronic regions. Both variable and constant regions of the heavy chains are 
coded by the exons in this locus. There are three groups of variable region exons: V(ariable), 
D(iversity) and J(oining) that make up for the whole heavy chain variable locus. In the mouse, 
there are around 150 different VH exons, 9 DH exons and 4 JH exons. When all variable exons 
are present in the locus, its configuration is considered to be germline. Each VH exon is 
preceded by a corresponding promoter (PV1, PV2, etc.) and a leader (L-) sequence. This leader 
peptide directs the immunoglobulin to the endoplasmic reticulum for membrane expression or 
secretion.
Genes coding for the heavy chain constant region can be found downstream of the 
outmost 3’ JH exon. In the mouse, there are 8 of them, and they are named µ, į, Ȗ, Į, İ. They 
code for different antibody class or isotype: IgM, IgD, IgG1, IgG3, IgG2, IgG2b, IgA and 
IgE, responsible for different effector functions. Each gene coding for the constant region 
contains several exons, each exon coding for a single immunoglobulin domain or the flexible 
hinge within the constant region. Some constant genes have 3 exons, others have 4. 
Additional coding sequences can be found downstream of regular exons that code for the 
transmembrane and cytoplasmic domain, with a second polyadenylation signal. Alternative 
splicing directs the formation of the secreted or the membrane form of the heavy chain.
Each CH gene segment, except for the Cį gene, is preceded by a specific 5’ IH-exon 
and SH-region. SH regions are the sites of initiation from class switch recombination (CSR) 
process (detailed in Chapter II.6.1). All SH region are composed of repetitive sequences, 
mostly pentamers like GAGCT and GGGGT; however, each SH region is different and can 
contain the two mentioned sequences organized in tandem repeats or interspersed with other 
sequence motifs, creating complex patterns. The I-H exon was detected from germline 
transcripts initiated from the previously unknown CH-germline promoter sequences prior to 
class switch recombination. This transcription is shown to be necessary for the efficient 
opening of the locus and to facilitate access to the CSR-initiating factors. These sterile 
germline transcripts contain IH exons and CH exons in the mature form, but since the IH exon 
contains many stop codons in all reading frames, no protein products of these transcripts are 
detected. 
There are two different light chain loci: one, named ț, is found at the chromosome 6 
and comprises 140 Vț genes and 4 Jț genes. Only one Cț gene is found. The variable region 
of light chains does not contain any D exons. The other light chain locus, Ȝ, is found on the 
chromosome 16 and is the smallest Ig system known; it comprises three functional VȜ exons 
and three JȜ. Each JȜ exons is immediately followed by the corresponding CȜ gene, disrupting 
the classical clustering of J exons as in heavy or ț chain locus. Each light chain C gene codes 
  
Figure 3 . Mechanism of V(D)J recombination.  
For more details, see text. RSS: recognition signal sequences; DNA-PK: DNA protein kinase. 
Source: (Murphy et al., 2012) 
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for only one immunoglobulin region of the light chain constant domain, for which there is no
specific effector function. This limited VȜ and JȜ exon diversity accounts for a disequilibrium 
in the usage of ț and Ȝ light chains in mouse antibody assembly (ț:Ȝ = 95:5 % of mouse 
serum Ig). 
If looked at closely, VH genes can be grouped into families under the condition that 
each family member shares 80% of the sequence identity. Altogether, mouse VH can be 
regrouped in 3 clans and a total of 14 families, together with 3 different families of DH exons. 
As already mentioned, HV1, HV2 and HV3 hypervariable regions are comprised 
within variable regions of IgH and IgL chains. Their positions relative to V, J and DH coding 
sequences are known (Figure 1C): while HV1 and HV2 are entirely embedded within the V 
exon, HV3 in the heavy chain encompasses the whole D exon and comprises as well V-D and 
D-J junction. In the light chain, HV3 is exactly at the V-J junction. When all diversification 
mechanisms at the junction sites are taken into account, no wonder HV3 region is considered 
as the most variable one.
I.1.2. Primary diversification of immunoglobulin genes 
One of the hallmarks of B-cell development is V(D)J recombination, a somatic 
recombination event that rearranges V, D and J exons at the heavy chain locus and V and J 
exons in light chain(s). Bringing one V, one D and one J tightly together is the prerequisite for 
synthesis, assembly, and expression at the cell surface of a complete BCR. V(D)J 
recombination proceeds in a stepwise manner, each joining event characterizing a B-cell 
development stage (Figure 3). First, D and J exons at the heavy chain locus are joined, 
followed by VH-DH joining. The heavy chain locus of all B-cells starting from their late pro-B
development stage is therefore irreversibly rearranged. After the first checkpoint in B-cell 
development where this µ heavy chain is briefly expressed at the cell surface to test its 
functionality, one of light chain’s V and J exons are joined and a full BCR is expressed. 
V(D)J recombination proceeds by double-strand cleavage within specific signaling 
sequences that are positioned at 3’ of the chosen D exon and 5’ of the chosen J exon, 
separated by dozen kilobases. These signaling sequences ensure the directionality of exon 
joining throughout the whole process. The cleavage is carried out by the recombination-
activating gene products, RAG1 and RAG2. Covalently closed hairpin DNA ends, products of 
the DNA cleavage by RAG proteins, are resolved further, resulting in formation of P 
nucleotides (P for palindromic, due to the Artemis-mediated asymmetrically opening of DNA 
hairpins) and allowing the addition of N nucleotides (N for nucleotide, randomly added by 
terminal deoxynucleotidyl transferase TdT, template-independent DNA polymerase). Finally, 
unaligned protruding ends of the coding joints are re-filled and ligated (Figure 3). In 
conclusion, this primary diversification of immunoglobulin genes is a compulsory step in B-
cell development that takes place independently of antigen presence. In absence of RAG1 or 
  
 
 
 
 
 
 
Figure 4. Steps in transcription, splicing and protein synthesis of heavy and light 
antibody chain. Source: (Murphy et al., 2012) 
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RAG2 protein, B cells as well as T-cells are blocked in their development at the earliest stage 
since they cannot express rearranged B-cell or T-cell receptor, predisposing the concerned 
individual to a high susceptibility to infections in a form of primary immunodeficiency 
syndrome (severe combined immunodeficiency, SCID)(Brandt and Roth, 2008; Shinkai et al., 
1992). V(D)J recombination is as well a source of three types of diversity in immunoglobulin 
gene sequences, 1) a combinatorial diversity which is provided by random joining of a V, J 
and DH sequences within a locus, 2) another layer of combinatorial diversity by pairing 
rearranged heavy and light chains. After the heavy chain is rearranged and checked for 
activity, large pre-B cell divides actively and gives rise to daughter cells which will all have 
the same rearranged heavy chain but each one of them can proceed to their own, unique 
rearrangement of one of the light chains in order to finally assemble them in the BCR; 3) a 
junctional diversity due to the addition of uncoded nucleotides (P and N) at the sites of DH:JH
junction and less extensively at the sites of VH:DH junction (due to the short time frame of 
TdT expression in late pro-B cells). If all three diversity components are taken into account, 
the final result of theoretical total diversity is astonishing (5x10
13
combinations!).
I.1.3. Transcritpional regulation of Ig genes 
V(D)J recombination provided for the immediate vicinity of the variable region exons 
in Tonegawa’s experiments, thus allowing the synthesis of a final RNA transcript of the Ig 
genes. Another consequence of the V(D)J recombination is bringing the rearranged V 
promoter into proximity of Ig locus enhancers, the first one localized in the intron between the 
last J and C gene (IgH and Igț intronic enhancer, not found in Ȝ locus) and the second one 
found downstream of the last C gene (IgH and Igț 3’ regulator element or 3’RR and IgȜ 2-4
enhancer, Figure 2). Therefore, this promoter of the rearranged V exon will be the preferred V 
promoter from which high-level transcription of the rearranged V-region genes will start. Ig 
promoters will thus drive Ig gene transcription only in B-lineage cells. 
In the primary RNA transcript of immature or naive mature B-cell, the whole intronic 
region downstream of the rearranged JH exon is transcribed altogether with the unrearranged 
JH exons left (if any), and a CH gene (Figure 4) . In case of immature B-cells, transcription 
will stop immediately after Cµ. In case of a mature B-cell, both Cµ-containing and Cµ+Cį-
containing transcripts can be detected. Cį is directly joined to the rearranged JH at the RNA 
level by alternative splicing and yields a membrane IgD that is the hallmark of mature B-cells. 
Transmembrane domain-coding sequence, coded by one of the CH exons, will be included in 
the primary RNA transcript depending on the differential usage of the 5’ or 3’ polyA signals 
that flank this exon within CH coding gene segment. If 3’ polyA signal is used, synthesized Ig 
molecule will be directed to the cell membrane and tethered. The factors that govern the 
choice of polyA signals, either in Cį inclusion within the primary transcript or transcription of 
transmembrane domain-coding exon still remain to be discovered.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5. Many effector functions of antibody constant region. See text for more 
details. &Đɶ͕&ĐɸZ/ƌĞĐĞƉƚŽƌƐ– ƌĞĐĞƉƚŽƌĨŽƌĂŶƚŝďŽĚǇ/Ő'ĂŶĚ/ŐĐŽŶƐƚĂŶƚƌĞŐŝŽŶ͖
NK cell – ŶĂƚƵƌĂůŬŝůůĞƌĐĞůů͖ ϯďƌĞĐĞƉƚŽƌ– ĐŽŵƉůĞŵĞŶƚƌĞĐĞƉƚŽƌϭ͘ 
Source: (ďďĂƐ͕ďƵů<ĞƚĂů͕͘ϮϬϭϬͿ 
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The same splicing process takes place in maturation of ț or Ȝ primary transcripts. As 
already mentioned, B-cell can switch antibody classes from IgM/IgD by replacing them with 
another constant region-coding gene. The mechanism bringing that alternative CH gene at the 
DNA level in the proximity of rearranged V(D)J region is a part of secondary diversification 
processes of immune repertoire and is dictated by antigen nature. 
I.1.4. Secondary diversifications of immune repertoire 
When a B-cell in mice or humans comes across the cognate antigen and receives help 
from the cognate T-helper cell in the secondary lymphoid organs (Chapter I.2.3c), an 
immediate choice is made between two ways to act against the antigen. The first one is to 
develop immediately into an effector cell and secrete low affinity, mostly neutralizing IgM 
antibodies (which buys more time for the more adapted immune response to take place). The 
second choice is to populate a germinal center where clones of activated B-cells are triggered 
to mutate their variable region-coding genes (by somatic hypermutation) and exchange their 
IgM class BCR against some other heavy chain class (by class-switch recombination) that, 
once secreted, acts concertedly with other innate immune factors in order to completely 
eradicate the pathogen. Both molecular mechanisms are in the heart of diversification 
processes of the secondary immune repertoire, since they take place in mature B-cells and 
only in the presence of a cognate antigen. In other species like birds and rabbits, another 
antigen-independent diversification process takes place: a gene conversion, which creates 
additional diversity in the V-region by introducing chunks of different V-pseudogenes within 
the rearranged V exon. All three processes depend on a single initiating enzyme and share 
some similar steps, so they will be discussed in more molecular details in the next chapter.
I.1.5. Roles of different Ig classes 
The most logical consequence of an antibody binding an antigen determinant is to 
block the pathological effect of the antigen if the antigenic determinant happens to be a toxin 
or a viral coat protein. This antibody function is called neutralization (Figure 5). In the mouse, 
the most efficient neutralizing isotype is IgG1 and to a lesser degree, IgG2a. Other possible 
outcomes for an antigen within the immune complex is to be more easily phagocytosed by 
macrophages via their FcȖ receptors; this effect of antibody binding is called opsonisation. 
The best in this class is mouse IgG1. The third outcome is antibody-dependent cellular 
toxicity (ADCC), a process mediated by natural killer cells (NK) or eosinophils. Finally, 
antigen-antibody complexes may be recognized by the factors of the complement system, 
whose activation cascade leads to further lysis of the microbe or phagocytosis via receptors 
for complement fragments that opsonized the microbe. In mice, IgM is the most efficient
antibody for this function; beside IgM, complement activation is showed for IgG2a and 
IgG2b. IgA remains the mediator of mucosal immunity, by being transported through the cells 
 Figure 6. Different locations of hematopoietic stem cells throughout mouse development.  AGM 
– aorta gonad mesonephros. Source: (Orkin and Zon, 2008) 
Figure 7.  Schematic representation of hematopoietic stem cell differentiation. Grey line: 
putative unilateral differentiation pathways with progressive lost of multipotency, still under 
investigation. Source: (Alberts et al., 2002) 
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in epithelial barrier into body fluids like milk or mucus. If secreted alone, it forms the first 
immune barrier by inhibiting antigen adherence; when coupled to antigen in an immune 
complex, it enhances the complex evacuation through excretion in the lumen. 
I.2 B cell ontogenesis : from HSC to mature naïve B cell. 
I.2.1. Hematopoietic stem cells: preserve the source and provide 
for the diversity. 
All immune system cells stem from one precursor, hematopoietic stem cell (HSC, 
Figure 5) that allows the renewal of the whole blood cell pool throughout a lifetime. These 
stem cells keep the potential to differentiate into a few different lineages but their 
differentiation potential is not to be compared to the pluripotency of an embryonic stem cell 
that can give rise to cells from all three germ layers, ectoderm, mesoderm or endoderm. The 
location of these specific multipotent precursors in organs changes throughout the 
development, along with the intrinsic properties of HSC specific for the concerned site in 
terms of self-renewal and potential to differentiate. In mice, hematopoietic stem cells derive 
from ventral mesoderm, with the first wave arising in the form of a hemangioblast in yolk sac 
and aorta-gonad mesonephros (AGM) region starting from 7 days (E7.5) post-fertilization.  
The primary role of these cells is to produce red blood cells and endothelial cells in the next 
3-4 days of mouse embryo development. Controversy lingers about the relationship between 
yolk sac primitive HSC and definite adult HSC, concerning whether the latter descends from 
the former. By E12, it is the fetal liver that takes over the role of a major blood cell 
production site in a scheme that resembles more adult differentiation towards myeloid and 
lymphoid lineages. Hematopoietic stem cells will colonize thymus, spleen and it is only until 
a week after birth that hematopoiesis shifts definitively to bone marrow, which will remain 
lymphocyte production site until death (Orkin and Zon, 2008).
In order to characterize which fraction of isolated bone marrow cells contains true, 
long-term HSC, the most exploited way was to carry out adoptive bone marrow transfer into 
irradiated recipients. High-dose whole body irradiation leads to death of all proliferating cells:  
epithelial cells, germinal cells and especially hematopoietic precursors, which is the main 
raison of a fatal bone marrow failure and subsequent death. A single HSC from a 
immunologically compatible donor mice will suffice to repopulate the bone marrow of 
irradiated host (Kondo et al., 2003). Both HSC from fetal liver and adult bone marrow of a 
donor mouse, even though they differ in surface markers and in the mature blood cell types 
they are able to produce, are capable of colonizing the irradiated host. Fetal liver HSC were 
shown to reconstitute donor blood cells more successfully than adult bone marrow HSC, 
indicating a larger pool of long-term HSC (up to seven times more) with improved expansion, 
homing ability and wider differentiation panel. Moreover, it was shown that 25% of fetal liver 
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HSC are actively cycling cells while this category comprises no more than 4% of total adult 
bone marrow HSC (Morrison 1994, Morrison and Weissman, 1995).
The research of HSC biology is still ongoing in order to unveil the major factors that 
allow HSC to maintain their multipotency at the same time as to self-renew and maintain their 
number roughly stable. The decision-making events that promote differentiation over self-
maintenance are yet to be discovered. However, several findings have already allowed ex vivo
long-term culture and expansion of HSC, which is an inevitable step towards gene therapy 
interventions and transplantation. A modest expansion is achieved by growing HSC in 
defined cytokine milieu that stimulates division without loss of self-renewal (IL-3, IL-6, IL-
11, SCF, Flt-3 ligand, thrombopoïetin TPO, Notch ligands, insulin-growth factor 2, etc.). 
Several other factors are coming into light (pleîotropin , angiopoietin-like protein 5, co-
culture with mesenchymal stromal cells (Robinson et al., 2006)The choice of these factors 
was partially deduced from the analysis of the hematopoietic stem cells “niche” in bone 
marrow: in a apparently disorganized tissue, a ”niche” is defined by the immediate 
surroundings of the stem cell entity that provide the signals to maintain its multipotency 
through cell-to-cell contact and local cytokine secretion. In case of hematopoietic stem cells, 
these are osteoblasts and bone marrow stromal cells. A stem cell tends to lose its stem cell 
character as soon as it leaves the particular stem cell niche. One example of necessity for the 
cell-to-cell contact in order to maintain the stem cell identity is illustrated by the Kit-Kit 
ligand signaling pathway, Kit being a tyrosine kinase at the surface of hematopoietic stem 
cells and kit-ligand (stem cell factor SCF or steel factor) being a membrane-bound molecule 
of the surrounding stromal cells. Kit is one of the markers of long-term HSC and very early 
progenitors within a so-called LSK subset (lineage-negative Lin
-
, stem cell antigen positive 
Sca1
+
and Kit
hi
) (Welner et al., 2008)
However, cell culture in presence of soluble factors is only transient and short-termed, 
since HSC eventually differentiate and die. The second means is to transduce HSC with a 
retroviral vector encoding transcription factors that induce a burst of in vitro HSC 
proliferation, like HOXB4 (up to 80-fold, (Antonchuk et al., 2002) or HOXA10 
homeodomain fused to N-terminal domain of nucleoporin 98 (NUP98-HOXA10hd fusions 
(Ohta et al., 2007). The expansion post-transduction is impressive (1000-fold) over a short 
period (6-10 days) and promising for future therapy challenges (Sorrentino, 2004).
Long-term HSC after a division may give rise to a precursor that retains the 
multipotency but loses the ability to self-renew. This multi-potent progenitor cell (MPP) 
requires signaling through another cell-surface tyrosine kinase receptor, FMS-related tyrosine 
kinase 3 (Flt-3), triggered by the membrane-bound Flt-3 ligand on the surrounding stromal 
cells. This signaling pathway favors further differentiation towards two novel oligopotent 
lineage precursors, common lymphoid precursor (CLP) and common myeloid precursor 
(CMP, Figure 7). Further differentiation is depicted in a linear, stepwise manner that may not 
be perfectly respected in reality in terms of lineage “fidelity”, because cases have been 
  
 
Figure 8. Parameters of the HSC differentiation which can be potentially modulated 
by colony-stimulating factors in vitro as in vivo. Source : (Alberts et al., 2002) 
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observed in which myeloiod precursors retain the capacity to differentiate towards B cells 
(Hardy et al., 2007). For a cell precursor to be considered as lineage-restricted, two conditions 
are required: the loss of capacity to develop into other blood cell types at that specific stage 
and the irreversibility of this loss. For the moment, only CLP and CMP show a high degree of 
lineage commitment both in vitro and in vivo. Unlike true HSC, committed progenitors have 
to undergo many divisions (many, but finite), with the progeny of each one being driven 
towards a more differentiated stage with a smaller capacity to proliferate and a relatively short 
lifespan. Even with these limitations, a huge number of fresh blood cells is produced from a 
single division of a hematopoietic stem cell, which explains the HSC scarcity in total bone 
marrow cell count (1 in 10 000) and reduces the necessity for them to divide frequently. Each 
division brings in the risk of introducing mutations and telomere shortening (Kondo et al., 
2003), indicating a limited self-renewal potential even for the stem cells. Indeed, the majority 
of HSC appears quiescent, and several dye-dilution assays for proliferation indicate that HSC 
may divide only five times in a whole mouse lifespan (Zhang et al., 2012). Moreover, the 
efficiency of bone marrow reconstitution of irradiated mice worked less well with the 
hematopoietic stem cells that were driven into cycling prior to transplantation.
Red blood cells and megakaryocytes, precursors for platelets, descend from MEP 
(megacaryocyte-erythroid progenitor), the further step of commitment after CMP while mast 
cells, eosinophils, neutrophils, monocytes/macrophages and conventional dendritic cells stem 
from GMP (granulocyte-macrophage progenitor). CLP is supposed to yield B and T 
lymphocytes, as well as plasmacytoid dendritic cells and natural killer cells. There is an 
ongoing debate about even earlier progenitors of CLP, such as ELP (early lymphoid 
progenitor) or LMPP (lymphoid-primed multipotent progenitors), the latter designated upon 
the expression of early transcripts that are hallmarks of mature blood cell gene expression, a 
phenomenon known as “priming” (Hardy et al., 2007; Zhang et al., 2012). As already 
mentioned, intermediates between the common progenitor and finally differentiated cells 
retain a residual proliferation capacity without requiring the absolute contact with the 
surrounding cells. This allowed the creation of an assay of colony formation in a semi-solid 
medium: in this surrounding, the progeny cells cannot migrate but tend to accumulate and 
form a colony. The aspect of these colonies differs accordingly to the subsequent 
differentiation of the progeny and has contributed to identify and name the intermediate 
precursors as colony-forming units (GM-CFU, E-CFU, etc). 
This colony-forming capacity also provided the functional assay for examinating the 
impact of different factors that orientate blood cells precursors towards a particular lineage 
(colony-stimulating factors or CSF).  Some of the above-mentioned factors that modulate 
hematopoietic stem cell survival, division and uncommitted fate were discovered this way and 
subsequently tested on the true stem cells. CSFs are capable of regulating several parameters 
of the hematopoietic stem cell culture as indicated in the Figure 8.  However, they are not the 
  
 
 
Figure 9.  Schema of B-cell development from hematopoietic stem cell to differentiated plasma cell. 
More details in text. Source: (Murphy et al., 2012) 
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sole governors of the hematopoietic stem cell fate: it seems that a single HSC maintains a 
stochastic factor in deciding to orientate towards one lineage or the other. Even in the most 
carefully purified HSC culture, the difference in sizes as well as in the characters of the 
developing colonies can sometimes be striking. It seems that, as a whole, the systems 
perpetuates a reproducible development pattern, but at the individual cell level the process of 
commitment and programming to cell division can sometimes be considered as random 
(Alberts et al., 2002).
I.2.2. From common lymphoid progenitors to mature naive B cells 
B-cell lymphopoiesis continues in the bone marrow of bones like femur, tibia and to 
some extent in arm/fore limb bones throughout the lifetime. This is an antigen-independent 
process and includes progressive, stepwise changes in cytoplasmic determinants, surface 
markers and Ig gene configuration, as well as the proliferation and survival capacity of its 
intermediates (Figure 9). The survival is especially at stake since unsuccessful rearrangements 
and some of the negative selection processes take their toll in the bone marrow until immature 
B lymphocytes are unleashed in the bloodstream. 
Further steps of B-cell differentiation from common lymphoid progenitor involves 
pro-B cell, characterized by the initiation of Ig gene rearrangement, the V(D)J recombination 
(Chapter I.1.2). The very first B-cell governing transcription factors, PU.1, E2A and EBF 
emerge at the stage of a pro-B cell, initiating the expression of another transcription factor, 
Pax5 that acts as lineage-stabilizing factor, irreversibly committing this hematopoietic 
intermediate to the B lineage. Other targets of these early B-cell transcription factors are the 
two recombination-activating genes, RAG1 and RAG2 necessary for V, D and J exon 
rearrangement. In the first cascade of recombination events, early pro-B cell rearranges one D 
with one J segment of heavy chain immunoglobulin loci on both chromosomes. At this time, 
the expression of TdT polymerase is detectable, allowing for the N-nucleotides insertion. 
After DJ recombination, RAG1 and RAG2 proceed to rearrange heavy chain V exon with 
rearranged DJ segment, marking the transition towards late pro-B cell. This time, the 
recombination proceeds at only one chromosome. Small number of N-nucleotides is inserted 
at this stage as the expression of Tdt is turned off early in mice. If V exon is joined in frame 
with DJ segments, an entire µ heavy chain is synthesized, coupled with a surrogate invariant 
light chains (termed Ȝ5 and VpreB) since the light chain loci have not yet recombined, and 
sent to the cell surface for a test of its integrity and functionality. The expression of this so-
called pre-B receptor is the first checkpoint in B-cell development, marking the transition 
from late pro-B cell to a large pre-B cell. If the VDJ rearrangement on this chromosome is 
unsuccessful, it switches to the second heavy chain allele. If this second rearrangement fails, 
the late pro-B cell is destined to die by apoptosis. Around 45% pro-B cells die at this stage.
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If VDJ rearrangement at one of the chromosome is successful, the newly differentiated 
large pre-B cells start to actively proliferate for two reasons. The first one is to reduce but not 
to totally bring to an end the expression of RAG proteins. This way further rearrangement at 
the other heavy chain allele is prevented if the first one is successful. RAG-2 protein 
expression is conditioned by its G1/S-dependent phosphorylation that targets it to degradation 
outside of the G0/G1 phase (§ Chapter III.2). This is as well the probable trigger for allelic 
exclusion, an epigenetic event that turns off the heavy chain allele that is not to be used for 
the assembly of the future BCR. The second reason is to amplify the effect of the successful 
first recombination event in order to increase the chances of immature B cell formation, since 
the second fortuitous joining event is to be expected in the light chain loci in small pre-B
cells, the progeny of large pre-B cells. RAG proteins continue to operate in small pre-B cells 
by joining VL and JL in one of the light chain loci, ț or Ȝ. If the recombination goes on 
successfully from the start, a complete BCR is allowed to be assembled and is expressed at 
the cell surface, with the definitive shutdown of RAG protein expression and allelic exclusion 
of the other light chain alleles. However, if the first joining event fails, the RAG recombinases 
go on rearranging the remaining V exons of the same allele; if in vain, the other allele is 
tested for the rearrangement. If recombination completely fails at the kappa light chain locus, 
the RAG proteins will attack the lambda light chain locus, allele by allele. 
At last, an immature cell derived from the small pre-B cell is formed, expressing a 
surface IgM (sIgM) and two pan-B cell markers, B220 (CD45R) and CD19. CD19 appears as 
a consequence of Pax5 transcription factor expression and therefore persists from the earliest 
B cell precursors onwards. The B220 marker is being expressed prior to heavy chain 
rearrangement, thus earlier than CD19. The expression of the sIgM is considered to be the
second checkpoint in B-cell ontogenesis, since fully formed immature cells are exposed to a 
negative selection if they bind to a self-antigen. If some binding and downstream signaling do 
occur, the immature cell undergoes one of the following scenarios: receptor editing, apoptosis 
or forced unresponsiveness (anergy).
This is roughly the scheme that hematopoietic stem cells follow once they get engaged 
to the B-lymphoid lineage, be it in fetal liver or in the bone marrow. However, beside larger 
replenishing potential of fetal liver HSC when compared to adult HSC, the sole fetal HSC 
retain the capacity of producing another type of differentiated B-cells, the so called B-1
subset (Hardy et al., 2007; Kondo et al., 2003). These B cells express high levels of the CD5 
surface marker, high IgM and low IgD. They can be found mainly in the peritoneal and 
pleural cavities, and make up to 5% of the total B cell pool in the mouse. B-1 cells are capable 
of self-renewal. They are considered to be “natural antibody” producers – a majority of 
circulating IgM being secreted by these cells even in the absence of infection. The BCR of 
these cells is pre-selected to bind some self-antigens that largely resemble environmental 
antigens as those found in the microbial gut flora. It seems that exposure to these types of 
antigen has positively selected B-1 cells with an apparent auto-reactivity that is not 
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pathogenic, but might even be involved in cleaning up the senescent cells (Hardy et al., 2007; 
Shapiro-Shelef and Calame, 2005). They react extremely quickly upon antigen encounter, 
migrating towards spleen and differentiating into antibody-secreting cells without requirement 
for T-cell help (for more on this subject, §Chapter I.2.3b).
Hematopoietic stem cells can be found in direct contact with osteoblasts in the 
endosteum, the inner lining of the bone tissue. While generating oligopotent progenitors and 
other intermediary species, cells are dividing and pushing their progeny towards the central 
blood sinus in the middle of the bone marrow, where the non-autoreactive immature cells are 
released. Once in the bloodstream that carries them to the spleen, B cells shift from immature 
towards the mature stage by undergoing two consecutive transitional stages, T1 and T2.  T1 
cells are defined as IgM
hi
 IgD
-
 subset that receive a strong signal to home to spleen, but did 
not gain the ability to recirculate (Pillai and Cariappa, 2009). These transitional cells are 
discharged in the white pulp of the spleen after being carried by the blood flow through the 
central arteriole and marginal sinus. Until now, the only known requirement for T1 cell 
survival is the so-called tonic BCR signaling: even though the cognate antigen is not yet 
encountered, this non-specific and continual activation of the signaling pathway downstream 
of the BCR is indispensable. The second requirement is the ability to recirculate through the 
follicles of the spleen white pulp in which the other key molecule for terminal differentiation 
is encountered, the BAFF survival factor. If an immature lymphocyte fails to enter a follicle 
due to the fierce competition between other immature cells and preferential entry for mature 
B-cells, it dies shortly after release from the bone marrow. However, if the immature cell 
succeeds in entering the follicle, it needs both BCR tonic signaling and BAFF-BAFF receptor 
interaction in order to become T2 transitional cells that express IgM
hi
IgD
+
 markers. However, 
some other immaturity markers are kept at the surface, like AA4.1, known to be expressed by 
some early  multipotent progenitors. Every 3 days, 50% of the short-lived immature B cell 
population dies due to the impossibility to fulfill these requirements (Charles A Janeway et 
al., 2001). T1 and T2 cells are considered to proceed through additional rounds of negative 
selection in the spleen. Finally, with a different combination of extracellular ligands and the 
evolving strength of BCR signaling, T2 B cells transit towards mature B cells, expressing 
both IgD
hi
IgM
low
, termed B-2 cells to distinguish them from the B-1 subset. Among B-2 cells, 
two distinct subsets are further identified depending on their localization once they recirculate 
through the spleen: B-2 cells or follicular B cells (Fo-B) that recirculate through primary 
lymphoid follicles in lymph nodes and spleen, and marginal zone B cells that home 
exclusively around  the marginal sinus at the spleen white pulp-red pulp border (Chapter 
I.2.3a).
Marginal zone cells (MZ B-cells) remain resting and long-lived, with a capacity to 
self-renew but also with a potential of being replenished from marginal zone B cell precursors 
in case of rapid MZ B cell depletion.
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Their BCR seems to bind some self-antigens and common environmental antigens, with low 
affinity. This low level of BCR signaling is considered to be favored during some positive 
selection process in spleen while presenting specific self-antigens to T2 transitional cells 
newly homed to spleen. Their main role is considered to be getting in a direct contact with 
blood-borne pathogens, recognizing mostly T-cell independent antigens. Their most 
remarkable property is to respond rapidly to antigens, making them the very first B-cells that 
differentiate into plasma cells upon the antigen entrance, constituting an innate-like first line 
of defense (Hardy et al., 2007; Shapiro-Shelef and Calame, 2005).  
Mature naive follicular B cells continue to circulate via the bloodstream throughout 
the body, spending some time in draining lymph nodes or spleen white pulp. As detailed in 
the Chapter I.2.3a, these organs posses an architecture that enhances the probability of 
encounter between three major factors necessary for naive B cell activation:  x priming of B lymphocytes by a specific antigen via their BCR receptor in a direct 
contact with antigen, x naive T-helper cell differentiation through a contact with professional antigen-
presenting cell (dendritic cells, mostly) via their epitope-bound MHC II – TCR contact,x and the cognate interaction between the T-helper cell TCR and epitope-bound MHC II 
molecule at the B cell surface, which ultimately activates a mature B cell that is no 
longer considered naive.
These interactions allow for the further differentiation of activated B cell towards 
effector cells that sustain the function of humoral immunity: short-lived antibody-secreting 
plasma cells, long-lived plasma cells and memory B cells. 
I.2.3.Germinalcenterreactionandaffinitymaturation
I.2.3a. Secondary lymphoid organs: a place to be seen for follicular naive B cells 
Among all lymphoid organs, one can distinguish those that serve for the development 
and education of the major immune system cell types (the primary lymphoid organs) and 
others in which those cells can complete their development, acquire their definitive phenotype 
and get engaged in immune responses (secondary lymphoid organs). Bone marrow and 
thymus (the development organ for T cells, even though their early precursors arise in bone 
marrow and migrate towards thymus) belong to the category of primary lymphoid organs. We 
shall briefly detail the structure of the secondary lymphoid organs, which contribute to the 
formation of plasma cells and memory B cells through germinal center reactions: lymph 
nodes, mucosal-associated lymphoid tissue (MALT) and spleen. x Lymph node (Figure 10). 
 Figure 10. Schema of lymph node structure.  
Source : (Murphy et al., 2012) 
Figure 11. Structure of a Peyer’s patch in ileum. M cell – microfold cells. 
 More details in text. 
Source: (Murphy et al., 2012) 
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Lymph nodes are strategically positioned alongside lymphatic vessels, allowing the 
lymphatic fluid to be drained. One can imagine the lymph vessel network within the lymph 
node as a capillary network, where the afferent vessel branches in many side channels, 
vascularizing the cortex horizontally and vertically, which converge towards the medullary 
sinus and are drained through the efferent lymphatic vessels. Two major anatomical regions 
can be distinguished within the lymph node: the cortex and the medulla. The cortex is 
delimited from the medulla by a paracortical area containing diffusely arranged T-cells, 
(called T-cell zone). Lymphatic vessels bring in the free soluble antigen and antigen-
presenting cells that have captured the antigen in the extracellular space within the tissues,
allowing them to be “trapped” for a while in the node, searching for the T cell that can 
recognize the same antigen. Blood vessels vascularize the lymph node as well. A specialized 
blood vessel type, high-endothelial venules (HEV), allow lymphocytes that have been carried 
with the bloodstream to mingle between the endothelial cells and to get “squeezed” out on the 
outer side of the vessel wall. This is the way that mature naive follicular B-cells use to 
recirculate through the lymph node. Once outside of the HEV, B-cells directly come across T-
cells within the paracortical area. Antigen-primed B-cells migrate quite quickly towards the 
follicle zone of the lymph node if there were no retention mechanisms: peptides coming from 
the internalized and processed antigen are being exhibited on the B-cell MHC-II, at the same 
time allowing for activation of adhesion molecule and chemokine receptors that literally 
anchor them in the T-cell zone. This way, the chances of encountering the cognate T-cells are 
maximized; if otherwise, the odds would be between 1 in 10 000 and 1 in 1 000 000. 
At the outer border of T-cell zone, a so-called B-cell zone can be found, being 
organized in primary follicles. If a B-cell undergoes a cognate reaction, it returns to the 
primary follicle from the T-cell zone and transforms it into a secondary lymphoid follicle with 
a germinal center in its core.  After several weeks of proliferation leading to production of 
memory B-cells and plasmocytes, the germinal center reaction wanes, degenerate and become 
senescent. However, persisting germinal center-like structures were observed even 8 months 
after immunization with a specific antigen type, so-called particulate antigen (sheep red blood 
cells, vesicular stomatitis virus, protein-coated beads) (Gonzalez et al., 2011).x Illeal Peyer’s patches (Figure 11).
Peyer’s patches within the small intestine wall make up for an important the part of 
mucosa-associated lymphoid tissue, along with adenoid glands and tonsils. While the major 
role of the lymph node is to bring in contact cells that specifically recognize lymph-borne 
antigens (that entered through epiderm), Peyer's patches screen for the antigens that are 
brought in with food or changing microbial flora. They are localized immediately beneath the 
intestinal epithelium, forming a cupola-like structure tightly filled with primary and secondary 
follicles and surrounded by a T-cell zone. Specialized M-cells (for microfold, referring to 
their apical protrusions) are found in the follicle-associated intestinal epithelium that have the 
role to sample the antigens caught on the inner mucosal lining of the intestine, phagocyte 
  
Figure 12. A schematic view of the anatomy of the spleen.  
Source: (Pillai and Cariappa, 2009) 
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them and transfer them across the whole cell body to be released on the cell’s basal side. 
Immediately beneath the epithelium is a network of dendritic cells that take up the antigen 
and pursue the antigen presentation in the T-cell zone.  In the well-irrigated Peyer's patches, B 
and T lymphocytes enter by bloodstream and leave after germinal center reaction through the 
efferent lymphatic channels.x Spleen (Figure 12).
Spleen is not directly connected with the lymphatic vessel network, so all the antigens 
that circulate through it are blood-borne. When one takes into account diverse roles of spleen, 
it is makes it easier to imagine its organisation: spleen serves as a disposal for used red and 
abnormal blood cells, with the important network of iron retrieval and stocking; spleen stocks 
as well platelets, polynuclear neutrophils and specialized spleen macrophages that eliminate 
directly the antigen brought by the bloodstream and are able to tackle huge pathogens like 
protozoa. The majority of spleen tissue is made up of red pulp in which red blood cells are 
deposited for destruction. In-between red pulp, dispersed spots of white pulp can be found, 
grouped around the trabecular arteries bringing in the fresh blood. These radially disposed 
vessels branch into transversally orientated central arterioles enveloped in the first layer of T-
cells making up the periarterioral lymphoid sheath (PALS). Central arterioles branch 
beyond T-cell zone into sinuses, specialized fenestrated blood vessels that lack the classical 
rigid organization of the capillary network. Surrounded by these sinuses, a B-cell zone can be 
found, composed of the follicles surrounded by the so-called marginal zone that separates 
them from the surrounding marginal blood sinuses. PALS, follicles and marginal zone 
constitute together the spleen white pulp. Once again, spleen organization allows bringing in 
contact mature B-cells with T-cells from PALS primed for the cognate antigen, and on the 
other side, the traffic of the immature B-cells that complete their differentiation within the 
follicles and marginal sinuses of the white pulp in order to become sedentary marginal zone 
B-cells or follicular mature B-2 cells. 
I.2.3b. The first requirement: antigen
The versatility of antigens that an individual’s B-cell repertoire is able to recognize is 
amazing: protein/sugar/lipid antigens; natural or synthetic low-molecular weight chemical 
compounds, complex antigens containing multiple chemically diverse epitopes (virus 
particles, other species’ blood cells...), antigens with unique or highly repetitive moieties...  
As we have seen so far, blood/lymph circulation system and secondary lymphoid organs have 
evolved to match the incoming antigen from a defined entry point (epiderm, extracellular 
space, inhalation, ingestion, blood) with the most appropriate adaptive immune response. The 
recognition of a specific antigen can be mediated with or without T-cell help, and the 
outcomes of further naive B-cell differentiation are different. Two classes of antigens can be 
distinguished whether the necessity for the T-cell help exists or not. The ones that need the 
 Figure 13. Most important cell-to-cell interactions for B-cell activation : activation of the 
cognate T-cell by interaction with dendritic cell (left) and activation of B-cell through triple 
interaction with T-cell. Source: (Alberts et al., 2002) 
Figure 14.  Cognate B-T cell interaction. FDC – follicular dendritic cell. More details 
in text. Source : Abbas, Abul K et al., 2010) 
Zivojnovic Marija –L’hypermutation somatique des gènes des immunoglobulines -2013
57 | P a g e
intervention of T-helper lymphocytes to activate B-cells are called T- or thymus-dependent 
antigens, and comprise mostly protein antigens or antigens carrying a protein component. T-
independent antigens are divided into two subgroups, TI-1 and TI-2. TI-1 class comprises 
antigens that can induce B cell proliferation but manage to bypass the BCR signaling 
pathway. These antigens are called B-cell mitogens; they will activate any B-cell, mature or 
immature, independently of its BCR specificity, like bacterial lypopolysaccharide (LPS) that 
signals through innate-immunity receptors like TLR-4 (Toll-like receptors). The TI-2 class of 
antigens, like pneumococcal polysaccharides, possesses repetitive moieties that are able to 
cross-link the BCR of a mature cell and send a downstream signal strong enough to trigger 
antibody production. This type of antigen is recognized by special subsets of B- cells trained 
to react quickly and without outside help for development into effector cells (B-1 cells, 
marginal zone B cells). However, only one type of antigen can initiate a germinal-center 
reaction, somatic hypermutations and most importantly, B-cell memory: the ones whose 
recognition is mediated by T-cell help, and those are the ones that we will take into account 
when tackling the key issue of this study.
I.2.3c. Cognate B cell-T cell encounter
At this point, we shall concentrate more closely on the prerequisites for the germinal 
center reaction. For it to happen and for a B-cell to survive, the B lymphocytes have to be 
present at the right place and at the right time. Once more, three major actors must juxtapose: 
the cognate antigen, the mature naive follicular B-cell specific for the antigen and the T-cell 
primed with the cognate antigen thanks to the previous interaction between the MHC-II of a 
dendritic cell and a compatible TCR (Figure 13). After having acquired the mature phenotype, 
B-cell may encounter its cognate antigen while recalculating or interacting with dendritic cells 
and macrophages. Antigen-bound BCR is internalized; antigen is processed and presented 
through MHC-II. As we have seen previously, the structure of the secondary lymphoid organs 
facilitates direct contact with recalculating primed B-cells and T-cells within different T-cell 
zones. The first direct contact between the two is established through epitope-presenting 
MHC-II of the B-cell and TCR of the primed cognate T-cell. The second contact, delivering 
another necessary signal for the B-cell activation, happens through CD40:CD40 ligand, the 
latter being expressed at the T-cell surface upon the TCR- B cell MHC-II contact. Finally, the 
last activation step is engaged, with T-cell producing specific cytokines (IL-4, TNF, IFN-Ȗ) in 
a polarized manner, exclusively at the site of TCR-MHC-II interaction (Figure 14). These 
cytokines bind to the appropriate receptors at the surface of the B cell and trigger the 
signaling cascade that creates a certain number of decisions within B-cell transcription 
networks: first one, expression of AID protein, and the second one, sterile transcription of the 
IgH constant region genes, µ and the one that B-cell is supposed to switch to and which is 
mostly appropriate to respond to the given antigen. After this triple embrace between B and 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Germinal center reaction in vivo and in schema. A) Micrograph of a secondary follicle 
within a lymph node with distinct germinal center histological zones and labeling of key cell 
populations. FDC: follicular dendritic cells, GC: germinal center, TBM: tingible body macrophages. 
Source: (Victora and Nussenzweig, 2012) 
B) Schematic overview of B-cell passage through germinal center. The “flow” of B-cells through 
germinal centeris never straightforward;  there are several rounds of proliferation and 
hypermutation, followed by FDC and follicular T cell-mediated selection before a B-cell which 
received all necessary survival signals is released. Here, no distinction between histological zones 
since proliferation seems to happen in both light and dark zone. Source: (Abbas, Abul K et al., 2010) 
A 
B 
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T-cell, B cells can form extrafollicular foci if they undergo immediate proliferation and IgM 
production. These extracellular foci can sometimes be observed alongside PALS in the
spleen. Some evidence exists that these cell can undergo an extrafollicular isotype switch 
(Shapiro-Shelef and Calame, 2005). Otherwise, an activated B-cell migrates into the follicle 
zone of the secondary lymphoid organ and engages itself into a germinal center reaction.
I.2.3d. The germinal center architecture and reaction
A germinal center is traditionally considered to be a de novo formed structure that 
welcomes activated B-cells. Instead, both B and T cells which recognize different epitopes 
physically linked within a present antigen colonize a primary follicle and transform it into a 
secondary follicle. Primary follicles already contain follicular dendritic cells, a special type of 
dendritic cells organizing future germinal centers, making up a network of their protrusions 
where naive B-cell of diverse BCR specificity are constantly moving. 
Activated B-cells that enter the primary follicle engage immediately into successive 
rounds of massive proliferation, pushing other naive B cells towards the follicle periphery, 
forming the follicular mantle. On the micrographs showing active germinal centers, one can 
separate two zones surrounded by the mantle: a dark zone and a light zone. Dark zone, closer 
to the T-cell zone, is formed of massively proliferating B-cells, while the impression of 
“light” texture of the light zone, situated towards the lymph node capsule or spleen marginal 
zone, is given by the mesh formed from the protrusions of follicular dendritic cells. For a long 
time, it was considered that a passage through the dark zone towards the light zone was 
unidirectional: however, this old model was revised after discovering that proliferation is 
ongoing in both zones (Gonzalez et al., 2011; Victora and Nussenzweig, 2012). Moreover, 
this anatomical separation fades as time goes by. GC B-cells acquire a phenotype distinct 
from naive B-cell: they express no more IgD but they express high levels of n-
glycolylneuraminic acid (which serves as a ligand for GL-7 antibody, the marker of activated 
T-cells as well), Fas receptor (CD95) and bind to peanut agglutinin (PNA). 
In germinal centers, the Burnet’s clonal selection theory comes clearly into light: 
during the heavy proliferation, the rearranged variable Ig genes acquire random mutations that 
will affect the affinity of GC B-cell BCR: modification can vary from slight to extreme, 
changing the BCR’s affinity for the better or for the worse. This process, termed somatic 
hypermutation, is the central subject of this work. 
After the first cycling round, B cells enter the competition for the intact antigens 
presented on the surface of follicular dendritic cells (Figure 15). Follicular dendritic cells are 
antigen-presenting cells that capture the antigen but not in the same manner as conventional, 
migratory dendritic cells: this GC-specific antigen, recognized by some pre-existing antibody, 
is enclosed within immune complexes-coated bodies or iccosomes, that persist on the surface 
of the FDC by being presented via complement and Fc receptors. These intact antigen 
  
Figure 16. The destiny of the immature cell from transitional to effector B-cells. ASC: antibody 
secreting cells; CSR – class switch recombination. Adapted from: (Pillai and Cariappa, 2009; Shapiro-
Shelef and Calame, 2005) 
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complexes can keep activating cognate B cells for much more than a week after 
administration, justifying their nomination for long-term antigen reservoirs.
The quantity of this presented antigen is limited, so the competition is once again 
ferocious: only the cells with marked increase in affinity against the cognate antigen will 
receive survival signals, potentially from follicular helper T-cells, which allows them to re-
enter cell cycle and try to modify the BCR of their progeny. This phenomenon in which the 
somatic hypermutation alternates with affinity-based selection in order to yield B-cells 
expressing a BCR with high affinity for the cognate antigen is named affinity 
maturation. Affinity maturation does not only allow the mutagenic shift (amino acid change 
in BCR peptide sequence, submitted to a further selection) but also a B-cell clone drift 
(change in the present germinal center B-cell repertoire by the outgrowth of previously poorly 
represented clones, which got selected and undergo further somatic hypermutation) (Berek 
and Milstein, 1987).
The B-cells bearing mutations that result in an incorrectly folded BCR, 
unchanged/weakened BCR affinity or rendered auto-reactive, will undergo immediate 
apoptosis, and their bodies will be cleared by tingible-body macrophages. In fact, it is 
considered that the default fate of the GC B-cell is to die by apoptosis, knowing that Fas is 
highly expressed on the surface and that the expression of anti-apoptotic genes like bcl-2 is 
turned off (Victora and Nussenzweig, 2012). If GC-B cells are placed in culture without any 
stimulation factors, they die within few hours. However, if a minimum of stimulation signals 
is provided, GC-B cells are capable to keep proliferating in culture for few more days.
After rounds of affinity-based selection, germinal center B cells can commit to several 
fates. One is becoming a plasma cell precursor, named plasmablast, that will have its 
transcription programs modified once again: proliferating cells cease to cycle, increase their 
endoplasmatic reticulum and Golgi aparatus to accommodate the incredible antibody 
production and become secreting plasma cells (Figure 16). These effector cells either stay 
within lymph nodes, small fraction of them migrates to the spleen and majority lodges in the 
bone marrow, constantly releasing highly specific antibodies in the bloodstream. Exhaustion 
of these cells’ endoplasmatic reticulum and emerging pro-apoptotic signals will make them 
undergo apoptosis in few days after the final differentiation step (~2 weeks from the infection
onset). However, some of these cells will manage to uncover a survival niches within bone 
marrow that will allow them to persist in secreting low levels of soluble antibodies (referred 
to as persistent antibody) into the bloodstream up to one year after infection (Radbruch et al., 
2006).
As we have already discussed, another modification of the GC B-cell transcription 
program turns them into memory B cells that keep exhibiting modified high-affinity BCR at 
the surface and keep patrolling down the bloodstream until the next encounter with the 
familiar antigen. A memory B cell is a true Methusalem among long-lived cell populations 
that is capable of spanning the individual’s lifetime. These cells remain quiescent and 
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continue to circulate or stay in the lymph node. Two layers of this memory response in mice 
are described in case of immunization with a particulate antigen: switched memory B-cell that 
differentiate immediately into plasmocytes and contribute to the immediate protection, and 
IgM+ memory B-cells that return to GC and undergo proliferation and class switch 
recombination in order to replenish the switched memory pool (Dogan et al., 2009).
  
Figure 17. Dynamics of the humoral immune response 
during the successive encounters with an antigen. 
Source: (Murphy et al., 2012) 
B 
Figure 18. Changes in amino acid 
variability in association with the 
affinity for the antigen. A) amino acid 
variability plots; B) Kd (dissociation 
constant of an antibody), the inverse 
measure of the antibody affinity, 
drops as B-cell accumulates mutations 
in both framework and CDR regions. 
These mutations are the subject of 
cell-based selection in germinal 
centers. CDR – complementarity 
determining region. Source: (Abbas, 
Abul K et al., 2010) 
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Chapter II: Somatic hypermutation, the real-time 
adaptive mutagenesis 
The clearest picture one can get about the advantages conferred by the secondary 
diversification of the immune repertoire is when studying successive immunizations. When an 
individual gets in contact with a never-seen-before pathogen (e.g. when a mouse is 
immunized for the first time), the primary immune response is triggered and activated B-cells 
secrete IgM starting from one week post-immunization. Only two weeks post-immunization 
do IgG antibodies barely attain the peak of maximal IgM concentration (Figure 17). However, 
secreted IgM antibodies are polyvalent and of low affinity for the given antigen, while IgG 
affinity for the eliciting antigen improves with time. The picture is radically different during 
the second antigen encounter: predominant antibodies in serum are switched IgG, IgA or IgE, 
depending on the antigen nature. Switched antibody titers peak colossally high and in much 
shorter time following the secondary immunization (less than a week). Switched antibodies 
improve their affinity in quicker pace than during the first immunization, and even more after 
a third immunization. This dynamics of humoral immunity beautifully illustrates all the 
differentiation stages of a mature B-cell, from activation to terminal differentiation: IgM 
secretion in extrafollicular foci, affinity maturation and class switching in a germinal center, 
differentiation towards plasma cell and memory cell, the “wake-up” call for memory B-cell 
with switched BCR upon secondary immunization.
For modifications affecting antibody affinity, the most concerned regions of the 
antibody molecule are the IgH and IgL hypervariable regions HV1, HV2 and HV3 
(respectively CDR1, CDR2 and CDR3, Figure 1C), with the last one having the largest 
amino-acid variability. If one looks at the genomic regions in hybridoma cells (fusions of a 
myeloma and GC B-cell clones) encompassing hypervariable regions and simultaneously 
measures antibody affinity at different time points (Berek and Milstein, 1987), one may 
observe a peculiar phenomenon presented in the Figure 18. Nucleotide substitutions (along
with infrequent, small insertions and deletions) accumulate with time after primary 
immunization, and even more after secondary and tertiary immune responses. Most mutations 
cluster in hypervariable regions (especially HV1), but a few of them occur in the V
framework as well. 
As a result of concomitant affinity-based selection and further mutagenesis of a 
selected BCR, a sharp decrease in the dissociation constant of the antibody is detected, 
reflecting the net increase of the antibody affinity. These mutagenic events underlying 
antibody affinity improvement following the clonal selection are named somatic 
hypermutation (SHM). 
The phenomenon is somatic since these mutations do not occur in the germ lines; 
mutations will die with the individual, but the somatic hypermutation retains characteristics of 
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Figure 19. Properties of somatic hypermutation : A) mutated regions in IgH locus (no SH or CH 
genes shown) ; B) mutation profile, with red letters indicating transitions ; C) graphical 
representation of pooled transitions or transversion per base ; D) relative frequency of individual 
mutations at A:T base pairs in coding strand; E) individual mutations at C:G base pairs as read off 
the coding strand.  Ts-transition, Tv: transversion, Pyr-pyrimidine, Pur-purine. TSS: transcription 
start site. Adapted from: (Di Noia and Neuberger, 2007) (Peled et al., 2008) 
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Darwinian evolution on a micro scale because the B-cell progeny inherits these mutations and 
undergoes further rounds of selection.
The prefix “hyper” comes from the fact that mutations occur every 1000 
basepairs/cell/division, which is 10
6
times higher than the frequency of spontaneous 
mutagenesis in the genome. In the classical turnover of hypermutating B-cells in germinal 
center, this means that every B–cell survivor leaves the germinal center with up to 10-15
mutations in V-regions and about 2-3 amino-acid substitutions (per each replacement 
mutation, three or four silent mutations are acquired) (Honjo and Alt, 1995), mostly targeted 
to the hypervariable regions. Deleterious mutations in form of stop codons or mutations that 
impair antibody folding do occur, but requirement for constant BCR expression and signaling  
in the competitive environment of the germinal center allows them to be purged from the V 
sequence . 
II. 1 Somatic hypermutation span and major properties 
Once regions beyond V-exon and V(D)J junctions in hybridomas became accessible 
by DNA sequencing, the entire span of somatic hypermutation could be appreciated (Figure
19) It appeared that mutations start to accumulate at a sharp boundary 150 bp downstream of 
the promoter of the rearranged V exon, around the transcription start site (TSS). They peak at 
the level of the V(D)J region and gradually drop down in frequency some 1-2 kb downstream 
of the TSS, becoming undetectable in the 3' enhancer region. A second wave of mutation is 
observed downstream of the IH promoters, extending within the switch region. However, 
mutations are never detected in Cµ genes and rarely in CȜ(Honjo and Alt, 1995).
Mutations in parts coding for variable regions are highly biased after rounds of 
affinity-based selection, but mutations in regions that are not subjected to selection (J intron, 
S regions, passenger transgenes) offer the less skewed mutation pattern of somatic 
hypermutation but are not totally exempt of other influences (proximity of the control regions, 
base composition). The major properties of somatic hypermutation are the following: x In activated GC B-cells, all four bases are mutated. A is the most mutated base, 
followed by G, C and the least mutating T;x A and T basepairs grouped together (A:T) mutate at the same rate as G and C basepairs 
together (G:C);x as recorded from the non-transcribed strand (referred to also as top strand or coding
strand) G mutates equally as cytidines, but between A:T basepairs a particular bias is 
observed since mutations seem to occur twice more often at A than at T positions ;x concerning different types of mutation, the overall SHM pattern is biased for transition 
mutations (purine to purine or pyrimidine to pyrimidine) at all base positions. 
 Figure 20. Widely adopted model of somatic hypermutation in Ig genes, consisting of initiation phase 
in which AID deaminates cytosines, and resolving phase where uracil is handled by mutagenic 
pathways, giving rise to the mitations at all four bases. AID: activation-induced deaminase, UNG: 
uracil-N-glycosylase, WŽůɸ͕WŽůɷ͗ƌĞƉůŝĐĂƚŝǀĞƉŽůǇŵĞƌĂƐĞƐ͖DƐŚϲ-DƐŚϮ͗ŵŝƐŵĂƚĐŚƌĞƉĂŝƌƐĞŶƐŽƌ
ĐŽŵƉůĞǆ͖WŽůɻ͗ŵĂŝŶ͗dŵƵƚĂƚŽƌĂŶĚƚƌĂŶƐůĞƐŝŽŶĂůƉŽůǇŵĞƌĂƐĞ͘ 
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x Transitions represent a little more than half of total mutations, while randomly they 
should occur in only one third of the cases (4 transition types versus 8 transversion 
mutation types;x mutations tend to concentrate within mutational hotspots; many of G:C mutations in 
vivo occur in WRCY and RGYW motifs (R for purine, Y for pyrimidine, W for 
“weakly” paired bases A or T, underlined base being mutated) (Rogozin and 
Kolchanov, 1992) while A:T mutations arise in WA and to a lower extent at TW motif 
(Rogozin et al., 2001). However, one thing to keep in mind is that mutations are never 
strictly confined to these hotspots, nor do all hotspot consensus sequences in IgV 
region accumulate mutations;x transcription is necessary for somatic hypermutation of IgV genes, and the rate of 
transcription correlates to the rate of mutation (Peters and Storb, 1996).
Since the experimental confirmation of Lederberg’s proposition on mutating 
mechanisms enhancing the best antibody-antigen fit (McKean et al., 1984), somatic 
hypermutation has for a long time remained an intriguing phenomenon since the factors 
responsible for the introduction of mutations had given much trouble to researchers in quest to 
identify them. The ultimate mutator protein that initiates the whole process was long sought 
for until the landmark 1999 paper of Tasuku Honjo's group (Muramatsu et al., 1999)
introduced activation-induced cytidine deaminase (AID) on the scene and forever changed the 
landscape of research on somatic hypermutation. 
II.2. Current model of molecular mechanisms underlying 
somatic hypermutation 
Even back at the time when the Ig gene mutator or recombinase was still unknown, the 
following steps were agreed upon as indispensable for the somatic hypermutation to proceed 
(Figure 20):x the initial entry in one of DNA strands: on the basis of widely adopted models in the 
scientific community, a cytidine deaminating enzyme AID introduces uracils along the 
region that is subject to hypermutation in Ig genes. Uracil in DNA is a frequent product 
of spontaneous deaminations and as such is quickly treated by classical repair 
pathways, but these pathways are somewhat subverted from their role in high-fidelity 
repair when recruited onto Ig genes during somatic hypermutation;x a subsequent spreading of mutations on the surrounding bases: studies on knock-
out mice suggest that uracil recognition happens the same way as in canonical error-
free pathways. The base excision repair component uracil-N-glycosylase (UNG) 
recognizes and cuts off the uracil base, leaving abasic site (AP site) behind. Mismatch 
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x repair pathway recognizes the uracil within the U:G mismatch and proceeds in 
degrading the DNA surrounding the lesion. Both pathways rely on the special class of 
highly error-prone translesional polymerases to either restart the replication fork that 
stalled opposite the abasic site, or to fill in the gap after strand degradation. These 
polymerases have the intrinsic ability to misincorporate when facing certain template 
nucleotides. The joint action of these mutagenic repair pathways along with 
translesional polymerase recruitment accounts for mutations on all four template 
bases, even though the entry was initially made through cytosine only.
II.3. Initiating phase: AID as a mutator 
The milestone paper of (Brenner and Milstein, 1966) predicted a “restriction enzyme”  
that made its way in DNA and allowed for a single-strand patch degradation and error-prone 
gap filling by some polymerase lacking proofreading qualities. Usual suspects, the proteins 
known to incise DNA like RAG1 (Zheng et al., 1998) were checked for their participation, 
but none of them seemed to contribute to the process.
In 1999 in Honjo's lab, Muramatsu identified a novel B-cell protein based on the 
subtractive hybridization of transcriptional programs between a resting B-lymphoma cell line 
and the same line induced to undergo isotype switching (Muramatsu et al., 1999). This new 
24-kDa protein belonged to a APOBEC family (ApoB mRNA editing component) of RNA 
deaminases, whose member APOBEC1 in vertebrates was known to deaminate cytidines 
within the RNA transcript of apolipoprotein B, a component of low-density lipoprotein 
(Davidson and Shelness, 2000). By changing C to U in this RNA, a premature stop codon was 
created and allowed for translation of a shorter apolipoprotein B isoform. This newbee 
APOBEC member, dubbed activation-induced cytidine deaminase (AID) was shown shortly 
after to be indispensable for somatic hypermutation and class-switch recombination due to the 
complete impairment of these processes in AID-deficient mice (Muramatsu et al., 2000), as 
well as by the discovery of human AID deficiency in sufferers of hyper-IgM syndrome 
variant (Revy et al., 2000). The SHM mutator protein was finally unveiled.
II.3.1 Biochemical properties of AID activity 
AID possesses a unique enzymatic activity in vertebrates since so far known cytidine 
deaminations in DNA happen either spontaneously or induced by chemical reagents (nitrosic 
acid, bisulfite). AID shares cytidine deaminase active domain with members of APOBEC 
family and with other bacterial cytidine deaminases acting on free cytosines (Neuberger et al., 
2003). Different AID deletion mutants allowed for dissection of a C-terminal domain which is 
indispensable for class switch recombination and an amino-terminal domain responsible for 
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SHM and gene conversion, another Ig gene diversification mechanism (Barreto et al., 2003; 
Shinkura et al., 2004) (Chapter II.6). Therefore, two functions are physically unliked in AID 
protein and their respective deletion mutants do not influence the other diversification process 
(Shinkura et al., 2004). CSR-inducing domain overlaps with the specific AID nuclear export 
sequence and intimately links AID’s capacity to perform class switch with AID shuttling 
capacity (Geisberger et al., 2009).
According to the latest consensus, AID deaminates cytidines within DNA. Several 
pieces of evidence account for this specific enzymatic activity within a family of RNA 
deaminases, since:x AID was found to mutate endogenous genes and episomal substrates when expressed in 
bacteria (Petersen-Mahrt et al., 2002) and endogenous V-regions in hybridoma 
transfected with AID-encoding vectors (Martin et al., 2002);x AID was found localized in chromatin of SH regions when assaying for class switch 
recombination in cells, and these regions do not exist in mature RNA (Ranjit et al., 
2011);x in vitro, AID binds and mutates single stranded DNA but never dsDNA or RNA-DNA 
hybrids (Bransteitter et al., 2003; Dickerson et al., 2003; Pham et al., 2003);x in vitro AID mutation pattern was soon confirmed by mutation profiling of Ung-/-Msh2-
/-
mice lacking all mutagenic pathways that further diversify AID-generated uracil 
(Rada et al., 2002a). The Ig genes of these mice allow the analysis of in vivo AID 
footprint, which matches perfectly RGYW/WRCY focusing in somatic hypermutation 
hotspots in vivo.
One should also mention that, if Apobec-1 was the only known member of the family 
at the time of AID discovery, the eventual characterization of Apobec-3 genes, which are 
markedly expanded in primates and are all DNA-based cytidine deaminases, and the later 
appearance of Apobec-1 in evolution compared to other members of the family, has turned 
the activity of Apobec-1 into the exception and not the rule (Conticello et al., 2007).
II.3.2. AID expression is induced upon B-cell activation and 
controlled at post-transcriptional level 
The limiting factor for SHM and CSR to occur is the AID expression level. 
Consequently, both processes can be regulated by fine-tuning of AID expression or AID 
activity at multiple levels. It is always the story about being 1) at the right place on the 
genomic level (Ig locus with all issues on SHM/CSR targeting, Chapter II.5) as well as at the 
cellular level (nucleus where AID catalyzes versus cytoplasm where it is more stable but 
inoperative); 2) at the right time (AID expression is under transcriptional repression outside 
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of activated B cell status; 3) at the right amount, not too little (appropriate transcriptional
activation, post-translational modification that enhances SHM and CSR targeting) but not too 
much either, for the consequences can be pathological (post-transcriptional regulation).      
Mouse Aicda gene is localized on chromosome 6 and encodes for 5 exons, all of them 
included in the mature RNA transcript. In humans, four regions were identified to govern 
hAicda locus expression (Tran et al., 2010): region 1 contains immediate upstream core 
promoter, region 2, which is identified within first hAicda intron, contains binding sites for 
Myb and E21 transcriptional inhibitors but also a B-cell transcriptional activator Pax5-binding 
site. In non-activated B-cells, these two regions recruit factors that act in convergent manner 
to maintain AID expression at extremely low basal level. Only upon B-cell activation, T-cell 
secreted cytokines (IL-4, TNFȕ, interferon-Ȗ) induce a signaling cascade that allows for 
expression and binding of transcriptional activators Stat6, NFțB and C/EBP to the sites in the 
enhancer region 4, localized 7 kb upstream of Aicda transcription start site. No known 
transcription factor binding sites were identified within region 3, localized in the 3’ 
untranslated region.
Therefore, AID is expressed at the adequate levels for somatic hypermutation and
isotype switching only in activated mature B-cells. It is detected at 10-fold lower levels in 
normal mouse embryonic stem cells and primordial and mature germinal cells where it has 
been proposed to participate in modifying DNA methylation patterns (Fritz and Papavasiliou, 
2010; Wu and Zhang, 2010).
Aicda transcripts possess miRNA-binding sites within 3’ untranslated region that 
allows binding of miRNA-151 and miRNA181b. Binding of the first miRNA is known to be 
upregulated in class switch recombination (Dorsett et al., 2008; Teng et al., 2008) and 
probably contributes to the AID level decrease in post-germinal center reactions, preventing 
the unneeded AID from further accumulating in the cell and inflicting genomic damage. 
Expression of the 181b miRNA was downregulated in CSR in vitro, potentially allowing for 
AID amounts to reach a peak when it is necessary for CSR to occur (de Yébenes et al., 2008).
II.3.3. AID activity is modulated by protein localization, stability 
and post-translational modifications 
AID is considered to be small enough to passively diffuse through nuclear pore 
complex, but this could never be observed (McBride et al., 2004). It was generally thought 
that AID actively shuttles between nucleus and cytoplasm, since it is predominantly 
cytoplasmic in lymphocyte B-cell lines (Aoufouchi et al., 2008a; Patenaude et al., 2009; Rada 
et al., 2002b). However, this view is being questioned after a correlation was proposed 
between AID localization in the DT40 cell line and the cell cycle status of DT40 (Ordinario et 
al., 2009).
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Several mechanisms contribute to AID localization in the cytoplasm:x active CRM-1 mediated export using nuclear export sequence in AID C-
terminus (McBride et al., 2004);x active nuclear import via yet unidentified import factors (karyopherin-Į
importin, CTNNBL1, GANP) using a putative conformational nuclear localization 
sequence within AID (Patenaude et al., 2009);x cytoplasmic retention by sequestering AID in cytoplasmic complex with EF1Į
(Häsler et al., 2011; Patenaude et al., 2009).
The equilibrium of these three DNA localization mechanisms regulates the level of 
operative AID. This level can be maintained constant, or it can be further modulated to 
increase the AID level for the purposes of diversification downstream of some signaling event 
or depending on the cell cycle.
Furthermore, the AID protein is stabilized upon leaving ER by being funneled from 
DnaJa1-Hsp40 complex (Orthwein et al., 2012) into a complex with Hsp90. The latter AID 
partner permanently checks for any misfolding, correcting it by ATP-hydrolysis and 
protecting AID from proteasomal degradation in cytoplasm (Orthwein et al., 2010). However, 
AID is found to have shorter half-life in nucleus than in cytoplasm due to nuclear proteasomal 
degradation, mediated by both ubiquitin-independent pathway (Uchimura et al., 2011) and 
ubiquitination-dependent mechanism (Aoufouchi et al., 2008a). Therefore, modulating AID 
stability is another way of controlling AID levels in hypermutating cells.
Several phosphorylation sites were identified, but currently only S38, the 
phosphorylation target of protein kinase A (Basu et al., 2005) was found to associate with 
RPA protein (Chaudhuri et al., 2004; McBride et al., 2008). This phosphorylated AID-RPA 
association upregulates CSR and SHM and accounts for AID targeting to Ig variable genes 
(see further). The function in vivo of of other AID phosphoforms awaits further 
characterization. 
II.4.  Resolving phase: mutagenic repair pathways are not just 
another oxymoron  
After spontaneous or chemically induced deamination of a cytidine, the resulting uracil 
within DNA will not impede normal processes of replication or transcription. If uracil is left 
intact at the deamination site, replicative polymerases will elongate opposite to the uracil base 
without stalling and give rise to G:C transition mutations in newly synthesized DNA
molecules (C ĺ T and G ĺ A). However, due to its premutagenic potential, uracil in DNA is 
efficiently removed by two DNA repair processes: base-excision repair (BER) and mismatch 
repair (MMR). Some 100-200 uracils that are generated per day in the human 
 Steps in repair BER MMR factors...... ....in complexes: 
Removal of.... 
spontaneous deaminations and 
dUTP incorporations   
mismatches and replication 
slipping errors 
Damage 
recognition  
UDGs: UNG 1 and 2, 
 TDG, SMUG, MBD4 
MSH2 -MSH6 DƵƚ^ɲ 
MSH2 -MSH3 DƵƚ^ɴ 
Entry into DNA APE1 : 5’ endonuclease 
PMS2 -MLH1 DƵƚ>ɲ 
PMS1 -MLH1 (?) DƵƚ>ɴ 
Handling the 
neighbouring 
DNA 
long patch short patch:1bp 
EXO-1: 5’ї3’ activity 
FEN1/DNaseIV WŽůɴĂƐĚZWĂƐĞ 
Gap filling WEнWŽůɴ WŽůɴ WEнWŽůɷ 
Ligation lig 3/XRCC1 ligase 1 ligase 1 
Table T1. A summary of conventional base-excision repair and mismatch repair. 
Figure 21. Schematic representation of base-excision repair (BER) pathway. 
The lesion recognition step and entry into DNA are common for two branches of BER pathway : one 
of uracil glycosylases recognizes the uracil base and excises the N-glycosyl bond, leaving an abasic 
site. APE-1 endonuclease excises the phosphodiester bond at 5’ of the abasic site, while in short-
patch BER repair polymerase ɴ removes the remaining deoxyribose-phosphate and fills the one 
nucleotide gap by inserting the correct one. LIG3/XRCC1 complex proceed to ligation. In case of an 
altered abasic sites difficult for deoxyribose-phosphate elimination by polymerase ɴ, PCNA is 
recruited to the site and allows for 2-13 nucleotide-long patch synthesis by polymerase ɴ. The 
existing strand is displaced and progressively degraded by exonuclease complex FEN1/DNaseIV. 
Patch is finally religated by ligase 1. Source: (Wilson and Bohr, 2007) 
APE-1: apurinic/apyrimidinic endonculease 1; XRCC1: x-ray cross-complementing protein 1; 
PCNA: proliferating cell nuclear antigen ; FEN1: flap endonuclease. 
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genome (Kavli et al., 2007; Lindahl, 1982) are thus repaired quickly and in an error-free 
manner. These repair processes appear partially modified in somatic hypermutation: uracils 
administered by AID are undoubtedly being recognized the way they are used to. 
Nevertheless, not only a fraction of them escapes and keeps on being fixed, but the outcomes 
of uracil handling get more diversified, with even more mutations introduced in the flanking 
sequence. How do C:G transversions and surrounding A:T mutations occur in the 
hypermutating region?
II.4.1. Canonical repair pathways 
BER- and MMR-implicated enzymes remained the all-time favorites in deciphering 
the somatic hypermutation puzzle, so a brief overview of each repair mechanism is given in 
captions of Figures 21 and 22. Both pathways follow the canonical workflow when facing a 
DNA damage that they are specialized for (Table T1):x damage recognition or modification that makes it more convenient to handle; x entry in the DNA strand containing the damage after ensuring which one of the two is 
the damaged one;x removal or displacement of neighboring DNA segment;x gap filling by a high-fidelity DNA polymerase;x ligation of the synthesized patch and the old DNA sequence.
Different UDG glycosylases. Most frequent lesions that can be easily removed by 
short-patch conventional BER are hydrolytic depurinations (leaving an apurinic site), 
spontaneous deaminations with a strong premutagenic potential (cytosine deamination 
generating uracil, 5-methyl cytosine deamination generating thymidine, etc.) and dUTP 
misincorporation by replicative polymerases when facing template A.  Different uracil DNA 
glycosylases (UDGs), like UNG (uracil-N-glycosylase) 1 which is mitochondrial, UNG2, 
which is nuclear, and SMUG (single-strand selective monofunctional uracil-DNA 
glycosylase) traditionally attack uracil in DNA. Thymidine opposite to G (T:G) and less 
frequently uracil facing G (U:G) can be as well recognized by thymine DNA glycosylase 
(TDG) and methyl-CpG binding domain protein (MBD-4). All uracil DNA glycosylases leave 
an abasic site (AP site) as the common intermediate after deglycosylation. However, 
requirements for substrate configuration and limiting steps are not the same among 
glycosylases: UNG2 (called UNG for the sake of simplicity in further text) can attack uracil 
in both single and double stranded form, whereas TDG needs to make sure that T is mispaired 
with G in the other strand before proceeding to base excision. 
Strand discrimination in canonical mismatch repair. In contrast to uracil DNA 
glycosylases that tightly fit uracil/thymidine within their active site, the mismatch recognition 
component MutSĮ is capable of identifying a non-Watson-Crick pairing geometry within a 
DNA heteroduplex. However, since mismatch repair identifies mispaired bases that are not 
 Figure 22.   Model for eukaryote mismatch repair mechanism (MMR). 
Mismatch repair recognizes typical post-replicative errors like small deletion/insertion loops 
due to polymerase slippage or single nucleotide misincorporations. MutSɲ heterodimer 
(MSH2 and MSH6 for MutS homologs) recognizes the mismatch englobed in double-
stranded DNA and recruits MutLɲ heterodimer (composed of MutL homolog MLH1 and 
post-meiotic segregation increased PMS2). The latter complex scans for clues that indicate 
which strand is newly synthesized and therefore carrying the replication error. Once 
established, exonuclease Exo1 makes its entry and degrades the DNA strand comprising the 
error, while the single stranded DNA is protected by RPA proteins. PCNA clamp loaded onto 
the free 3’ end of the degraded strand recruits Pol ɷ in order to fill the gap in error-free 
manner. Lig1 seals the remaining nick after gap filling.  MutSɴ is another mismatch 
recognition complex (composed of MSH2 and MSH3) which recognizes insertion/deletion 
loops of more than two nucleotides and whose resolution converges with MutSɲ towards 
MutLɲ intervention. However, another secondary mismatch complex MutLɶ is recently 
identified, comprising MLH1 and MLH3, and is known to participate in meiotic 
recombination or as a MutLɲ backup. A third resolving mismatch complex MutLɴ is 
composed of MLH1 and PMS1 whose function is yet to be identified. Source : (Martin and 
Scharff, 2002) 
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unusual in DNA, the problem of identifying which base of the mismatch is wrong requires 
some additional information. Mismatch repair is considered to be a post-replicative 
mechanism, therefore the wrong base in the mismatch is probably the one which got 
misinserted by replicative polymerases. Dilemma of newly synthesized strand in bacteria is 
solved by MutH, the sole mismatch repair factor with no homologues in yeast or humans. 
Indeed, due to a small time window between completion of DNA synthesis and methylation 
of adenines in newly synthesized DNA strand in bacteria, MutH has enough time to detect 
and nick the transiently unmethylated strand on either side of the mismatch (Kunkel and Erie, 
2005; Längle-Rouault et al., 1987). However, in the absence of adenine methylation in 
eukaryotes, it is thought that early interaction of MutLĮ and PCNA localized at the nearby 3’ 
end of the priming strand may help the strand identification (Lindahl et al., 1997; Shibahara 
and Stillman, 1999; Umar et al., 1996). Knowing that a canonical mismatch repair acts on 
post-replicative errors, the second proposition is that MutLĮ complex takes advantage of 
detecting the free 3’ end of leading strand or 3’ or 5’ termini of freshly synthesized Okazaki 
fragments to  “sense” on which strand the replication is still ongoing (Holmes et al., 1990; 
Lacks et al., 1982). However, the 3’ end of a discontinued strand can be quite far away; 
furthermore, the 3’ end can be located on the 3’ side of the mismatch, meaning that EXO-1
5’-3’ degradation will proceed away from the mismatch. Recently, a third source of single 
strand nicks has been identified: once a remote 3’ free end is detected, nicks can be 
administered in the vicinity of the mismatch (and also at its 5’ side) by the PMS2 protein, 
which possesses a cryptic endonuclease activity (Kadyrov et al., 2006, 2007).
A new controversial issue emerged with a recent study on EXO-1 separation-of-
function mutant (Schaetzlein et al., 2013) showing that the exonuclease activity of this 
enzyme is dispensable for canonical in vivo mismatch repair, meiosis, somatic hypermutation 
and class switch recombination; the only process that was downregulated in presence of this 
EXO1 mutant was double strand break repair. Therefore, it seems that only the structural 
function of EXO-1 is indispensable in somatic hypermutation, while some other exonuclease 
can be recruited as backup to create the gap. 
II.4.2. Translesional polymerases 
DNA damage usually hampers vital processes carried on during the cell cycle like 
replication, induces signal transduction at cell cycle checkpoints and arrests further progress 
through phases. Depending on the environmental cues and the overall condition of the cell, 
DNA damage can be tackled in two ways. It can be efficiently repaired error-free via classical 
multiprotein repair pathways. However, if damage is neglected until S-phase or inflicted in 
the course of replication, it can hamper the progression of the replication fork. If the stalling 
goes on for a while, replicative machinery can disassemble and both double strand breaks and 
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Error rate 
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d DNA 
SHM phenotype 
in single KO mice 
Y Rev1 REV1 
N
2
-G adducts; 
AP site 
dCTP 
transferase; 
catalytic function 
dispensable 
 10
-2
-10
-3
 
decreased G:C Tv 
(Jansen et al., 
2006) 
B Pol ɺ REV3  
(POL Z) 
all damages will 
do 
Most frequent 
extender 
 10
-4
 
embryonic lethal 
(Bemark et al., 
2000; Esposito et 
al., 2000a) 
Y Pol ɻ RAD30 
(POLH) 
CPD  
8-oxoG ; 
G-cysplatin-G 
accommodates 
base dimers in 
the active site 
No 10
-2
-10
-3
 
decreased A:T 
(Delbos et al., 
2005; Martomo 
et al., 2005) 
Y Pol ɿ RAD30B 
(POLI) 
ɶHOPdG; 
8-oxoG ; 
AP sites 
Hoogsteen base-
pairing favored; 
inserts G facing 
T; 
dRP lyase 
No 10
-1
-10
-5
 
no change 
(Delbos et al., 
2005) 
Y Pol ʃ DINB  
(POLK) 
N
2
-G adducts; 
ɶHOPdG 
Extender; 
introduces -1 
frameshifts 
No 10
-3
-10
-4
 
no change 
(Schenten et al., 
2002) 
A Pol ɽ POLQ AP sites 
DNA-dependent 
ATPase; 
dRP lyase 
 10
-2
-10
-3
 controversial 
Table T2.  DNA polymerases participating/proposed to participate in somatic hypermutation.  
For comparison, fidelity of replicative polymerase with proofreading activity is 10
-6
-10
-7
; when 
replicases lack proofreading activity: 10
-4
-10
-5
. 
Abbreviations: G- guanin; C-cytosin; T-thymine; AP sites – apurinic/apyrimidinic sites; ex. CPD – 
cyclobutan photoproducts; T^T – thymine dimers; G-cysplatin-G : intrastrand cross-linkage by 
cysplatin; dRP lyase – deoxyribose-phosphate lyase; ɶHOPdG –ɶ-hydroxy-1, N2-propano-
2’deoxyguanosine; TLS – translesion synthesis; Tv-transversions; Ts –transitions. Data pooled 
from(Casali et al., 2006; Foti and Walker, 2010; Goodman, 2002; Kunkel, 2003; Prakash et al., 2005; 
Weill and Reynaud, 2008) 
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chromosome translocations can be generated. Two options remain in a cellular decision-
making scheme: either triggering apoptosis or inducing damage tolerance. The latter one was 
shown to be preferred over apoptosis even in highly developed eukaryotes. Damage tolerance 
is represented by two mechanisms, DNA lesion bypass and template switching. Not many 
details are available on template switching; it is generally considered as an error-free process 
that borrows the other newly synthesized daughter strand from in order to allow the 
replication fork to skip the blocking lesion. Lesion bypass can be also mediated by 
translesional DNA polymerases that are shown to be more error-prone than replicative 
polymerases. Once the lesion site bypassed by TLS polymerases, replication fork can resume 
and initial DNA damage can be further ignored but at the cost of introducing new potentially 
harmful mutation. DNA damage tolerance remains a risky interplay of odds for survival by 
successfully completing the cell cycle and for permanently altering an essential cell function. 
II.4.2a. Properties of translesional DNA polymerases
Translesional polymerases, grouped according to their cellular function, belong to 
distinct DNA polymerases families regarding their structure or fidelity. Rev1, Pol Ș, Pol ț and 
Pol Ț belong to Y-family polymerases, Pol ȗ belongs to B-family polymerases and Pol ș is 
among A-family polymerases. A summary of each polymerase classification, substrate 
specificity, associated activity and fidelity can be found in Table T2. We shall limit our 
introduction only to translesional polymerases that are confirmed or suspected to participate 
in somatic hypermutation, therefore we will left out Pol ȝ and Ȝ in spite of the important place 
they occupy in other diversification processes in B-cells.
Y-family polymerases. A boom in unraveling diverse members of Y-family
polymerases occurred around 1999, quite some time after the two first member had been 
described, Umu complex (for UV-mutagenesis or Pol V) in bacteria and REV1 (reversionless 
locus) in S. cerevisiae. UmuD’C complex is responsible for SOS-bypass reaction in bacteria 
in response to UV mutagenesis or specific chemical treatments (Radman, 1974). However, 
eukaryotic polymerases have gone long way from Pol V and adapted to the specific but 
diverse roles in lesion bypass, with a common trait of being rather error-free when facing a 
cognate DNA damage subset.  However, many of them remain error-prone when copying 
undamaged DNA, in vitro and in vivo.
PCNA (proliferating cell nuclear antigen) sliding clamp remains the principal docking 
platform for various TLS polymerases and provides for “polymerase switch” at the site of 
stalled replication fork by replacing a replicative with a translesional polymerase, and 
inversely when the fork is about to resume; 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
Figure 23.  Structural properties of Y-family polymerases. 
A) Schematic representation of different functional domains. The color code of the boxes 
corresponds to the domains shown in B. DinB, Dpo4, UmuC: bacterial Y-family polymerases. 
B) Crystal structure of the human Y-ĨĂŵŝůǇEƉŽůǇŵĞƌĂƐĞWŽůɻŝŶĂƚĞƌŶĂƌǇĐŽŵƉůĞǆǁŝƚŚĂ
cyclobutane pyrimidine dimer (CPD). The template strand is shown in rust colour, and the 
primer is olive green. The incoming dNTP is shown in yellow. The burgundy stick represents 
the position of the CPD. The small blue spheres represent the metal ions. The protein 
backbone is represented by ribbon surrounded by semi-transparent solvent accessible 
surface.  Source: (Sale et al., 2012; Yang and Woodgate, 2007) 
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In spite of the reputation of being functionally divergent, Y-family polymerases share 
some general structural features:x N-terminal 350-450 amino acids are well conserved since they shape the catalytic core. 
These residues are structured as to resemble a right hand: a palm, finger and a thumb 
(Figure 23). With finger and thumb smaller and stubbier than in replicative 
polymerases, the active site is much more solvent exposed and less constrained to 
Watson-Crick base pair geometry, hence more spacious. This allows for 
accommodation of bulky base adducts and crosslinks that would otherwise discourage 
replicative polymerases; however, a trade-off against this unusual catalytic site 
architecture is the smaller processivity and decreased fidelity of Y-family polymerases. x C-terminal appendage is somewhat less conserved, and contains little finger domain 
(LF), polymerase-associated domain (PAD) that provides for contact among 
polymerases (discussed further), PIP boxes in some polymerases (PCNA-interacting 
peptide) allowing for the interaction with PCNA, UBM (ubiquitin-binding motifs) or 
UBZ (ubiquitin-binding Zn finger) that account for the specific interaction with K164 
monoubiquitinylated PCNA. By contrast, the BRCT domain in REV1 N-terminus is 
the one responsible for PCNA binding. x Little finger domain is the unique feature of Y- family polymerases; it contributes the 
most to the specificity of each Y polymerase, adopting different configurations when 
accommodating the most suited substrate for the catalytic activity of a given 
polymerase;x none of the Y-family polymerases possesses the proofreading 3’ĺ¶ H[RQXFOHDVH
activity;x among Y-polymerases, a task repartition when bypassing some of the lesions can be 
discerned: one polymerase is especially adept at incorporating an appropriate 
nucleotide opposite to the DNA damage (inserter), but another polymerase carries out 
the extension step from the unusual base pair (extender). When a DNA is not way too 
much distorted from Watson-Crick geometry after the insertion step, the same 
polymerase can carry out extension (Pol Ș, Pol Ț, Rev1). Other Y-polymerases are 
almost or exclusively extenders (Pol ț) or require the extender activity of a polymerase 
from other family, like Pol ȗ.
Other SHM candidates outside of Y-family. Pol ȗ (zeta) is a B-family polymerase 
composed of two subunits, Rev3, the catalytic subunit and Rev7, the regulatory subunit. 
Many biochemical studies on this polymerase were done with the yeast enzyme since the 
cloning of the mammalian Rev3 was particularly tricky due to the its size. In yeast, Pol ȗ is 
extremely inefficient in incorporating nucleotides opposite many lesions (except for 
thymidine dimers), but it turned out to be a perfect extender.
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This was the unique case among TLS polymerases whose knockout in mice was not 
viable.  Ever since, many models of REV3 downregulation were tested: Burkitt lymphoma 
cells BL2 knockout for REV3 had increased UV sensitivity and were delayed at S/G2 
transition; Rev3
-/-
mouse embryonic fibroblasts barely divided; mice with Rev3 knockdown 
were healthy, with fewer B-cells in the spleen, weakened antibody affinity upon 
immunization and less mutation in IgVH genes of memory B-cell, but the mutation pattern 
was unchanged from normal . Conditional knock-out in B-cells, in contrast to the last study, 
showed no impact on SHM, but a decreased CSR efficiency, increased chromosomal 
instability and impaired proliferation capacity (Schenten et al., 2009).
Pol ș (theta) conserves high domain homology with other members of the A-family 
polymerases; however, its fidelity is much lower. It is a preferential A inserter and is known 
for robust performance in bypass of an abasic site. Contrasting results on SHM participation 
were reported by three different teams. On the basis of the work performed by the team of P. 
Gearhart, it seems nevertheless safe to conclude that the contribution of Pol ș is minor, if any 
(Martomo et al., 2008; Masuda et al., 2006; Zan et al., 2005)
II.4.2b. PCNA: replication and repair tool belt
In eukaryotes, PCNA is a homotrimer loaded onto the DNA template-primer end 
junction by replication factor C (RFC) and in itself has no enzymatic activity, but it slides 
along the DNA axis and recruits partners by protein-protein interactions. However, its most 
important function is to help the loading of DNA replicative polymerases and enhance their 
processivity.  Most PCNA partners, among them replicative polymerases, bind PCNA via a
PCNA-binding peptide (PIP) domain. By so doing, PCNA maintains its role of “replication 
traffic cop” or “matchmaker protein” even in translesion bypass. When the replication 
machinery assembled around PCNA stalls at a DNA lesion, an event cascade is initiated via
the Rad6/Rad18 complex in order to monoubiquitinylate PCNA at conserved Lys 164 residue 
(Hoege et al., 2002). This modification is considered to weaken PCNA-replicative 
polymerases interaction and favor high affinity binding of translesional polymerases to PCNA 
via their PIP boxes and ubiquitin-binding domain/Zn motifs. The event order in reverse 
polymerase switch remains speculative: PCNA can get deubiquitinated or polyubiquitinated at 
the same residue but via non-canonical K63 intra-Ub linking (considered to entail error-free 
template switching mechanism) or translesional polymerases in their turn can undergo 
ubiquitinylation and dissociate away from the clamp.
Another role of PCNA comes from its polarity when getting loaded onto the template-
primer 3’ end in replication: namely, RFC loads it always with PCNA’s so-called C-side (side 
with protruding C-termini from homotrimers) orientated towards the 3’ end. This C-side 
contains the hydrophobic pocket that accommodates different PIP boxes of PCNA partners, 
replicative polymerases included. This polarized orientation with PCNA C-side always facing 
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the 3’ growing end of nascent DNA strand is thought to contribute to strand discrimination 
during mismatch repair. This explains early recruitment of PCNA during mismatch 
recognition outside of its “coordinator” function during gap filling with error-free 
polymerases.
Lastly, PCNA was shown to interfere when the mismatch repair detects a 3’ free end 
situated 3’ of the mismatch, therefore risking the degradation of the right strand but in the 
wrong direction due to EXO1 5’ĺ¶ RULHQWDWHG DFWLYLW\ 7RJHWKHU ZLWK 5)& DQG PD\EH
dependent of the mismatch “nature”, PCNA is shown to activate PMS2 cryptic endonuclease 
function that will allow for the novel incision at the 5’ end of the mismatch and the entry of 
EXO1 (Kadyrov et al., 2006).
II.4.2c. Polymerase eta in the spotlight 
Pol Ș was already known in S. cerevisiae as RAD30 gene product at the time when a 
study of human Pol Ș deficiency in xeroderma pigmentosum variant (XPV) patients appeared. 
These patients were extremely sensitive to sunlight (Johnson et al., 1999; Masutani et al., 
1999). These two works provided the first clear demonstration of the eukaryotic cell 
preference for lesion bypass over apoptosis. Cyclo-butane pyrimidine dimer (CPDs) is a UV 
lesion shown to be difficult to resolve by nucleotide-excision repair. However, Pol Ș was 
shown to readily insert two adenines opposite thymidine dimers, qualifying as principal actor 
in suppressing this UV-induced damage. Pol Ș was shown to accurately bypass other lesions, 
like 8-oxo guanine and guanine-guanine intra-strand links due to the action of cysplatine. The 
synthesis fidelity opposite these lesions was the consequence of a unique active site among 
polymerases: while normally a replicative polymerase lodges one single template base in its 
active site and the previous one is pushed outside, Pol Ș accommodates both pyrimidine 
dimers when bypassing this UV lesion and takes care not to loop them out to avoid 
frameshifting, typical for Pol ț bypass. Pol Ș is not processive; it incorporates only a few 
bases past the lesion before dissociating from the strand, and dissociates even faster after a 
misincorporation (Washington et al., 2001).
Pol Ș carries out UV-lesion bypass in S-phase by being recruited to stalled replication 
forks, that are detectable in nucleus 8h maximum after irradiation by specific granulations, 
termed repair foci (Kannouche et al., 2001). This Pol Ș recruitment is dependent on 
ubiquitination of PCNA on conserved Lys164  (Kannouche et al., 2004a).
Whereas Pol Ș remains the rare enzyme capable of correctly bypassing CPD lesions, it 
retains high error rate (10
-2
) opposite to this cognate lesion, as well as when copying 
undamaged template. Biochemical studies of Pol Ș reported a stunning ability to polymerize 
over two hundred base-long gaps in lacZ gene substrates (Matsuda et al., 2001) or Vțox gene 
substrates (Pavlov et al., 2002) in spite of its low processivity. PolȘ preferentially inserted 
dGTP when facing T, and to lesser extent dATP facing A. The efficiency of the former 
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misincorporation was however behind Pol Ț, a champion in low fidelity synthesis opposite to 
thymidines. 
With such pronounced inclination towards low-fidelity synthesis, it is clear that Pol Ș
should be tightly controlled in eukaryote cells at multiple levels. Studies mostly done in S.
cerevisiae showed transcriptional control of RAD30 gene (McDonald et al., 1997) and 
persistent proteasomal degradation of RAD30 gene product, somewhat loosened in case of 
UV irradiation when the protein was transiently stabilized (Skoneczna et al., 2007). Pol Ș can
be phosphorylated in human cells, which enhanced translesion activity (Chen et al., 2008) or 
it can be in turn ubiquitinated (Bienko et al., 2010).  It is thought that Pirh2 Ub ligase-
mediated mono ubiquitination of Pol Ș weakens its interaction with monoUb-PCNA, 
therefore allowing to more “avid” polymerase, e.g. bypass extender, to access PCNA (Chen et 
al., 2008; Moldovan et al., 2007). 3ROȘFDQEHSRO\ELTXLWLQDWHGE\0GP8E-ligase which 
targets it for proteasomal degradation (Jung et al., 2012). Another way of being recruited to 
repair foci is via Rev1, notorious for being necessary in UV lesion bypass independently of its 
polymerase function (Moldovan et al., 2007). Mouse Rev1 contains a unique domain in its C-
terminal moiety allowing it to interact with other Y-family polymerases via their polymerase 
associated domain PAD domain (Guo et al., 2003) and at the same time with monoUb-PCNA, 
and might therefore serve as a scaffold for polymerase swapping while browsing for the right 
one to handle the lesion (Friedberg et al., 2005).
II.4.3. Properties of MMR-mediated mutagenesis in SHM 
Knock-out studies in mice turned out to be the most straightforward and reliable way 
to figure out the implication of different repair factors in somatic hypermutation. Mutation 
rate and pattern in hypermutating regions were used as readouts to evaluate the impact of the 
absence of the manipulated factor (Table T3).
When the mismatch repair pathway in somatic hypermutation was dissected, some 
surprising discoveries allowed for the distinction of error-free “canonical MMR” and highly 
error-prone “mutagenic MMR” (non-canonical or SHM MMR). Both pathways share the 
essential sensor complex, MutSĮ, and both knock-out mice (Msh2-/- and Msh6 -/-) have the 
same SHM mutation profile with decreased relative frequency of A:T mutations (Table T3,
discussed further in Chapter III.1). This mutation pattern is reproduced for EXO-1 and PolȘ as
well, indicating that all four factors (MSH2, MSH6, EXO-1, PolȘ) contribute to the error-
prone MMR generating A:T mutation load. 
MutSȕ (comprising Msh2-Msh3) does not seem to play a significant role. 
Surprisingly, the absence of the transducer complex MutLĮ (composed of Pms2 and Mlh1) 
also did not seem to result in a disequilibrium in the mutation pattern or a major change in the 
mutation rate. 
 Table  T3.  Summary of generic knock-out studies for different repair factors and accessory proteins 
and their impact on somatic hypermutation. 
 
Knockout 
genotype 
Mutation 
rate 
Mutation spectra References 
Ung 
-/-
 no change 
slight G:C increase= 
decreased G:C Tv; 
increased G:C Ts; 
A:T no change 
(Rada et al., 2002a) 
SMUG 
-/-
 no change no change (Di Noia et al., 2006) 
TDG 
-/-
 
embryonic 
lethal 
 (Cortázar et al., 2011) 
MBD4 no change no change (Bardwell et al., 2003) 
APE-1 
-/-
 
embryonic 
lethal 
 (Xanthoudakis et al., 1996) 
MSH2 
-/-
 decrease 
Total load decreased= 
decreased A:T; 
increased G:C Ts; 
no change G:C Tv 
(Ehrenstein and Neuberger, 1999; 
Rada et al., 1998) 
MSH3 
-/-
 no change no change (Wiesendanger et al., 2000) 
MSH6 
-/-
 decrease 
Total load decreased = 
decreased A:T; 
increased G:C Ts; 
no change G:C Tv 
(Wiesendanger et al., 2000) 
MLH1 
-/-
 no change no change (Phung et al., 1999) 
PSM2 
-/-
 no change no change (Winter et al., 1998) 
EXO-1 
-/-
 decrease 
Decreased A:T; 
increased G:C Ts; 
no change G:C Tv 
(Bardwell et al., 2004) 
PCNA
K164R
  Abolished A:T (Langerak et al., 2009) 
Ung 
-/-
 Msh2 
-/-
 No change No A:T; no G:C Ts (Rada et al., 2004) 
Ung 
-/-
 Msh6 
-/-
 No change No A:T; no G:C Ts (Shen et al., 2006) 
Rev1 
-/-
 No change Decreased G:C (Jansen et al., 2006) 
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This opened the question on how the entry for EXO-1 is provided outside of the 
replication context of canonical mismatch repair; with following attempts to provide an 
answer:x an interplay between error-prone mismatch repair and BER components was proposed, 
especially when two AID-induced uracils were found close to each other(Pham et al., 
2003; Xue et al., 2006) . One may be already occupied by MutSĮ, but the second one 
can be readily processed by UNG and half-cut by APE-1 endonuclease introducing a 
single-stranded nick and providing for EXO-1 entry (Schanz et al., 2009). However, 
the absence of impact of Ung inactivation on the A/T mutation pattern speaks against 
this proposition (Chapter III.1).x others suggest an intervention of  NBS1-MRE11-Rad50, exonuclease complex in 
homologous recombination double-strand repair, shown to promote somatic 
hypermutation (Yabuki et al., 2005). Apparently, this complex can be recruited 
downstream of UNG action, so another scenario of cooperation between two pathways 
in SHM may be possible (Larson et al., 2005).
Further characterization of the nicking machinery may also shed more light on the 
strand discrimination of mutagenic MMR. In a context where the term of nascent strand is 
irrelevant (as in somatic hypermutation), mutagenic mismatch repair can introduce the 
incision in U-containing strand as well as in the unmutated strand. The lack of directionality 
was demonstrated for MutLĮ-mediated nicking of a heteroduplex DNA substrate containing a 
bubble in a system reconstituted with pure enzyme components (Pluciennik et al., 2010).
The gap filling in conventional mismatch repair is delegated to high fidelity, 
proofreading-capable replicative polymerase Polį. However, error-free gap filling in somatic 
hypermutation is highly compromised by unusual partnership between MutSĮ component and 
error-prone Pol Ș translesional polymerase. Two studies revealed almost simultaneously the 
implication of Pol Ș in somatic hypermutation: by analyzing A:T mutagenesis hotspots in 
somatic hypermutation and comparing them with the in vitro Pol Ș pattern (Rogozin et al., 
2001) and by assessing somatic hypermutation in XPV patients (Zeng et al., 2001).
XPV patients, although heterogeneous in different mutations that abolished Pol Ș
expression, yielded overall pattern that closely resembled the one of Pol Ș knockout mice 
(Delbos et al., 2005; Martomo et al., 2005). Pol Ș deficiency did not impact general mutation 
and maintained the A/T bias. By contrast, A:T and G:C were importantly unbalanced, with 
residual 15% of mutations at A:T (against normal 50%), accounting for the involvement of 
another unknown polymerase in A:T mutagenesis. Pol Ț was discarded as Pol Ș substitute 
since double knockout Polh
-/-
Poli
-/-
showed the same profile as Polh
-/-
only (Delbos et al., 
2005). In Polh
-/-
residual A:T mutation pattern, A:T transversions prevailed over transitions 
with a Pol ț recognizable pattern. In a subsequent study of double knockout Polh-/- Polk-/-
(Faili et al., 2009) A:T mutagenesis dropped to 7%, showing that Pol ț can be recruited in 
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SHM as back-up. To our knowledge, no new polymerase candidate accounted for the 
remaining 7% of A:T mutations.
A surprising discovery came out of Msh2/PolȘ double knockout mice analyses in 
which all A:T mutations were completely abolished (Delbos et al., 2007). Moreover, Msh2
-/-
and Msh2
-/-
Polh
-/-
mice shared similar properties, like 50% decrease in overall mutation load 
and clustering of remaining mutations within G/C hotspots (more in Chapter III.1). This 
report imposed several conclusions:x Pol Ș is the sole contributor of A and T mutations in mice; A:T mutagenesis takes place 
through joint intervention of MutSĮ and PolȘ;x If A:T mutations are reduced but persist up to 15% in Msh2 absence and are entirely 
abolished in  Msh2/Pol Ș double knockout, this means that in the absence of mismatch 
signal complex Pol Ș is recruited in a A:T mutagenesis salvage pathway via UNG. It is 
not known whether this may occur in physiological conditions. x As long as MutSĮ is operational in the cell, it will remain the principal inducer of A:T 
mutagenesis independently of UNG presence. If Pol Ș is missing, other translesional 
polymerases (like Pol ț) may get involved but will always depend on MutSĮ direction. 
Pol Ș recruitment in mutagenic MMR. Biochemical approaches had shown that 
MSH2-MSH6 associate with Pol Ș in the chromatin of cultured cells and that this complex 
even improves the rate of PolȘ-catalyzed in vitro synthesis (Goodman and Scharff, 2005; 
Wilson et al., 2005). Another piece of the puzzle came from a PCNA knock-in mouse 
designed to replace the conserved Lys 164 residue in mouse PCNA. Unmodified PCNA 
clamp loader was long ago shown to be the partner in error-free MMR (Umar et al., 1996).
PCNA knock-out mice are not viable. However, this PCNA
K164R
mice generated a drastic 
drop in A:T mutations load in somatic hypermutation (Langerak et al., 2007). PCNA 
K164R
mutant is known for Lys164 importance in PCNA ubiquitinylation (Hoege et al., 2002) and 
for the mutant inability to recruit polymerase Ș in UV-irradiation assays (Kannouche et al., 
2004a), suggesting a role for ubiquitinylated PCNA in polymerase Ș enrollment in SHM 
MMR in just the same manner as in polymerase switch. However, residual A:T mutagenesis 
in PCNA 
K164R
knock-in mice is proven to be independent of PCNA-ubiquitinylation and 
further dropped to the level of A:T mutation is Ung
-/-
Msh2
-/-
mice when PCNA 
K164R
mice 
were crossed with Polh
-/-
mice (Krijger et al., 2011). Namely, Ub-PCNA is dispensable even 
in classical translesion across UV and cisplatin-induced lesions, although the translesion 
efficiency and rate are significantly reduced (Hendel et al., 2011).
This casting for error-prone MMR actors is not restricted to the isolated case of SHM. 
In response to oxidative damage, BER operates at the damage site along with Ub-PCNA and 
Pol Ș recruitment which was relying exclusively on MSH2-MSH6 (Zlatanou et al., 2011).
When DNA damage is inflicted by alkylating reagents, creating base intermediates which 
normally bind MSH2-MSH6 in vitro, there is an increase in PCNA ubiquitinylation and Pol Ș
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recruitment to the chromatin highly dependent on MMR proficiency of the cell (Peña-Diaz et 
al., 2012). Unlike in oxidative damage, this Ub-PCNA-Pol Ș engagement in alkylating 
damage handling was impossible without MLH1 and therefore MutLĮ complex. In the same 
study, a situation of SHM MMR facing U:G mismatch was simulated in vitro: substrates 
containing U/G mismatches were repaired in presence of MMR-proficient B-cell extracts 
whose BER pathway and replicative polymerases were inhibited. MutLĮ complex was 
required for this artificial substrate repair and only in its presence did Ub-PCNA accumulate.  
The length of  Pol Ș synthesized patch. Another mystery of Pol Ș recruitment 
concerns the length of the gap it is able to fill in during somatic hypermutation. 
Aforementioned studies tried to deduce this patch length in vivo according to the mutation 
spread measured from the fixed deamination site.  It seems that mutations spread away from 
the deamination site in both directions, predicting a filled patch size of 57 bp (Unniraman and 
Schatz, 2007) or up to 200 bp (Frieder et al., 2009). Others estimated it to be no more than 20-
30 bp (Chahwan et al., 2012). It remains unclear what restricts this patch length in vivo since 
EXO-1 5’ĺ¶nibbling in cell extracts can go as far as 150 bp (Genschel et al., 2002).
II.4.4. Potential outcomes of UNG intervention in SHM 
Genetic studies of knock-out mice for different BER-implicated glycosylases had 
provided clear evidence for UNG involvement in somatic hypermutation (Table T3). Another 
potential candidate is thymidine glycosylase whose knock-out phenotype is embryonic lethal, 
probably due to its implication in epigenetic processes (Cortázar et al., 2011; Cortellino et al., 
2011). SMUG was shown not to be highly expressed in mutating B-cell, to process uracils in 
rather error-free manner with  a very limited capacity to supplement UNG-induced 
mutagenesis in somatic hypermutation (Di Noia et al., 2006; Rada et al., 2004). MBD-4
knock-out had no major impact on somatic hypermutation pattern or mutation load.  
Ung
-/-
mice showed no change in total mutation frequency compared to wild type 
mice, with an important decrease in G:C transversions and only slight decrease in A:T 
mutation load. This G:C transversion decrease was in line with the results obtained with 
Rev1
-/-
mice (Table T3), showing a dramatic depletion of G:C ĺ C:G transversions which is 
consistent with Rev1 deoxycytidyl-transferase activity. The mystery on G:C transversion 
persists since no  G:C ĺ T:A inverter polymerase has been identified. 
G:C transversions were always considered as hallmark of UNG-mediated active 
mutagenesis whereas G:C transition were thought to arise exclusively as replicative 
polymerases elongate the nascent strand across uracils that escaped other SHM pathways. 
However, GC transitions can be actively generated even during UNG-mediated mutagenesis, 
if the recruited translesional polymerase applies the “A-rule” (inserting A no matter the nature 
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of the facing base) when polymerizing across the abasic site (Reynaud et al., 2009; Weill and 
Reynaud, 2008). 
Mutation pattern of UNG knockout mice provided other interesting conclusions:  x mutagenic MMR seems fully independent in generating A:T mutations; x strand nicking by APE-1 downstream of UNG is dispensable for MMR processing of 
uracils, since MMR-generated A:T mutations remain unchanged in UNG absence. 
Either another glycosylase can take over the role of uracil removal and subsequent 
APE-1 recruitment at the abasic site in somatic hypermutation (a putative role for 
thymidine glycosylase) or other propositions on strand nicking may come into play 
(see paragraph on MMR strand discrimination). 
Regarding other BER components downstream of glycosylase intervention in 
canonical pathway, all of them remain essential for individual’s survival as indicated by the 
absence of BER-related cancers and embryonic lethal phenotype of all knockout mice (APE-
1, Polȕ, XRCC1). Irradiation chimera mice transplanted with Polȕ knock-out cells was shown 
to affect more class-switch recombination than somatic hypermutation (Esposito et al., 2000); 
furthermore, some B-cell lines with enhanced hypermutation on G:C basepairs  seem to have 
downregulated Polȕ (Poltoratsky et al., 2007) and therefore promoted UNG-mutagenesis on 
G:C. XRCC1 heterozygous mice had 50% increase in total mutation load and unchanged 
mutation pattern (Saribasak et al., 2011), adding to the proof of error-free BER in ongoing 
somatic hypermutation in V(D)J region. 
 
II.5Targetingofsomatichypermutation
Due to the high risk of introducing deleterious mutations elsewhere in the genome, 
AID was thought to be strictly targeted to the Ig loci. Therefore, somatic hypermutation 
targeting used to be the synonym for AID targeting. Other non-Ig genes were reported to be 
mutated by AID (Shen et al., 1998) but it was not until the seminal work of Schatz group (Liu 
et al., 2008) that AID was acknowledged to mutate on the genome-wide scale. Further deep-
sequencing studies reported even bigger number of AID genomic targets (Yamane et al., 
2011) but the doubt persists whether this technique overestimates AID “anchor” sites in the 
genome.  
Another objective of the study by Liu et al. and another group (Hasham et al., 2010) 
was to temperate the risk of AID-mediated whole genome mutagenesis by showing the 
importance of repair pathways in correcting AID-induced mutations outside of the scope of Ig 
variable region genes. AID was first shown to mutate genome-wide at a basal level which is 
50-100 times lower than in the Ig loci. The control of the mutation load (as some mutagenesis 
persists in genes like BCL-6, CD83 or Pim-1) or total elimination of mutations were 
dependent on classical repair pathways (MMR, BER, homologous recombination). By  
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contrast, the effect of AID-mediated mutagenesis in the immunoglobulin genes is further 
exacerbated by the action of specific error-prone repair at this region. Outcomes of AID-
mediated mutagenesis became the matter of region-specific equilibrium between error-prone 
and error-free repair: in non-Ig genes, the error-free repair largely prevails; in Ig gene 
diversification, error-free repair is not absent but is overthrown by the error-prone 
mechanisms (Liu and Schatz, 2009). Hence the need to reformulate the term of somatic 
hypermutation targeting, since the problem became two-headed: there is AID targeting and 
there is error-prone repair pathway favoritism at the Ig loci. For the moment, we shall 
concentrate on the AID targeting, based on three major levels:
1) at the global level, where Ig gene diversification contrasts the rest of the genome that is 
mutated at the basal level. The common denominator of Ig genes and AID-mutated genes 
elsewhere in the genome was the high transcription level. Somatic hypermutation was 
already shown to depend on transcription that provides to AID the substrate it catalyzes 
the best: single stranded DNA within transcription bubbles. However, there were highly 
expressed genes that were not shown to mutate; therefore, cis-acting sequences of Ig 
genes become the favorites for AID targeting. Known transcriptional regulator sequences, 
such as IgV promoter, intronic enhancer and 3’ enhancer did not prove to be sufficient to 
target SHM (Betz et al., 1994; van der Stoep et al., 1998); however, new locus-specific 
sequences were identified to be necessary and sufficient for AID recruitment to the Ig 
locus in chicken DT40 cell line separately from transcription requirements (Blagodatski 
et al., 2009; Kothapalli et al., 2008), but these sequences await validation in mammal 
models. 
The second means of attracting AID specifically to the Ig locus were trans-acting factors, 
proteins that are able to bind it and retain it in the chromatin context of Ig genes. This 
quest for B-cell specific trans-acting factors was somewhat discouraged by the studies of 
eukaryotic systems other than B-cell lines (and of  prokaryotic systems) in which 
ectopically expressed or endogenous AID was mutating transcription cassettes that 
contained Ig genes or other substrates like GFP (Bachl and Olsson, 1999; Petersen-Mahrt 
et al., 2002; Yoshikawa et al., 2002).
Another way for AID to access the Ig locus was proposed by the means of interacting 
with E2A, a typical B-cell transcription factor. E2A binds to E-boxes, sequences found in 
Ig locus. Multiple E-boxes inserted within an Ig transgene increased somatic 
hypermutation of the transgene (Michael et al., 2003). Even though these sequences were 
able to modulate SHM frequency and therefore participate in targeting, the direct 
interaction of E2A and AID is yet to be demonstrated. 
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2) at the regional level, by delimiting the boundaries of SHM at Ig loci (no mutations in 
promoters and C-genes). There is a clear requirement for a promoter; IgH or Igț
promoters themselves are dispensable if replaced by other strong promoters. 5’ boundary 
of somatic hypermutation would shift the same way as the upstream promoter is moved; 
if a promoter is inserted just 5’ of the C-genes, they would start acquiring mutations as 
well.  These observations allowed further study of AID interactions with RNA 
polymerase II complex and proved that AID associates with this complex only when 
transcription is stalling via the specific stalling factor Spt5 (Pavri et al., 2010). Another 
aspect of regional targeting is the apparent difference in targeting rearranged VDJ exons/J 
intron compared to S-region repeats. S-region, beside being enriched in hotspot 
sequences, are G-C rich as well, which accounts for a number of secondary structures 
forming in this region. Among them are DNA structures called R-loops that are formed 
when a transcribed DNA strand pairs with nascent RNA. R-loops appear to be the 
recognition motifs for AID, which can further attack looped-out non-transcribed DNA 
strand. 
These structures do not form in V genes. So far, two targeting requirements for V-region 
genes are identified:  transcription bubbles which are the only means of providing ssDNA 
in this region of the Ig loci, and interaction of phosphorylated AID at Ser38 with RPA, 
which binds single-stranded regions in rearranged VDJ genes and recruits AID at the 
same time (Chaudhuri et al., 2004).
Protein factors known to participate in AID targeting in other diversification processes 
are further detailed in section dealing with class switch recombination for a simple reason 
that most of them have validated interactions with AID when recruiting it to the S-
regions. Further evidence is needed to confirm the direct implication of the same factors 
in targeting variable region genes in vivo.
3) at the local level, comprising targeting of AID to the hotspots. As we have already 
mentioned, not all hotspots sequences are targeted and cytidines outside of hotspots 
mutate as well. However, one group identified a motif in AID protein sequences that 
modulates recognition of C within WRCY classical motif and when replaced with the 
corresponding sequence from APOBEC3G, the preference for the hotspot changed along 
with the reduction in CSR and SHM (Kohli et al., 2010; Wang et al., 2010).
Unregulated AID activity is proven to yield pathological consequences: T and B-cell 
tumors due to AID overexpression in transgenic and bone marrow transplantation models 
(Komeno et al., 2010; Okazaki et al., 2003), double strand breaks initiated by AID which 
contribute to c-Myc-IgH translocations (Matsumoto et al., 2007), other off-target AID-
dependent DSBs in non-Ig genes that contribute to germinal center-derived lymphomagenesis 
(Pasqualucci et al., 2008; Robbiani et al., 2009).
 Figure  24.  Class-switch DNA recombination (CSR) exchanges the gene encoding the immunoglobulin 
heavy chain constant region (CH) with one of a set of downstream CH genes. The figure depicts CSR 
between Sʅ and Sɲ1 in the human immunoglobulin heavy chain (IGH) locus. ʗ, pseudogene; 3഻ɲE, 3഻
ɲ enhancer; iEʅ, IGH intronic enhancer; IH, IGH intervening region. Source: (Xu et al., 2012) 
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II.6 Other secondary diversification processes with a same 
denominator: AID 
II.6.1. Class-switch recombination 
Class-switch recombination is the molecular mechanism for isotype switching, 
allowing for modification of antibody constant region and yielding new functions in antigen 
clearance. It can happen outside of germinal centers as well as during GC reaction. This 
modification happens by literally swapping the Cµ gene with another C gene located 
downstream, therefore bringing it immediately after the JH intron and the EP enhancer and 
closest to rearranged V(D)J segment (Figure24).
Isotype switch is disrupted in Aicda knockout mice, indicating that AID-mediated 
cytosine deamination is required for the reaction onset. AID was shown to deaminate 
cytosines within or near the S region preceding the Cµ gene (donor region) and S-region 
upstream of specific C gene towards which isotype switch takes place (acceptor region). 
Two signals elicit class switch recombination: primary signals that induce the 
expression of AID and other factors implicated in CSR, and secondary signals that contribute 
to the choice of the C-gene coding for the new isotype. Primary signals include CD40-CD40L 
interaction with helper T-cells in case of T-dependent antigens. Coupled signals from 
simultaneously activated TLR-4 and cross-linked BCRs in case of T-independent  antigens 
(eg., bacterial lypopolysaccharide LPS) can also serve as primary signals for CSR. Secondary 
signals comprise cytokine requirements defining which acceptor S-region is to be selected and 
therefore direct class switch towards one of IgGs, IgE or IgA. 
Two other requirements for isotype class switch are proliferation (B cells have to 
undergo a minimum number of divisions) and ongoing transcription over CH genes directed 
from the corresponding promoter regions upstream of IH exons (Chapter I.1.1). All acceptor IH
promoters contain cytokine-responsive elements, and the onset of the transcription from a 
single IH promoter is dependent on the nature of cytokine signaling. Transcription is 
constitutive from Iµ promoters. Nowadays one can take advantage of this process and induce 
the switch of isolated mouse splenic B cells in culture by applying the recombinant cytokine 
cocktail known to stimulate cell proliferation and shift the switching towards one particular 
isotype (LPS only to induce transcription of IȖ3 promoter and switching to IgG3, LPS and IL-
4 towards IgG1 and IgE, TGFȕ for IgG2b and IgA synthesis, IFNȖ for IgG2). This assay is 
particularly useful to delineate the capacity of mutant or modified CSR factors to restore the 
switch in vitro in cultured B cells deficient for the tested factor.
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The synthesis of these sterile germline transcripts contributes to CSR at several levels:x the chromatin structure at the donor and acceptor S-region is relaxed and allows for the 
access of initially recruited proteins, like 14-3-3 protein with its intrinsic affinity for 
binding 5’-AGCT-3’ sequences (subset of WRCY motifs). This motif is highly 
enriched in the core of both acceptor and donor S-regions. It was demonstrated that 
AID interacts with this protein (Xu et al., 2010) through a C-terminal peptide sequence 
within its nuclear export signal, finally connecting dots on why AID NES and C-
terminus are essential for class switch recombination to occur (Ranjit et al., 2011) .x During the ongoing transcription mediated by RNA polymerase II transcription 
complex, the nascent RNA transcript hybridizes with the transcribed DNA strand, 
looping out the non-transcribed strand to form the R-loops. It is thought that these 
DNA secondary structures can impede transcription progression (Kenter, 2012), while 
recruiting factors to the stalled site. Other way of inducing transcription pausing may 
be RNA II polymerase collision with another polymerase molecule, elongating the 
transcript from an antisense promoter in S-region. In any case, one of these “stalling” 
factors, Spt5, is shown to interact and recruit AID onto the stalled RNA Pol II complex 
(Pavri et al., 2010). AID can be imagined to tether RNA Pol II complex via Spt5 and 
continue to “ride” it as the transcription goes on, scanning for the precise spot within 
the S-region where it can further interact with 14-3-3 protein. x the whole IH-SH-CH region is being transcribed, after which this sterile transcript is 
spliced to IH-CH mature transcript. Although this final transcript is non-coding, this 
splicing step is vital for CSR. This RNA processing in situ might account for the 
recruitment of splicing factors PTBP2 (Nowak et al., 2011) and others,  known to
further interact with AID. Enrollment of RNA exosome in S-region transcription has 
finally explained the mystery of how AID accesses the transcribed strand, occupied by 
the hybridized RNA: RNA exosome simply degrades it and opens the way for AID to 
act (Basu et al., 2011).
The major difference between SHM and CSR is found once AID is done with cytosine 
deamination: during CSR, uracils are processed to yield double strand breaks in Sµ and 
acceptor S region. This processing is however still not explained in detail, but it is considered 
that UNG contributes to uracil base removal and subsequent endonuclease recruitment that 
will introduce single-strand breaks. Two SSB created this way from the uracils not far from 
each other create a double strand break in one S-region. Remote SSB within a single S-region 
are postulated to be further processed with participation of MMR factors and some 
translesional polymerases in order to give rise to blunt or nearly blunt double strand breaks 
(Stavnezer et al., 2008). The MRE11-RAD50-NBS1 complex that is an early genome-wide 
detector of double strand breaks, triggers a phosphorylation cascade via ATM kinase to enrich 
phosphorylated DSB histone marks ȖH2AX in the CH region and allow the entry of the 
 Figure 25. Scheme of class switch recombination. More details in the text. DSBR: double strand break 
repair. Source: (Murphy et al., 2012) 
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classical non-homologous end-joining pathway (NHEJ). NHEJ starts by the double-strand 
break sensor protein Ku70/Ku80 surrounding the free DNA ends and loading DNA protein 
kinase that will recruit other downstream effector proteins of NHEJ, Cernunnos and 
XRCC4/Ligase4. Finally, the intervening region between the double strand breaks in two S-
regions will be removed and DNA ends will be joined into a hybrid Sµ/Sx region in a joint 
action of XRCC4 and ligase 4 (Figure 25).
Only few SHM factors are essential in isotype switching. UNG-deficient mice showed 
considerable reduction in switched isotypes, accounting for the molecular basis of hyper-IgM 
syndrome 4 in humans (Imai et al., 2003). MutSĮ and MutLĮ knockouts were shown to have 
reduced CSR, and it has been proposed that mismatch repair is involved in the gap-filling 
process processing two distant nicks into a double-strand break (Stavnezer and Schrader, 2006).
The absence of different SHM translesional polymerases, among which only the mutagenic 
signature of pol Ș is recognizable in S-regions (Faili et al., 2004), do not affect CSR.
Another form of AID targeting to S-region is by modifying the existing epigenetic 
marks. Specific histone modification H3K9me3, reputed as repressive, was widespread in IgH 
locus in resting B cells until the initiation of CSR induction, when it was retained only in 
donor S region. This histone modification is shown to impair CSR if ablated in a B cell line 
(Stanlie et al., 2010) and can tether a protein complex which can further bind AID  (Jeevan-
Raj et al., 2011) . In CSR, only the 3’ regulatory region (cis-acting region located far 
downstream of CH genes, 30kb in size and comprising four hypersensitive DNA sites) was 
identified as the one necessary and sufficient to trigger AID deamination independently of its 
role in transcription (Rouaud et al., 2013; Vincent-Fabert et al., 2010) .
 
II.6.2. Gene conversion 
This form of diversification process of immunoglobulin genes takes place in chicken 
and rabbit B-cells to generate the pre-immune repertoire. Chicken variable region genes, 
contained within one single light chain and a heavy chain loci,  are much less numerous 
compared to mouse and humans. In Ȝ light chain locus, there is only one functional VȜ and JȜ,
preceded by 25 non-functional V pseudogenes (Reynaud et al., 1987). These pseudogenes 
lack 5’ or 3’ end of the coding region in order to be operative. AID was discovered to be 
responsible for triggering gene conversion (Arakawa et al., 2002) by deaminating cytosine in 
coding V-exon . These deaminated cytosines are further processed to become a single or 
double strand break, allowing for unilateral transfer of genetic material  between different 
parts of pseudogenes and corresponding parts in the single coding VȜ gene (Figure 26). These 
non-reciprocally exchanged regions can range from 10 to 100 base pairs. The pseudogene 
sequence remains intact after transfer and is available for novel rounds of gene conversion. 
Factors other than AID known to participate in this intra-chromosomal homologous 
 Figure 26. Overview of gene conversion in chicken B-cells. See text for detail.. Source: (Murphy et al., 
2012) 
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recombination are Rad54, XRCC2/3 and Rad51B. In DT40 avian cells deficient for the last 
two factors, gene conversion is remodeled into classical somatic hypermutation on the V gene 
that is normally only minor in chicken B cells (Sale et al., 2001). Deletion of all pseudogenes 
similarly restricted AID-induced modifications to point mutations, thus providing a cellular 
model of somatic hypermutation that is easy to manipulate but whose results should be taken 
with caution, due to the prevalence of G:C mutation in the total pattern.
Chapter III : A place for cell cycle in somatic 
hypermutation 
III.1.  Hypothesis of cell cycle-mediated coordination of 
mutagenic repair pathways involved in SHM 
The absolute mutation rate in WT mice is considered to be a balance between 1) active 
mutagenesis by mutagenic repair pathways, 2) error-free repair that still operates in 
hypermutating regions and 3) uracil “ignorance” in which none of the two uracil handling 
mechanisms takes place and where uracils are replicated giving rise to G:C transitions 
(“passive” mutagenesis). Change in the total load reflects a disequilibrium between active 
error-prone and error-free pathways, while further increase in absolute G:C transition 
frequency may be explained by more G:U mispairs escaping both mutagenesis and error-free 
repair, and lingering in DNA before they are fixed in replication. Altogether, it makes one 
error-free pathway, two mutagenic mechanisms, replication as a shortcut and five different 
outcomes (A:T transitions and transversions, G:C transitions and transversions, high fidelity 
U repair), all against a single substrate: a cytosine deaminated by AID into uracil. A question 
that one cannot help asking is how do all different repair pathways split the work on AID-
generated uracil in somatic hypermutation? 
What is the precise mechanism by which UNG generates mutations? Two 
alternatives are suggested, the most praised one includes UNG as the sole component of 
classical BER pathway engaged in somatic hypermutation. Other less accepted alternative 
involves some downstream players as in long-patch BER. Both alternatives of Ung processing 
may account for the way UNG uses to recruit pol Ș and generate residual A:T mutations in the 
non-physiological context of Msh2 absence. 
First proposed model starts with UNG-mediated processing of the single-stranded 
uracil, towards which UNG shows slight catalytic preference (Kavli et al., 2005).  Once the 
target is recognized, UNG glycosylates the N-bond and leaves an abasic site. This partially 
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processed deamination site can be found in multiple single-stranded configurations: 1) in 
the transcription bubble, just after AID deamination; 2) prior to gap filling in MMR repair
action, after the strand containing a mismatch is degraded; 3) during replication, when a lag 
between replicative helicase and  replicative machinery leaves template DNA in single-
stranded form. This last proposition is accepted as the main pathway of G:C mutagenesis 
governed by UNG,  where replication factory stalled at the abasic site seeks help of a 
mutagenic translesional polymerase (Rev1 or another), whose misincorporation gives rise to 
G:C mutations in general (Di Noia and Neuberger, 2007; Weill and Reynaud, 2008).
Second proposition is that uracil recognition by UNG happens while it is still in 
double strand DNA. Once recognized by UNG, a subsequent long-patch repair would be 
initiated with a remarkable difference – instead of PCNA and Pol ȕ/į, mono-ubiquitinylated 
PCNA and a translesional polymerase would be recruited (Krijger et al., 2009; Otterlei et al., 
1999).
A role for a partially processed deamination site in mutagenic MMR: cooperative 
pathways. Lasting debate about partially processed deamination site comes from the fact that 
we do not really know to which extent the error-free BER processing of uracil can be 
exploited in somatic hypermutation. Many studies hold their focus on two immediate 
outcomes of potential post-UNG processing:  the abasic site and the subsequent incision of 
the strand, requiring an endonuclease or dRP lyase activity downstream of UNG and giving 
rise to single strand break. Other groups defend the possibility of joined efforts of UNG and 
MMR factors in generating Ig gene mutations by using one or both of these processing 
intermediates. Otherwise said, error-prone pathways would rather cooperate. 
In this light, two reports placed the abasic site as a major event next to U:G detection 
in mismatch-induced mutagenesis. An abasic site in the middle of MMR processing in SHM 
would appear in the non-degraded strand prior to gap filling.  One possibility is it would arise 
as a previous MutSĮ choice of sparing the U-containing strand when deliberating about U:G 
mismatch. UNG produces AP site from U left in the non-degraded strand (Frieder et al., 
2009). The other possibility is that an abasic site can emerge prior to gap filling as a 
consequence of AID-mediated targeting of a single-stranded cytosine recognized in the strand 
spared from EXO-1-degradation. Authors of this proposition previously “inculpated” error-
prone MMR pathway for generating a portion of G:C transversions, until then thought of as 
an exclusive right of UNG-recruited Rev1 polymerase (Krijger et al., 2009). In both cases, 
gap filling across the abasic site would be the trigger for PCNA ubiquitinylation and a 
translesional polymerase recruitment, e.g. Rev1 as first-choice inserter (yielding G:C 
transversions) and Pol Ș as a extender (generating A:T mutations).  
Single strand break will remain the Gordian knot of the Ig gene diversification 
processes: if introduced in both strands not far away from each other, it can yield a double 
strand break so much sought for in class switch recombination and so much dreaded 
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elsewhere in the genome. If introduced in the only functional V gene in chicken, the gene 
conversion has half-way succeeded; and if introduced at a reasonable distance from the 
double-stranded U:G mismatch already recognized by the MutSĮ, this UNG-generated single 
strand break can spare MutLĮ from seeking the free 3’ end (Schanz et al., 2009) or constantly 
“waking” the endonuclease activity in PMS2. While ones favor classical UNG partner APE-1
as single strand “nickase” in somatic hypermutation, others bet on MRE11/RAD50 complex 
and its susceptibility to assume AP-lyase function behind UNG and even stimulate mutagenic 
repair (Larson et al., 2005; Yabuki et al., 2005).
Mismatch repair impinges on UNG in SHM: competitive pathways. Our group had 
adopted a competitive model of interaction between mutagenic pathways based on data 
interpretation from Ung
-/-
, Msh2
-/-
and Msh2
-/-
Polh
-/-
mice, (Delbos et al., 2007; Reynaud et 
al., 2009). Firstly, as long as the MMR sensor complex is present, A :T mutagenesis is 
independent of UNG according to the results from Ung
-/-
mice ( Chapter II.4.4). Error-free 
MMR does not seem to be engaged during somatic hypermutation, otherwise mutation load in
Ung
-/-
mice would be decreased. 
On the contrary, MSH2 deficiency reduces overall mutation by 50%, a decrease that 
combines largely reduced A:T mutagenesis with relative increase of G:C transition, while 
G:C transversions remained the same. This counter-intuitive imbalance in relative frequency 
of G:C transitions is further explained by their clustering to AID hotspot sequences, as if 
AID-generated uracils remained protected from UNG-mediated error-free repair within 
hotspots until the replication fork  arrival. Other non-protected uracils in background that 
would be normally handled by MutSĮ, are efficiently repaired by error-free base excision 
repair and therefore contribute to the general decrease in mutation frequency. Therefore, 
mutation pattern in Msh2
-/-
mice confirm there are both BER error-free mechanism and UNG-
mediated region-specific mutagenesis operating in somatic hypermutation and they both 
employ UNG for the onset (Saribasak and Gearhart, 2012). The reason for different 
management of UNG-generated intermediates may be embedded in the sequence context of 
processed uracils (Pérez-Durán et al., 2012). As a result, it seems that the presence of MMR 
factors greatly downplay UNG activity in both error-prone and error-free handling of uracils. 
Third point, residual A:T mutagenesis in Msh2
-/-
mice was totally absent in Msh2
-/-
Polh
-/-
mice, indicating that in the non-physiological context of Msh2 absence, Pol Ș kept on 
generating remaining A:T mutations, only this time being recruited by UNG. This “uracil 
overtaking” by one mutagenic pathway when the other is absent, together with MMR 
impinging on UNG activity, fostered the idea that these pathways act in competitive manner 
and that their outcomes are better balanced if one confines the other to temporally separated 
action frames. 
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MutSĮ requirement for a mismatched base embedded in double stranded DNA would make it 
an ideal candidate to act on uracils generated in G1 phase of dividing germinal center B-cells. 
UNG is known to act on both double-stranded and single-stranded uracil (Kavli et al., 2005); 
many cultured cell lines specifically upregulate UNG expression from the background level 
starting from G1/S phase transition (Chapter II.4.1); and translesional polymerases would 
perform their standard role of bypassing the non-instructional abasic site generated by UNG 
during replication. All these arguments converge towards the idea that UNG is better suited to 
induce mutagenesis in S-phase. With Pol Ș as a sole contributor to A:T mutagenesis 
downstream of MMR-mediated recruitment, all A:T mutations would arise in G1 phase, while 
G:C mutagenesis would be limited to the S phase. 
If one could manage to limit the activity of a single SHM effector to the phase 
considered “suboptimal” for its performance according to our model, one might expect to 
detect an important disbalance in A:T vs. G:C mutagenesis as an outcome (Chapter III.3, 
Figure 28). This change in frequency on A:T or G:C basepairs depending on the restriction to 
G1 or S phase is a reliable readout that would allow us to confirm or infirm our hypothesis. 
Before going into technical rationale of how this phase-specific restriction of a SHM factor 
might be done, let us take a quick tour of the cell cycle in general in order to understand the 
layers of regulation in this cell cycle-regulated coordination of somatic hypermutation. 
III.2.Cellcycleinbrief.
From fertilized egg cell until death, cells undergo the same cyclic succession of 
processes that allows them to duplicate their mass, their genetic material, maintain genetic 
integrity of daughter cells and divide. Many cells are terminally differentiated in adulthood 
but others like epidermal cells, hair cells, cellular lining of the gut, blood cells and germ cells 
continue to perpetuate this cycle in highly controlled manner in order to renew the used up 
tissue. It is therefore logical for these cells to subject all house-keeping processes to the 
cycling rhythm of divisions in order to optimize the whole mechanism and carry it out with 
outmost precision.  In the case of large pre-B-cells, proliferation can be exploited to rather 
downregulate some key development factors like RAG2, which is stable only in G1 and 
degraded in other phases, in order to control the V(D)J recombination (Chapter I.1.2 and 
I.2.2).  
Cell cycle phases. Cell cycle is organized around three major events: genetic material 
duplication, equal share of genetic material between two future cell poles and splitting up all 
cellular material in two. First process is carried out during the period termed S phase for 
synthesis period; others two succeed one another during official cell division process, mitosis. 
In rapidly dividing embryo, cells literally jump from mitosis to DNA duplication, not even 
taking the time to double cell mass to maintain the size of daughter cells. However, two 
additional “gap” phases exist in adult dividing cells: gap phase preceding the DNA synthesis  
  
Cyclin-Cdk complex Vertebrates Role 
 Cyclin CDK  
G1-CDK cyclin D (D1, D2, D3) CDK4, CDK6 cell cycle entry if environment is 
favorable 
G1/S CDK cyclin E CDK2 transition to S; DNA replication and 
centrosome duplication 
S-CDK cyclin A CDK2, CDK1 DNA replication, centrosome 
duplication and mitosis 
M-CDK cyclin B CDK1 mitosis 
 
Table T4. Summary of cyclins and cyclin-dependent kinases (Cdk) that build different complexes and 
their role according to the timing of their activity. Source : (Alberts et al., 2002) 
Figure 27. Overview of the eukaryotic cell cycle phases, major events and different cyclin-Cdk 
complex expression. Adapted from: (Morgan, 2008) 
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called G1 and the second gap phase between S phase and mitosis, named G2 phase. Those 
two additional phases are implemented in the “long” version of cell cycle allowing the cell to 
estimate the quality of the accomplished work and integrate environmental stimuli into further 
decision-making in the cell cycle.
Cell cycle checkpoints. Control points are identified between some phases of the cell 
cycle at which the cell will arrest further progress, try to solve problem and, if failing at that,
trigger programmed cell death. The first checkpoint is at the G1/S transition, where the cell 
checks for free deoxynucleotide level and availability of enzymes, nutrients and growth 
factors before launching into DNA duplication. Second checkpoint is reached when entering 
G2/M transition, when the cell takes time to verify if the total DNA is duplicated only once 
and whether any other DNA damage persists, in which case post-replicative mechanisms will 
be engaged. The final control point is spindle assembly checkpoint, just before anaphasis 
(separation of sister chromatids and pulling each one toward opposite cell poles) when the cell 
makes sure that every sister chromatid is lined up and attached by a spindle fiber, which 
guarantees to each daughter cell the exact same quantity of genetic material as in the mother 
cell before duplication.  
Cell cycle effector proteins. The famous “cell cycle engine” that ensures the timing 
and succession of cell cycle phases is made up of a regulatory system of proteins: cyclin, 
cyclin-dependent kinases (Cdk) and Cdk-inhibitory proteins (CIP) specific for each cell cycle 
phase. Central actors in this system are cyclin-dependent kinases that can inactivate or 
activate their substrates by phosphorylation within a defined phase. However, Cdks are 
inactive and with no defined substrate specificity unless bound to cyclins, which can be 
considered as regulatory subunits of these kinase complexes. The quantity of CDK within a 
dividing cell is in most cases constant; it is the abundance of their cyclin partner that varies 
according to the cell cycle phase (Figure 27).
In absence of cyclins, Cdks are inhibited by Cdk-inhibitory protein.  If a signaling 
cascade gives a green light for a transition into the next stage, the corresponding cyclin is 
upregulated just before the transition and persists throughout. CIPs are then removed and the 
cyclin can associate with the corresponding CDK within the active complex, promoting the 
movement through the cycle.
The three major classes of cyclin-Cdk complexes whose activity oscillates with phase 
succession are: G1/S cyclin-Cdk complex, S cyclin-Cdk and M cyclin-Cdk complex with 
their name indicating their position in the cycle. G1 complex controls the G1 phase length, 
leaving more time to the cell to integrate the information from the environment to ensure that 
all conditions are favorable to entail the risky  business of DNA duplication and cellular 
material segregation. The list of cyclins and cyclin-dependent kinases that make up for these 
complexes in vertebrates is given in the Table T4.
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M-CDKs are degraded if the signal is positive at metaphase-anaphase transition. With 
no Cdk-cyclin complexes left then to supervise the rest of mitosis, another indispensable 
component of cell cycle machinery comes into spotlight: anaphase-promoting complex or 
cyclosome (APC/C), an ubiquitin ligase that is activated from mid-mitosis (anaphase) until 
the end of G1. Once activated, it targets S and M-cyclins for ubiquitinylation and degradation, 
allowing for the completion of M phase and safely landing daughter cells in the new G1 
phase. 
Cell cycle regulators. The protein level of cyclins, Cdk kinase inhibitors and other 
regulatory factors in cycle are under permanent control of ubiquitin-dependent degradation. 
This layer of control is achieved through two classes of cell cycle ubiquitin ligases, the 
aforementioned APC/C and SCF complex (SKP1-CUL1-F box protein). Both complexes have 
similarly organized structures, containing common invariable components making up the core 
of the complex and a variable substrate-specific subunit (named activator for APC/C and one 
of F box proteins for SCF). Taking for example the Skp2/SCF ubiquitin ligase complex: SCF 
is permanently active throughout the whole cycle, in contrast to APC/C which needs 
activation to become functional. SCF can associate with one of its variable substrate-
recognition component, S-phase kinase associated protein 2 (Skp2). Skp2/SCF has a detailed 
list of potential targets (among which G1, G1/S and S cyclins and negative cell cycle 
regulators like CKI), but these will remain untouched unless phosphorylated at a precise point 
of the cycle by one of Cdks. Therefore, while degradation of APC targets begins immediately 
after APC activation, ever-active SCF-F box complexes depend on timed phosphorylation of 
their substrates in order to target them to degradation and allow progression through S and G2 
phases. The window of SCF targeted ubiquitination spans late G1 until early mitosis. 
Dependent on phosphorylation or not, the portion of the protein sequence that is 
sufficient and necessary to bring about the recognition by SCF or APC/C complexes is named 
degron. An example would be Myc protein, which is stabilized in many human tumors due to 
the mutation of two residues in its Myc box 1 (MB1) degron. In normal conditions, 
phosphorylation of MB1 residues leads to recognition by FWB7/SCF complex and 
subsequent proteasomal degradation of Myc. The second example is cyclin B from M 
complex: its N-terminal domain harbors a destruction box (D-box) which is recognized by the 
APC/C complex, making it a degradation substrate starting from anaphase. 
General scheme of eukaryotic cell-cycle control. Cyclin-CDK phosphorylating 
activity is almost absent in G1, while it is highly active in S, G2 and M phase. While in G1, 
appropriate mitogen signals and information on cell size allow further stabilization of G1 
cyclins, which associate with G1 Cdks and help activate the gene expression of G1/S and S 
cyclins, as well as other factors participating in S-phase events. Being assembled the first, 
G1/S complex phosphorylates S complex-inhibitory CKIs, therefore providing the first 
substrates for SCF-mediated ubiquitination. In G1/S transition and throughout S phase, G1/S 
and S complexes collaborate on initiation of DNA replication and duplication of the spindle 
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poles. Whereas M-cyclins start to accumulate already in G2 phase, their cognate M-CDKs 
remain inactivated by another form of cell cycle “brakes” – inhibitory non-Cdk kinases, 
which phosphorylate inhibitory sites on M-CDKs and prevent them from associating with M-
cyclins M-complexes. These inhibitory kinases are targeted by another F-box ȕ-TRCP/SCF 
complex at the onset of M phase, while M-CDKs get rid of inhibitory phosphates, and, within 
the M-complex, promote the mitotic spindle assembly and other preparations for chromosome 
segregation. After one last check on whether sister chromatids are properly attached to the 
spindle, the M-complex triggers its own extermination by phosphorylating and therefore 
activating APC/cyclosome ubiquitin ligase. APC/C associates with different activators for 
targeting all M-cyclins and securin, a protein whose destruction separates sister chromatids 
and unleashes the spindle contraction. APC/C keeps ubiquitinating throughout G1 phase until 
its substrate-specific subunit is inactivated by G1 cyclin-Cdk complex at the beginning of the 
next cell cycle. 
The activities of APC/C and SCF complexes seem to be perfectly delineated 
throughout the cycle. Even though there is no direct experimental evidence, it is thought that 
there is a tight interplay between the two, allowing them to work separate shifts during the 
cell cycle watch. 
III.3.  Timing of individual SHM players during cell cycle 
Ig locus in general. E2A transcription factor is one of the first transcription factors to 
regulate pro-B cell genes (Chapter I.2.2). Its binding to E-box motifs, which are found in Ig 
gene loci, does not alter Ig gene transcription but is suspected to have a role in AID targeting 
(Chapter II.5). A cell model for visualizing position of rearranged IgȜ locus in the nucleus of 
constitutively mutating DT40 cell line allowed the observation that transfected E2A does 
colocalize with IgȜ genes. Furthermore, colocalization studies indicate that this association 
takes place only in G1 phase on the basis of correlating cell cycle phase with observed cell 
nuclear radius (Yabuki et al., 2009)..
AID. AID expression level during the cell cycle does not seem to change according to 
the cell cycle analysis of AID-EGFP knock-in BL2 cells (Aoufouchi et al., 2008b). Furthermore, 
this study showed that AID is longer-lived in cytoplasm compared to nuclear location, where 
it is ubiquitinylated and targeted for degradation. Endogenous AID in stimulated mouse 
splenic B cells is present in all phases, even though it is difficult to establish whether the 
expression level varies significantly (Schrader et al., 2007).
Concerning cell cycle phase-specific activity of AID, two studies examined the 
evolution of AID-deamination products, mutations and single-strand breaks. Immediately 
after upregulation of AID expression in the Burkitt's lymphoma cell line BL2 inducible for 
somatic hypermutation, mutations are introduced as a single strand event in rearranged VH
gene during G1 and G2/M phases. However, mutations become fixed in DNA only if 
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introduced in G1 phase. Frequency of mutations introduced in G2/M was reduced 24h after 
mutation triggering in G2/M sorted cells (Faili et al., 2002). Only G1-arrested activated 
splenic B-cells, fully proficient for AID, were able to generate double strand breaks in Sµ 
regions (Schrader et al., 2007).
When considering the possibility of cell cycle-dependent localization of AID in the 
cell, not much is reported on sub-cellular localization of endogenous AID in dividing 
germinal center B cells. AID localization was studied in Ramos B-cell line either by AID-
GFP chimeric protein overexpression (Rada et al., 2002b) or by endogenous AID detection 
(Patenaude et al., 2009); in AID-YFP transfected DT40 chicken cell line (Ordinario et al., 
2009) and in AID-EGFP-transfected BL2 cell line (Aoufouchi et al., 2008b). All studies 
indicated the predominant cytoplasmic localization of AID except for (Ordinario et al., 2009),
whose authors tried to take a freeze frame shot of AID-YFP in DT40 nucleus by treating cells 
with nuclear-export drug leptomycin B and localizing YFP fluorescence after the treatment. 
While one can debate whether this is the most physiological way of catching a “snapshot” of 
AID localization, authors managed to show that during the short half life of AID in nucleus, it 
is at least more stable in G1 phase nuclei than compared to S phase nuclei.
Pol Ș. PolȘ is usually recruited at the site of UV-induced lesion and replication 
stalling, therefore in S-phase replication foci. As commented in (Phillips and Sale, 2009),
formation of foci does improve  local concentration of molecules and enhances reaction 
kinetics, but the molecule localization in itself does not necessarily imply the ongoing activity 
in the foci. In the previously described model of rearranged IgȜ locus visualization in DT40 
nuclei, Pol Ș was found to colocalize with this locus preferentially in G1 phase (Ordinario et 
al., 2009). Furthermore, focal organization of PolȘ was shown to emerge upon UV irradiation 
of permanently G1 phase-arrested cell population, independently of PCNA or nucleotide 
excision factors recruitment. It was postulated that Pol Ș might be just setting up in G1 foci 
and getting ready in case of UV-bombing with clustered, dense lesions (Soria et al., 2009). In 
the same report, authors showed that pol Ș accessed thymidine dimers independently of foci 
formation in all phases of the cell cycle in the U2OS cell line.
Uracil DNA glycosylases. :  Expression of different uracil-glycosylases during cell 
cycle was assessed in several studies. MBD4 (Hardeland et al., 2007) and SMUG (Nilsen et 
al., 2001) were shown to be constitutively expressed and active during the cell cycle. 
However, major differences in temporal pattern of expression were attributed to UNG2 and 
TDG (Hardeland et al., 2007):  UNG levels increased above the background at G1/S 
boundary, reached the peak in early S and started to gradually decline from mid-S onwards, 
reaching the null level at the end of DNA replication. By contrast, TDG protein level has the 
exactly opposite behavior: it starts to accumulate in G2, reaches its peak in G1 and is kept 
under proteasomal degradation control from G1/S transition until G2.  Interestingly, UNG 
was found to be phosphorylated at residues within a motif highly resembling the G1/S cyclin 
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phosphodegron (Hagen et al., 2008). This UNG phosphoform is further ubiquitinylated and 
subsequently degraded (Fischer et al., 2004; Hagen et al., 2008). With the additional proof 
that cyclin-dependent kinases can phosphorylate UNG in vitro (Hagen et al., 2008) and that 
UNG ubiquitinylation was inhibited by cyclin-dependent kinase inhibitors (Fischer et al., 
2004), one cannot help recalling the interplay of SCF and APC/C regulated expression of 
oscillating cell cycle effectors. However, ubiquitin-ligase for UNG and TDG are still 
unknown.
After all is said on the subject of UNG cell cycle-dependent expression, one must 
notice that all data were collected in different cell lines using not so physiological means to 
bring the cells to cell cycle arrest. A key question for UNG-mediated processes in somatic 
hypermutation remains, what about UNG protein levels and activity regulation through the 
cell cycle in fast dividing germinal center B-cells? 
XRCC1. The scaffold protein XRCC1 involved in recruiting DNA ligase III in the last 
step in BER repair shows some cell cycle-specific interactions via two different domains, 
BRCT1 and BRCT2. It was shown that BRCT1 domain of XRCC1 interacts with p38 subunit 
of DNA polymerase Į and thus recruits S phase-restricted single-strand break repair pathway 
(SSBR), involving PARP-1 and PARP-2 enzymes (Lévy et al., 2009). BRCT2 domain in 
XRCC1 binds DNA ligase III, and mutations in this domain were shown to abolish single 
strand break repair in G1 but not in S (Taylor et al., 2000).
Mismatch repair factors. Protein levels of MSH2, MSH6, MLH1 and PMS2 did not 
vary in different phases of the cell cycle in cell culture of non-transformed, non-immortalized 
human embryonic fibroblasts (Meyers et al., 1997; Szadkowski and Jiricny, 2002). However, 
mRNA levels of PMS2 remained very low and fluctuated between 50% drop and 50% 
increase in late G1 and S/G2/M, respectively. MSH6 mRNA increased 2.5-fold at late 
G1/early S phase, whereas the protein level did not follow this upregulation (Szadkowski and 
Jiricny, 2002). The rationale for this mRNA increase remains a mystery, since any free MSH6 
protein is degraded unless protected within MSH2-MSH6 complex. 
Association of monoUb-PCNA and PolȘ with the MSH2-MSH6 complex, shown to 
occur in response to oxidative (Zlatanou et al., 2011) and alkylating damage (Peña-Diaz et al., 
2012) in cell lines, takes place independently of S-phase. In case of alkylating damage, this 
non-canonical MMR is confirmed to be activated in G1 phase. 
Winners of the competition for cell cycle-restricted mutagenesis. In order to test our 
hypothesis on cell-cycle coordinated mutagenic repair pathways in SHM, we decided to pick 
two SHM factors whose activity is to be confined to a single phase of the cell cycle, 
preferentially the one that would allow us to discriminate its optimal timing in somatic 
hypermutation. Our search among aforementioned SHM factors for a candidate in cell cycle 
dependent-restriction concluded with AID and Pol Ș. Criteria guiding this choice included 
background on potential cell cycle-dependent gene expression or cell cycle-regulated activity 
 A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
Figure 28.  Different outcomes for G1-phase or S-phase restriction of two major SHM factors, AID 
(A) and Pol ɻ (B). More details in text. 
Expected mutation pattern : 
Expected mutation pattern : 
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of candidates, as well as clear readouts of their cell-cycle restricted mutagenesis (Figure 28). 
According to our model, if AID activity is confined to G1 phase, A:T mutations would prevail 
over G:C; conversely, if AID is to deaminate only in S phase, G:C mutation would dominate. 
With Pol Ș restricted to S phase, there would be no MMR’s preferred A:T mutator to generate 
the majority of A:T mutations in G1 phase and their frequency would be reduced. 
The main hurdle in testing our cell cycle hypothesis was physically confining these 
proteins to a precise cell cycle phase. Several promoters were known to confer cell cycle-
regulated expression, other peptides could bestow cell cycle-controlled localization to the 
fusion with fluorescent protein. However, we were looking for fluorescent marker technology 
that would allow us to rapidly detect the B cell population expressing the confined SHM 
effector, reliably verify its cell cycle status by measuring cell DNA content and sort out this 
population from total hypermutating B-cells for the purpose of establishing the mutation 
pattern. Luckily, an existing technology for tracking cycle in living cells allowed us to resolve 
all these issues with one bold stroke. The sesame word: Fucci. 
III.4.  Cell cycle sensors can be used as protein activity 
restrictors 
In summary, successive transitions between the different cell cycle phases is achieved 
through a complex network of cell cycle effectors and regulators, themselves regulated at 
several levels:x differential expression throughout the cycle (e.g. G1/S-complex specific induction of S 
phase cyclin (CycA) synthesis)x dynamic protein-protein interactions (Cyclin-Cdk interactions, Cdk-CKI interactions..);x post-translational modifications leading to activation, inhibition (phosphorylations) or 
changes in stability (ubiquitinylation via APC/C and SCF);x phase-dependent compartmentalization of cell cycle factors (accumulated M-phase 
cyclin B being translocated from cytoplasm to nucleus in order to initiate mitosis).
It was just the matter of time when the functional elements (enclosed in DNA or 
protein sequence) that govern these spatiotemporal characteristics of cell cycle actors would 
be identified and exploited for further characterization of dividing cells within a tissue or at 
the whole organism scale. With the advent of a variety of fluorescent proteins and 
improvement of cell visualization techniques (microscopy, cytometry), tracking cell cycle 
became a matter of imagination and color palette availability. Here we shall expose in more 
detail the cell cycle-tracking fluorescent reporter system we chose in an effort to manipulate 
the activity of somatic hypermutation key players in dividing germinal center B-cells.
  
Figure 29.  The activity of components of the origin licensing system and their cell-cycle regulation. 
Whereas the licensing system is only active in G1, it is inhibited in S and G2 phase by Geminin 
(orange) and in mitosis by combination of Geminin and Cdk (violet). Mcm2-7: multimer complex of 
minichromosome maintenance helicase. Adapted from: (Blow and Dutta, 2005) 
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Fucci. Fluorescent ubiquitination-based cell cycle indicator is based on two 
ubiquitination-regulated proteins, Cdt1 and Geminin, both phase-specific and with mutually 
exclusive activity during the cycle. Degrons of these proteins were identified and C-
terminally fused to fluorescent proteins, giving rise to G1-restricted fast-folding variant of 
mKusabira Orange (orange to red mKO2-hCDT1 degron) and monomeric azami green 
protein confined to S/G2/M period (mAG-Geminin degron) (Sakaue-Sawano et al., 2008).
Cdt1 is a replication origin licensing co-factor participating in the assembly of pre-
replicative complex (pre-RC), a multi-subunit complex that gathers on many replication 
origins on chromosomes prior to DNA synthesis. Its role is to label the replication origin that 
will soon “fire” – initiate replication – and therefore let the cell know that this portion of 
DNA was already replicated once. The labeling proceeds by recruiting the minichromosome 
maintenance (Mcm) multimer helicase onto a replication origin that will further help opening  
the local DNA structure and ensure replication forks formation. Once other components of 
replicative machinery have gathered and started off, Mcm helicase will be pushed by the 
replication fork further away from the replication origin. Thereafter the replication origin will 
become delicensed for any further replication (Blow and Dutta, 2005).
Replication origin licensing takes place throughout the G1 phase. Once Mcm helicase 
is loaded, Cdt1 along with some other pre-RC factors is no longer needed – even unwanted 
because it threatens to re-license the same origin later on in the S phase. The main way of 
delicensing an origin is through downregulation of Cdt1 activity by means of both phase-
specific Cdt1 degradation and inhibitory protein-protein interaction with Geminin.
At the G1/S transition, Cdt1 is targeted for phosphorylation by G1/S complex within 
the PARRRLRL motif in 90 aa–long peptide sequence. This phosphorylated Cdt1 degron is 
tracked by Skp2/SCF complex for proteasomal degradation from G1/S transition onwards 
(Nakayama and Nakayama, 2006). Cdt1 interaction with Geminin has two-fold purpose: it 
figures as an additional safety-lock, in case any Cdt1 escapes degradation; paradoxically, 
Geminin-bound Cdt1 is spared from degradation and accumulates in this inactive form during 
mitosis, when SCF runs out of specific substrates. On the other hand, Geminin is one of the 
substrates for APC/C complex, being ubiquitinated within its N-terminal 110 aa-long degron 
and thus targeted for degradation, starting from anaphase until late G1. This APC/C-
dependent degradation sets free the accumulated Cdt1 in late mitosis, ready for some de novo
origin licensing. It is thought that Geminin is re-stabilized in the late G1 after G1-complex-
mediated inactivation of APC/C (Figure 29).
Fusing the whole sequence Cdt1 and Geminin to fluorescent proteins risked to perturb 
the cycle of the cells expressing them in two ways: first, by inevitably overexpressing them if 
introduced ectopically, and second by potentially behaving as dominant negative regulators of 
existing whole-length proteins in the cell. Since signal for SCF-mediated degradation is 
independent from Geminin-binding domain, the latter was removed along with other portions 
of Cdt1, leaving the minimal Cdt1 degron (amino-acids 30-120) still capable to translocate the 
  
 
Figure 30.  Illustration of the dual Fucci cell cycle sensor. For details, see text. Adapted 
from (Méchali and Lutzmann, 2008; Sakaue-Sawano et al., 2008). 
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fluorescent-protein fusion into the nucleus. A minimal Geminin destruction box was devised, 
leaving out the Cdt1 binding domain. Interestingly, degrons showed to be quite sensitive to 
the nature of fused fluorescent protein: Cdt1-30/120 maintained the expression confined to G1 
phase only when fused to mKO2 or mCherry, while Geminin-1/110 was shown to be 
permissive to a larger palette of fluorochromes. 
These colored cell cycle probes were simultaneously expressed in a variety of cell
lines, in germinal center B-cells, in transgenic mice or genetically labeled tumor cells injected 
in mice, even in zebrafish and fruit fly cells. In all contexts they showed the similar temporal 
pattern of expression: green fluorescence associated with Geminin degron was limited to 
S/G2/M status, while red fluorescence associated with truncated CDT1 colored cells that 
entered G1. An overlap of both colors yielding yellow nuclei was observed at G1/S transition. 
Therefore, an overlap of remnant APC/C and awaking Skp2/SCF activity can be monitored at 
G1/S transition by tracking these yellow nuclei. On the contrary, mitotic cells did not express 
any color, consistent with anaphase-dependent degradation of Geminin and a lag in 
accumulation of hCDT1 since no Geminin-binding ensured readily available Cdt1 stocks
(Figure 30). Both cell-probes were shown not to interfere with the normal cell cycle 
progression.
The elegant approach of these dual cell cycle probes was principally aimed at cell 
cycle monitoring and associating other cellular events to temporal order of phase transitions. 
However, at the time this project was initiated, no attempt was made to fuse these cell-cycle 
sensors to cellular proteins and turn them into cell cycle “restrictors” with clearly demarcated 
expression pattern in G1 or S/G2/M phase. With careful AID- and Pol Ș- fusion design and 
after many hours spent cloning, transducing cells and cell cycle analyzing, in the end there 
was nothing lovelier than a phase-synchronized colorful population emerging in the the ideal 
cellular context, ex-vivo cultured splenic B-cells of bone-marrow transplanted chimera mice. 
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Chapter IV : Mechanism and strand polarity of 
Pol Ʉ synthesis in somatic hypermutation  
“The devil is in the details” 
Somatic hypermutation is in many forms a skewed process, starting from the very fact 
of being one million times more intense than spontaneous mutagenesis. From that point of 
view, nothing guarantees the same randomness of spontaneous events to a mechanism 
deploying so many versatile actors to achieve such a high level of diversification.  In this 
section we shall focus on strand biases in somatic hypermutation, and especially the one 
concerning mutagenesis at A:T basepairs and thus implying Pol Ș misinsertion activity.
Many names for only two strands. Before taking off, we prefer to reduce the 
ambiguity of the nomenclature to the minimum by establishing the firm terms we shall use 
throughout the story. We shall deal with only two DNA strands, but these two entities can 
assume so many disparate functions that a clarification is at need. According to the 
convention, top DNA strand is always read by the experimenter in 5’ĺ3’ direction and will 
represent the strand that harbors the exact information of RNA transcript sequence coded by a 
given gene. Therefore, top strand of a displayed DNA sequence is always a coding strand. 
Transcription complex will synthesize RNA by transcribing the bottom strand, namely the 
non-coding or transcribed strand. 
During the replication, both DNA strands become replication templates but the 
synthesis on each one of them does not proceed in the same manner: one will be the template 
of the leading strand synthesis, while the other is the subject of discontinuous synthesis, 
giving rise to the lagging de novo strand. Top or bottom strand will assume their template 
roles depending on the closest replication origin and therefore, the direction of the replication 
fork – no convention fixes that as for the transcription. 
Finally, all observed mutations, whatever the strand they are originally introduced in, 
are reported directly as read from the top strand. With these notions in mind, we can start 
discussing strand biases in somatic hypermutation.
IV.1. Strand bias of mutations at G:C basepairs 
First occurrence for a strand bias in detailing somatic hypermutation mechanism came 
from the fact that not all bases mutate with the same frequency (Chapter II.1). A is more 
mutated than G and C, whereas T is the least mutated. In the final outcome of SHM, both G 
and C bases are equally mutated as read from the top strand. G:C mutations tend to 
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concentrate in so-called hotspot motifs (Rogozin and Kolchanov, 1992) of defined sequence 
WRCY or inverted RGYW sequence. If there was a strand preference for mutations on G:C 
basepairs, one motif sequence would be more mutated than the the inverted one within the 
same readout strand. This postulate, however, assumes the fact that there is equal distribution 
of both motifs on one strand, i.e. that the base distribution within the read DNA is 
randomized. This is not the case of V-D-J genes as CDR regions evolved so far as to skew 
codon usage in order to increase the hotspot concentration and therefore maximize the 
probability of targeting a precise amino acid replacement, most frequently the one that will
come in direct contact with the antigen. In the absence of selective pressure on the sequence 
of JH4 intronic region, its sequence is more randomized and the local targeting to these G:C 
hotspot sequences is still valid, but there is no strand discrimination when targeting them.
All SHM mutations stem from deamination events initiated at C bases by AID. It was 
thus intriguing to look at the potential strand bias introduced by AID during the initiation 
phase of somatic hypermutation. This pattern was available for analysis in Ung
-/-
Msh2
-/-
mice which allow for studying of the genuine AID footprint on G:C basepairs (Rada et al., 2004).
Once again, only mutagenic outcome in these mice is G:C transition, reflecting high-fidelity 
DNA polymerases  replicating over uracils. Counting unique, non-dynastically related 
mutations in Ung
-/-
Msh2
-/-
mice turned out to be a daunting task; mutation counts were either 
over- or underestimated, depending on the adopted analysis strategy. One pattern showed 
equal C and G mutation frequency, indicating no strand bias; however, other way of analyzing 
unveiled a slight “penchant” of AID for coding strand (C:G=60:40)(Reynaud et al., 2009).
In either case, AID was confirmed to target cytosines in both strands in spite of long 
persisting dilemma on how AID gains access to transcribed strand, occupied by RNA Pol II 
complex or hybridized with RNA within a transcription bubble (Chapter II.5). In S-regions, 
this is made possible by the action of RNA exosome (Basu et al., 2011).
IV.2. A:T mutagenesis strand polarity 
Let us for a moment neglect any hot-spot targeting or base distribution and imagine 
that A:T mutations were introduced at random with equal frequency on both DNA strands. 
The frequency at which an A ĺ7mutation occurs at the top strand would be equal to the 
frequency of Tĺ$PXWDWLRQ LQ WKH VDPH VWUDQG WKH ODWWHU PXWDWLRQ UHIOHFWLQJ WKHA ĺ7
mutation that occurred in the bottom strand.  As mutation databases in different 
hypermutating substrates were growing larger, a different picture of A:T mutagenesis was 
becoming increasingly evident in rearranged VDJ genes and flanking region: mutations at A 
bases are in twofold excess over mutations at T bases, both read off the coding strand. This 
bias could be explained neither by an imbalance in base distribution of the examined region, 
nor by the specific sequence context of mutating As or Ts (Milstein et al., 1998), suggesting 
1) that there was  a targeting mechanism that was directing the A:T mutator preferentially to 
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the one strand or another, and 2) that the A:T mutator was itself targeting As and Ts non 
equally.
In vitro Pol Ș mutation pattern. Even before it was straightforwardly demonstrated 
that Pol Ș is the sole contributor of A:T mutagenesis in vivo, in vitro pattern of Pol Ș synthesis 
was already qualifying it as a perfect A:T mutator. When copying undamaged single-strand 
DNA templates in vitro, recombinant human Pol Ș was incorporating opposite to all four 
template bases. However, a preference was clearly demarcated (Matsuda et al., 2000): Pol Ș
preferentially inserted dGTP when facing T and dATP when facing A in the template strand. 
T:dGTP misincorporation was four to five times more frequent than A:dATP misinsertion. 
This pattern was reliably reproduced with mouse Pol Ș and with different substrates as Pol Ș
templates (gapped LacZ gene, gapped VțOx gene) (Matsuda et al., 2001; Pavlov et al., 2002).
Therefore, when Pol Ș has no choice but to copy a single offered template strand 
outside of any context of being coding/non-coding, its most frequent mutations in the 
synthesized strand are AĺG and to 4-fold lesser extent, TĺA.
Rogozin et al. identified a hotspot motif for A:T mutagenesis, WA while analyzing 
many mutation databases from hypermutating regions in humans, mice, chicken and rabbit
(Rogozin et al., 2001) A WA hotspot subset, TA was claimed to accumulate frequencies of A 
mutations (Aĺ*$ĺ7DQG$ĺ& WKDWZHUH WKHVDPH LQ ,JJHQHVDQG LQDUWLILFLDOJDSSHG
LacZ substrate copied by Pol  Ș. This argument was used to prove good correspondence 
between the pattern of Pol Ș mutagenic synthesis in vitro and in vivo mutation data on A:T.
What preferentially directs Pol Ș to the coding strand?
With this intrinsically skewed mutagenic signature, it seemed that Pol Ș could explain 
the A:T strand bias as a whole if only correctly targeted to the top strand, in order to elongate 
it while using the bottom strand as a substrate. Therefore, in the quest to unveil the main 
genesis factor of A:T mutation bias, two points must be taken into account:x linking A:T mutations to a strand-specific deamination site (as uracil or abasic site), 
that would serve as the general trigger for Pol Ș recruitment. One team suggested that 
the transcriptional machinery, which drags AID behind it, can eventually deposit 
mismatch complex and Pol Ș preferentially onto uracils that were firstly introduced in 
the non-transcribed top strand (Mayorov et al., 2005). Others reasoned around creating 
an abasic site in the gapped bottom strand after MMR intervention. This AP site can 
work as a trigger for polymerase switch while gap filling opposite to it; one of favored 
polymerases in the switch would be Pol Ș (Frieder et al., 2009). Even though mutation 
analysis were in accordance with these hypothesis, none of them provided the 
satisfactory explanation on how uracils in one strand are more powerful in recruiting 
Pol Ș than onto the other strand.x strand directionality of SHM factors upstream of Pol Ș. By a mechanism that is yet to 
be detailed, it is generally accepted that Pol Ș is recruited in somatic hypermutation as 
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a part of non-conventional mismatch repair (Chapter II.4.3). Consequently, if one or 
more mismatch repair factors would have a strand preference, it would explain which is 
the strand that Pol Ș copies when filling the gap.  This was suggested in (Unniraman 
and Schatz, 2007) study, whose authors tried to standardize in vivo environment for Pol 
Ș synthesis by creating transgenic mouse lines containing Igț transgene with a specific 
substrate for dissecting Pol Ș targeting process. This substrate contained stretches of 
adenine and thymine bases in control version, dubbed TgA; in the test version, TgC, 
the access of Pol Ș to this substrate is governed after deamination of a single cytosine 
inserted in the middle of AT stretches in the top strand. A TgG substrate that contained 
the complementary AT sequence with C in the bottom strand was created as well. 
Authors first monitored the mutagenesis on test and control substrates, and concluded 
that TgG and control substrates accumulated very low number of mutations, thought to 
be engendered by recruiting Pol Ș to the neighboring deaminated Cs in the flanking
sequence. TgC had significantly more mutations that TgG and TgA, indicating that C 
in the top strand targets better the A:T mutator machinery. This bias was alleviated 
when transgenic mice were bred with Msh2-deficient mice, allowing the authors to 
conclude that MMR machinery is responsible for this targeting bias.
Although one must acknowledge the authors for a considerable effort in devising a 
model to control the impact of uracil mutagenic potential, many objections can be brought up 
to counteract the conclusions of this study. The first one concerns the uncontrollable behavior 
of Ig transgenes that are largely under impact of the integration site; as a consequence, AT-
containing substrates did not accumulate more than one mutation per sequence. This resulted 
in too small mutation database, compromising any statistically significant conclusions about 
the top strand C or about the impact of Msh2 absence. Many previous studies restrained from 
commenting A:T bias in Msh2- deficient mice due to the low number of A:T mutations, 
which did not prevent the authors from concluding about mutational asymmetry disruption 
due to Msh2 absence on the basis of 2-3 mutations left in the AT substrate.  Lastly, authors 
argued in the light of total mutation numbers that transgenes accumulated depending on the C 
position, but did not comment the mutational pattern that did not correspond to Pol Ș basic 
pattern in vivo at all (the most frequently detected mutation being Tĺ& in TgC which 
accumulated an exploitable number of mutations). When total Igț transgene mutations in 
transgenic mice with Msh2-proficient background were analyzed, they did not even present 
the usual A:T bias!  
 Figure 31. Different mutagenic outcomes in A/T-rich substrates if A :T mutator is targeted to repair 
the U-containing strand or to perform translesion synthesis on the opposite strand. Left, the case 
when U is in the non-coding strand; right, when U is in the coding strand. See text for details. 
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IV.3. Ʉ
it account for the A:T bias?  
We decided to improve the somatic hypermutation substrate from (Unniraman and 
Schatz, 2007) study DQG WHVW RQ LW WKH K\SRWKHVLV RI D GXDOPHFKDQLVPRI 3RO Ș DFWLYLW\ LQ
SHM depending on the orientation of the recruiting deamination site. Recruited by the non-
FDQRQLFDO005WRWKHGHJUDGHGVWUDQG3ROȘPXWDWHV$VDQG7VZKLOHILOOLQJWKHJDSLQWKH
error-prone manner. However, non-canonical mismatch repair has no constraints to obey the 
same strand signals as conventional mismatch repair in post-replicative repair. In other words, 
MMR in SHM can attack either U-containing strand or G-containing strand of the 
mismatched base pair, depending on the introduction of the nick (Chapter II.4.3 and III.1).
,Q WKLVFRQWH[WSRO\PHUDVHȘFDQSHUIRUPJDS ILOOLQJDFURVV WKH8 OHVLRQ-containing 
strand, and therefore carries out its physiological translesion bypass activity. If the U-
FRQWDLQLQJVWUDQGLVDWWDFNHG3ROȘSHUIRUPVWKHUHSDUDWLRQRIWKHXUDFLOE\HORngating the 3’ 
end of the degraded U-containing strand.  We wanted to verify which mechanism is favored 
LQ WKH FRQWH[W RI VRPDWLF K\SHUPXWDWLRQ 7KH SUHFLVH PHFKDQLVP DGRSWHG E\ 3RO Ș FDQ
generate different mutational outcomes at A:T basepairs if top or bottom strand U is attacked 
(Figure 31). In case of MMR attacking the top U-FRQWDLQLQJVWUDQG3ROȘZRXOGEHUHFUXLWHG
to the top strand to perform lesion repair and generate A:T mutations, among which Aĺ*
and Tĺ$ZRXOGEHWKHILUVWDQGVHFRQGPRVWDEXQGDQW mutations, respectively. Conversely, a 
single bottom strand U would yield a patch containing Tĺ&DQGPLQRU$ĺ7PXWDWLRQV LQ
the top strand.  Mutation readouts would provide the reverse picture for top strand U or 
bottom strand U if translesional synthesis mechanism was preferred in somatic 
hypermutation. A controlled hypermutating substrate would allow us to clearly discern 
between the two proposed mechanisms, if it contained mostly A and T bases and was 
integrated into normally hypermutating mouse Ig locus. This substrate has to be long enough 
to minimize the influence of flanking cytosines and has to contain its own deamination sites at 
central positions. Inserting this substrate into mouse Ig locus would not only allow us to 
obtain a more precise picture DERXW WKHOHQJWKRI WKH3ROȘ-initiated patch, but if inserted in 
both orientations, hypermutating substrates would enable us to follow the fate of both top and 
bottom-strand Us .  We chose to introduce not more than three of them into the substrate to 
mimic the physiological situation in which AID can deaminate on the same strand in a 
processive manner (Pham et al., 2003), enhancing somatic hypermutation and even providing 
us an insight into in vivo interactions between mutagenic pathways.  We hoped thus to have 
defined a better hypermutating substrate, which will acquire mutations at A:T basepairs in 
physiological context of immunoglobulin locus.  
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Part Two : Research article 
AID expression restricted to the G1 phase of the 
cell cycle recapitulates the mutation spectrum  
of immunoglobulin genes 
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Summary
Somatic hypermutation in immunoglobulin genes is the result of the processing of 
uracils generated by AID (activation-induced cytidine deaminase) achieved by two different 
repair pathways, uracil glycosylase for mutations at G/C bases and mismatch repair, together 
with DNA polymerase eta, for mutations at A/T bases. The apparent independent behavior of 
these two pathways revealed by gene inactivation of the different partners involved have led
to the formulation of hypermutation models in which each pathway would act at a distinct 
stage of the cell cycle. We performed transduction of hematopoietic stem cells from AID-
deficient animals with cell cycle-restricted variants of AID, and used them to restore Rag2-
deficient hosts and analyze mutations in B cells after immunization. We report here that 
restriction of AID expression to the G1 phase of the cell cycle is able to generate an equal 
proportion of A/T and G/C mutations at the Ig loci, thus demonstrating that uracils generated 
in G1 are substrates for both uracil and mismatch repair pathways.
Introduction
Affinity maturation of the immune response is the outcome of a mutagenic 
process targeted at the immunoglobulin (Ig) heavy and light chain loci (Berek and Milstein, 
1987). This process is triggered by AID, a cytidine deaminase that is preferentially induced in 
fast cycling B cells activated in germinal centers, where the T-dependent immune response 
takes place (Muramatsu et al., 2000). Mutations that accumulate in Ig V genes become 
selected upon appropriate T helper signals, during a complex process of cyclic trafficking 
between the dark zone of germinal centers, where mutagenesis is considered to take place, 
and the light zone where B cell proliferation slows down and allows for isotype switch and 
selection of variants with higher affinity (Victora et al., 2010). Isotype switch, the second 
molecular event targeted by AID at the Ig locus, is a non-homologous recombination process 
involving the concerted formation and processing of two double-strand breaks, resulting in 
the exchange of the heavy chain constant regions and subsequent acquisition of new 
functional capacities linked with each heavy chain isotype. 
Unrepaired uracils can generate C to T and G to A transitions if replicated 
over. However, two different repair pathways appear to contribute to enlarge the mutation 
spectrum at G/C bases and to spread mutations at distance from the initial deamination site. 
Uracil glycosylase generates abasic sites that will be substrates for translesional DNA 
polymerases, generating transversions (and also transitions) at G/C bases. A/T mutations are 
in contrast introduced during a patch of error-prone synthesis, mobilizing the Msh2/Msh6 
mismatch recognition complex together with ExoI, ubiquitinated PCNA, and DNA 
polymerase eta as the sole contributor of A/T mutagenesis (Di Noia and Neuberger, 2007).
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In B cells from Ung-deficient animals, no transversions at G/C bases are observed, but 
mutations at A/T bases appear relatively unaffected (Rada et al., 2002). In contrast, the impact 
of Msh2/Msh6 deficiency appears more complex: mutagenesis at A/T bases is markedly 
reduced, but the overall mutation frequency is also decreased, transition mutations at G/C 
bases are more prominent and the mutation pattern shows increased focusing at hotspot 
positions (Delbos et al., 2007). This dissociation lead to the suggestion that both G/C and A/T 
mutagenesis pathways may work independently, even though it is still unclear to what extent 
these two pathways may cooperate or compete for uracil recognition (Krijger et al., 2009;
Reynaud et al., 2009).
Models based on a distribution of tasks according to the cell cycle have been 
proposed, in which mismatch repair would preferentially handle uracils generated in the G1 
phase, preventing Ung from accessing the lesion, and Ung, the expression of which is 
increased when DNA replicates, would generate abasic sites in the S/G2 phase (Liu and 
Schatz, 2009; Weill and Reynaud, 2008).
Experimental data that contradict this model have been reported, in which 
expression of the Ung-specific UGI inhibitor was restricted to distinct phases of the cell cycle 
(Sharbeen et al., 2012). The authors used an elegant system of transduction by retroviral 
expression vectors of naive B cells harboring a transgenic anti-lysozyme B-cell receptor, and 
performed analysis of somatic mutations in vivo, after transfer of the transduced cells in a 
normal host and immunization with lysozyme. The authors concluded that Ung preferentially 
excises uracils in G1.  Consequently, another cell cycle based model, with opposite 
distribution of repair activities was recently proposed (Li et al., 2013).
We report here a cell cycle restriction study of AID expression, obtained by 
retroviral transduction of Aicda
-/-
hematopoietic stem cells and restoration of Rag-2-deficient 
mice, and show that AID expression restricted to the G1 phase appears to recapitulate 
mutagenesis produced by the two uracil glycosylase and mismatch repair pathways. 
Results and Discussion.
AID expression vectors with G1- or S/G2/M-restriction 
The Fucci system (Fluorescent, Ubiquitination-based Cell Cycle Indicators) 
described by Sakaue-Sawano et al. (2008) consists in fluorescent proteins coupled to peptides 
that target their degradation in specific phases of the cell cycle (degrons). These degrons 
comprise a 90 amino acid peptide of the hCDT1 replication licensing factor for restricting 
expression in G1 (30-120 N-terminal amino acids), and a 110 amino acid peptide from 
Geminin for S/G2/M restriction. 
We chose to fuse mKO2-hCDT1 and mCherry-Geminin reporters at the C-
terminus of AID. We also generated mutant versions in which the sites that regulate their 
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proteasomal degradation were abolished, to control for the functionality of the AID 
fusion proteins. This was performed by mutating the cyclin box in hCDT1 (RRL to AAA 
within the 
65
PARRRLRL
72
cyclin/Cdk binding consensus site of the protein) that targets its 
phosphorylation-directed degradation (Liu et al., 2004); and, for Geminin, by deletion of the 9 
amino acid destruction box (RRTLKVIQP) that begins at amino acid 33, a mutation that 
abolishes APC/C-mediated ubiquitination at the M/G1 transition (McGarry and Kirschner, 
1998).
Four different retroviral vectors were generated, based on the pMIG plasmid in 
which expression of constructs is driven by an MSCV (murine stem cell virus) promoter and 
which includes an EGFP reporter under IRES control. Transduction of NTZ cells (a 3T3 
derived cell line harboring a tetracycline-inducible EGFP reporter with a TAG stop codon) 
(Yoshikawa et al., 2002) was performed as a preliminary test of the functionality of the four 
constructs, and revealed in all cases an effective mutational targeting of the EGFP reporter 
(not shown). These four retroviral constructs were used to transduce bone marrow 
hematopoietic stem cells (HSC) from AID-deficient mice. Three days after transduction, the 
relative fraction of cells in each phase of the cell cycle was evaluated, based on EGFP, mKO2 
and mCherry expression (Fig. 1). For the mutant vectors, transduced cells co-expressed EGFP 
and either mKO2 or mCherry, with double-expressing cells on the diagonal of the FACS plot. 
For vectors with cell cycle restriction, two populations can be distinguished: an EGFP-only 
subset, and a double EGFP/mKO2 (or mCherry)-positive population. Analysis of the cell 
cycle indicated that approximately 75% of mKO2-positive cells were in G1, while G1 
represented 50% of the total population.  The non-G1 cells, in agreement with the initial 
description of this restriction system, were mainly in the early S phase in which expression of 
hCDT1 and Geminin fused proteins have been shown to partially overlap (Sakaue-Sawano et 
al., 2008). For mCherry-expressing cells, 85% were in S/G2/M, thus indicating for both 
vectors that appropriate restriction to the corresponding phase of the cell cycle was achieved 
in HSC. Conversely, restriction was abolished by the mutations introduced in the hCDT1 and 
Geminin peptides. 
It should be mentioned that these degrons have been shown surprisingly (and 
without straightforward explanation) to be sensitive to the fluorescent protein to which they 
are fused (Sakaue-Sawano et al., 2008). The hCDT1 peptide is notably unable to trigger 
degradation of EGFP or of RFP, but is functional with mKO2, while the Geminin degron has 
been previously validated with both mKO2 and mAG fusions (Sakaue-Sawano et al., 2008).
The use of mCherry reported here constitute a new addition to the Fucci system, with a cell 
cycle regulation similar to the one described for other reporters.  
Mice restored with these different constructs are thereafter referred to as AID
G1
for AID-mKO2-hCDT1 (and AID
G1-Mut
for the one including the mutated degron), and 
AID
S/G2/M
for AID-mCherry-geminin (AID
S/G2/M-Mut
for the mutated version).
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Restoration of Rag-2-deficient mice with transduced Aicda
-/-
hematopoietic stem cells.
Transduction efficiency ranged from 20-40% of HSC, and peripheral 
reconstitution, estimated 2-3 months later in the spleen showed an overall 3-fold reduction in 
EGFP
+
cells, thus mirroring the initial transduction rate with a moderate counter-selection of 
the transduced cells, and similar for all constructs tested. EGFP
+
cells represented 5-15% of 
total spleen cells, with a similar distribution within the B cell and T cell compartment (Fig. 2). 
The cell cycle profile was further assessed on splenic B cells blasts "ex vivo", 
i.e. obtained from restored animals, after LPS plus IL4 stimulation. This assay was performed 
to check the cell cycle restriction in the specific conditions of expression of mature B cells 
differentiated from transduced precursors (Fig. 3). Although the overall mKO2 or mCherry 
fluorescence intensity was lower than in HSC analyzed early after transduction, positive cells 
showed correct cell cycle restriction, a restriction completely abolished by the mutation in the 
degron peptide.
G1-restricted AID generates the complete spectrum of mutations at the Ig locus.
Two months after HSC restoration, mice were immunized by intra-peritoneal 
SRBC injection, PNA
high
EGFP
+
cells were sorted two weeks later and mutations in the JH4
intronic region were determined for the four types of AID-expressing vectors (Fig. 4).  
Mutation frequency induced by the two control AID-fusion constructs was low, 
with a high proportion of unmutated sequences. The frequency was 0.24 mutations per 
hundred base pairs for AID
G1-Mut
and 0.074 for AID
S/G2/M-Mut
. In both cases the G/C over A/T 
targeting ratio was normal, as expected for control AID vectors. Both controls showed a bias 
in transitions at G/C bases, a profile that appears to correlate with the AID-fusion proteins, 
but for which we do not have a straightforward explanation. 
Surprisingly, restriction of AID expression in G1 yielded similarly a balanced 
proportion of mutations at G/C and A/T bases, indicating that uracils generated in G1 are 
substrates for both Ung and Msh2 repair pathways. Importantly, this balanced ratio remains 
the same, whatever the stringency of the criteria used to eliminate clonal relationships, an 
important issue when analyzing small germinal center B-cell samples (see discussion in 
Material and Methods). The mutation frequency observed was three-fold lower than in the 
non-restricted control, a difference that likely corresponds to the lower accumulation of a 
protein that undergoes recurrent cell cycle degradation. 
In contrast, a negligible number of mutations over background was generated 
upon restriction of AID to the S/G2/M phase. The relative difference in mutation frequency 
with the unrestricted control was at least 10-fold, a ratio clearly underestimated since one-
third of the mutations observed are probably contributed by the PCR reaction. The much 
stronger difference between the mutated and unmutated AID
S/G2/M 
compared with the 3-fold 
difference between the mutated and unmutated AID
G1
suggests that AID-dependent 
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mutagenesis is specifically inefficient in S/G2/M. Moreover, since both degrons lead to the 
presence of the protein to which they are fused in early S and to the absence of both just after 
mitosis (Sakaue-Sawano et al., 2008), this would restrict the window of AID efficiency to the 
G1/late G1 phase.  
Normal G/C over A/T ratio in patients with compromised DNA polymerase epsilon activity.
Hypermutation is considered to take place in fast cycling centroblasts. Their 
division time was estimated around 6-7 hrs by the group of MacLennan, in 1988 (Zhang et al., 
1988), a figure that was reduced to 10-12 hrs in recent 2-photon microscopy approaches 
(Allen et al., 2007). It has been proposed that the rate of cell division may impact the A/T 
mutation frequency, fast cycling Ramos Burkitt's lymphoma B cells showing higher 
mutagenesis at A/T bases (Kano et al., 2011). We therefore attempted to study human genetic 
deficiencies in which alterations of the cell cycle have been described. We selected the 
recently described case of a family with DNA polymerase epsilon hypomorphic mutations, 
for which fibroblasts and EBV-transformed cell lines showed a protracted G1 phase with a 
marked delay in S-phase entry (Pachlopnik Schmid et al., 2012) (in collaboration with A. 
Fischer and G. de Saint-Basile). Whereas the number of CD27
+
memory B cells was strongly 
diminished, the overall Ig gene mutation frequency was only slightly reduced in these cells. 
No A/T over G/C imbalance was observed, thus suggesting that an increased length of the G1 
phase does not favor in vivo a specific dissociation of the two arms of mutagenesis (Fig. 5).
AID-induced mutagenesis in G1: restriction or repair?
This work reports two complementary observations. First, AID expression in 
the G1 phase is able to generate the complete spectrum of mutations observed in normal 
conditions at the Ig locus, suggesting that both uracil glycosylase and mismatch repair may 
operate within a similar time frame. Whereas this result contradicts our proposition of 
differential recruitment of these two pathways according to the cell cycle, it is in good 
agreement with the similar study performed recently by the group of Jolly, in which cell cycle 
restriction of Ugi, a specific inhibitor of Ung, was able to interfere with uracil excision only 
when expressed in G1 (Sharbeen et al., 2012). This observation provides also support to 
several studies proposing a cooperation between the two repair pathways, notably the 
involvement of Ung in excising uracil in the single-strand DNA patch exposed during Msh2-
driven error-prone synthesis (Krijger et al., 2009).
The second observation is the almost complete absence of mutation induced by 
AID expressed in S/G2/M. A trivial explanation could be a low efficiency of our S/G2/M-
restricted AID, which would fail to induce mutations above the threshold of PCR background. 
We think this interpretation unlikely, due to the large difference in mutation induction 
between the S/G2/M construct and its mutated control.  Another explanation could be that 
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AID generates mutations in S or G2, but that these events are correctly repaired, either during 
the same phase of the cell cycle, or in the next G1, in which error-free repair by Ung is also 
proposed to take place (Sharbeen et al., 2012). We have in fact previously reported in the BL2 
Burkitt's lymphoma cell line, that AID-dependent mutations introduced in G2 are repaired 
before the next cell division, whereas those occurring in G1 become fixed after replication 
(Faili et al., 2002). A third possibility could be a decreased efficiency of AID activity in 
S/G2/M, due to a specific subcellular localization (e.g. increased cytoplasmic 
retention)(Patenaude et al., 2009) or to an increased nuclear turnover, a proposition 
documented in another cellular model, the avian DT40 B cell line (Ordinario et al., 2009).
However the capacity of Burkitt's lymphomas or DT40 to precisely mimic the physiological 
mutation process is clearly questionable. 
Error-prone and error-free repair appear to coexist during hypermutation at the 
Ig locus, but their impact differ among AID off-targets, a few genes like Bcl-6 accumulating 
mutations while others - more numerous - being targeted and repaired (Liu et al., 2008).
Whether cell-cycle regulated gene specific features (e.g. early vs. late replication) may explain 
the differential outcome of AID-mediated off-target deaminations is an issue that deserves 
further studies.
This report describes for the first time the transduction of HSC to assay the 
impact of mutant proteins on the somatic hypermutation process. This approach can be 
similarly applied to shRNA-mediated down-regulation of gene expression, allowing for 
multiple inactivations through transduction of HSC from gene-targeted mouse lines. Even 
though the limiting factor will be whether a biologically significant level of expression can be 
achieved, this approach represents a manageable alternative to classical knock-out or knock-in 
strategies to study a mechanism for which no satisfactory in vitro model exists.
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Materials and Methods
Mouse strains.
C57BL/6 mice were purchased from Charles River.  Aicda 
-/-
mice, kindly provided by 
Prof. T. Honjo, had been back-crossed against C57BL/6 background for 9-10 generations at 
the time of present experiments and maintained in the Laboratoire d'Expérimentation Animale 
et Transgénèse (Faculté de Médecine Necker/Broussais).  RAG2-deficient mice originating 
from SOPF-conditioned mouse facility of Transgénèse and Archivage d’Animaux Modèles, 
CNRS, Orléans, were maintained in the Metchnikoff Immunology mouse facility of Institut 
Pasteur, Paris, during restoration experiments. All experiments and procedures were approved 
by the National Ethical Committee of the French Ministry of Agriculture. 
Construction of retroviral vectors. 
Mouse Aicda cDNA was amplified using PCR primers including a (Gly4-Ser)3 flexible 
linker sequence in 3'. AID was inserted by EcoRI/HindIII directional cloning in the 
expression vector pFucci-G1 Orange (MBL International) in 3' fusion with mKO2-hCDT1. 
Mutant mKO2-hCDT1 was generated by PCR mutagenesis by mutating RRL to AAA in the 
PARRRLRL motif responsible for its degradation.  
The fragments of mCherry and Geminin_1-110 aa degron were obtained from 
commercially available cloning vectors: pmCherry (Clontech) and pFucci –S/G2/M Green 
(MBL International), respectively.  Aicda cDNA was fused to mCherry and Geminin degron 
in successive steps of PCR assembly reactions using Phusion polymerase (New England 
Biolabs) and individual fragments as templates with the following cycling conditions: first 10
cycles without assembly primers (10 sec 98°C, 30 sec  55°C , 60-90 sec  72°C), then 20-25
cycles with same conditions except for annealing temperature (60°C) in presence of assembly 
primers. Mutant mCherry-geminin was made by PCR site-directed mutagenesis as an in-
frame deletion of the 9 aa destruction box sequence (RRTLKVIQP) that begins at amino acid 
33 in hGeminin_1-110 aa degron. 
pMIG and pMIGR1 (MSCV: IRES-GFP, Addgene entry:9044) retroviral vectors were 
used for cloning of finalized phase-restricted fusions for AID-mKO2-hCDT1 (AID
G1
) / AID-
mKO2-hCDT1 mutant (AID
G1-Mut
) and AID-mCherry-geminin (AID
S/G2/M
) / AID-mCherry-
geminin mutant (AID
S/G2/M-Mut
), respectively. All constructs were verified by DNA 
sequencing.
Production and titration of ecotropic retroviral particles.
HEK 293T Neo
R
were transiently transfected by X-tremeGene 9 DNA Transfection 
Reagent (Roche) with the genomic retroviral and structural vectors coding for ecotropic 
envelope. 48h post-transduction, 293T medium (DMEM F-12 10% fetal calf serum (FCS, 
(Hyclone)) was harvested, filtered through hydrophylic HighFlow 0.45 µm Minisart syringe 
filters (Sartorius) and concentrated by centrifugation 30 min at 3900 g at 4°C in Amicon Ultra 
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15 100K centrifugal filter devices (Millipore Miltenyi). Retroviral particles were titrated by 
transducing NIH 3T3 fibroblasts plated at 1x10
4
cells/cm
2
for 24h with pure and serially 
diluted retroviral supernatants. GFP expression was assessed 72h post-transduction by flow 
cytometry, yielding titers between between 3x10
7
and 10
8
pfu/mL.  
Hematopoietic stem cell transduction and adoptive transfer experiments.
Eight to twelve week-old Aicda
-/-
mice were euthanized by CO2. Total bone marrow 
cells were harvested by flushing femurs and tibias, and labeled according to the instructions 
of the Mouse Lineage Cell Depletion kit (Miltenyi Biotech). Lineage negative cells (Lin
-
)
were purified by negative selection after loading labeled bone marrow onto LS columns 
(Miltenyi Biotech) within strong magnetic field produced by QuadriMACS holder (Miltenyi 
Biotech). Purified Lin
-
cells were checked for purity and cultured for 48h in DMEM with 15% 
heat-inactivated fetal calf serum (Fetal Clone I, HyClone) supplemented with 1 mM sodium 
pyruvate and murine cytokines (Peprotech): IL-3 10 ng/mL, IL-6 10 ng/mL, SCF 100 ng/mL, 
Flt3 ligand 100 ng/mL, and human thrombopoietin at 60 ng/mL. One day before transduction, 
6-well plates (BD Falcon) were coated overnight at 4°C with 50 µg/mL retronectin solution in 
PBS (TaKaRa) at final concentration of 10 µg/cm
2
. Virus-free concentrated 293T medium 
(mock) or retroviral particles were first allowed to bind to retronectin-coated plates in 
presence of 4 µg/mL polybren solution for 4 hours at 37°C, followed by a gentle wash. Lin
-
cells were swiftly dispatched into mock- or virus-bound wells at 1x10
6
cells/mL density and 
allowed to transduce during 4 hrs at 37°C. Cells were detached from retronectin-coated wells 
by Cell Dissociation Buffer (Invitrogen Life Technologies), washed twice and resuspended in 
cold PBS prior to injection. A small sample of transduced Lin
-
cells was kept in culture for 
additional 72 h after which the percentage of GFP
+
cells and cell cycle-mediated restriction of 
mCherry/mKO2
+
cells were estimated by flow cytometry.
Eight to ten week-old Rag2
-/-
mice were irradiated 8 hours prior to injection with a 
lethal dose of 4.5 Gy total body irradiation (RS-2000, RadSource Technologies) and injected 
intravenously with 2x10
6
transduced or mock-transduced Lin
-
cells in 200 µL PBS per mouse 
on the same day of transduction. A group of 2-3 irradiated recipient mice was injected with 
mock-transduced Lin
-
cells; for each vector coding a phase-restricted fusion protein (4 groups 
in total), 3-5 siblings were injected and maintained in the same cage. Both sexes were used, 
but the sex of donor and recipient mice matched in every Lin
-
adoptive transfer experiment. 
Mice were monitored on a daily basis throughout the first week post-injection, and every 2-3
days from the second week on. Four weeks post-injection, peripheral blood blood was 
analyzed for the presence of GFP
+
cells, B cells, CD4
+
and CD8
+
T cells. 
Cell cycle analysis. 
72h post transduction, Lin
-
cells were harvested, washed and resuspended in pure 
DMEM (at 1x10
6
cell/mL). Diluted Hoechst 33342 (Invitrogen LifeTechnologies) (1mg/mL 
in water) was added to a final concentration of 2µg/mL and incubated at 37°C for 30 min 
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away from light. Cell cycle of mKO2
+
or mCherry
+
cells was assessed after excluding dead 
cells with SytoxRed (Invitrogen LifeTechnologies) at a 150-200 events/sec rate by exciting 
Hoechst 33342 with 355 nm-UV laser on BD LSR Fortessa cytometer (Beckton Dickinson). 
All cell cycle profiles were analyzed with FlowJo software (TriStar, San Carlos, CA, USA). 
In vitro activated B cells were processed similarly.
Other flow cytometry analysis.
Mouse peripheral blood cells isolated 4 weeks post-injection and splenocytes 
following the primary immunization were analyzed for the expression of activated B and T-
cell markers by the following panel of rat anti-mouse mAb antibodies: APC eFluor780-
conjugated B220 (eBiosciences), PerCP-eFluor710-conjugated IgM (eBiosciences), 
phycoerithrin (PE)-conjugated CD4 (BD Pharmingen), APC-conjugated CD8 (BD 
Pharmingen), Alexa647-conjugated GL7 activation marker (eBiosciences), biotinylated PNA 
(Vector) visualized with streptavidin coupled to PE-Cy7 (eBiosciences). Dead cells were 
excluded by forward and side scatter intensity and by subsequent gating after labeling with 
Sytox Blue Dead Cell Stain (Invitrogen Life Technologies). All cytometry profiles were 
acquired at BD LSR Fortessa or BD FACSCantoII cytometers and data were analysed with 
FACS Diva software (Beckton Dickinson)
Immunization, sorting strategy, genomic DNA extraction and sequence analysis.
Mice were immunized by injecting intra-peritoneally 5x10
9
sheep red blood cells 
(SRBC, Eurobio) per mouse, washed three times and resuspended in 500 mL PBS.  Mice 
were sacrificed 14 days after the primary immunization, or 5 days after the secondary 
immunization performed at a one-month distance. Spleen cells were prepared and labeled for 
sorting on FACS Aria I (Beckton Dickinson). Sorted B220
+
PNA
hi 
GL7
+
cells were heat-lysed
at 95°C for 10 minutes and proteins were removed after incubation 30 min at 56°C with 
proteinase K (Roche). Three to four aliquots of this preparation (up to 1000 cells/aliquot) 
were used as a genomic DNA template for amplifying the rearranged VDJ locus and adjacent 
JH4 intron in a 40-cycle direct PCR reaction. Five forward primers at a ratio 6:3:1:1:1 
amplifying VH1, VH5, VH3, VH7 and VH9 gene families and a reverse primer complementary 
to the downstream sequence of JH4 gene (5’ GAGTACTTGAAAACCCTCTCAC) were 
amplified by Phusion polymerase (New England Biolabs) as described previously (Delbos et 
al., 2005). The gel-purified PCR product was ligated into pCR2.1 cloning vector (Original TA 
Cloning Kit, Invitrogen Life Technologies). Plasmid DNA was extracted by Millipore 96-well 
Miniprep system (Millipore Miltenyi). Sequencing was carried out in ABI Prism 3130xl 
Genetic Analyzer. The diversity of VDJ junctions and mutations within 450bp of JH4 intron 
were analyzed with CodonCode Aligner software (Li-COR).
Three different types of mutation analysis were performed. In the first one, allowing 
the estimate of mutation frequencies (represented in Figure 3), identical sequences were 
removed. In the second one, mutations were discarded when two mutations or more were 
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shared by different sequences, even if they do not displayed clonal relationship (to account for 
possible PCR hybrids). The third one, the most stringent one, takes into account only one type 
of mutation at each position: this analysis, used by the SHMTool program (Maccarthy et al., 
2009), is not strictly scientifically neutral, since it underestimates recurrent base substitutions, 
notably at hotspot positions. 
In vitro B-cell activation. 
5x10
5
B220
+
EGFP
+
GL7
-
PNA
low
B cells were collected in parallel from restored 
SRBC-immunized animals. Cells were resuspended at 1x10
6
cells/mL in RPMI complete 
medium (fetal calf serum 15%, 0.1 mM ȕ-mercaptoethanol, 20 mM HEPES, 1 mM sodium 
pyruvate and non-essential amino-acids) supplemented with Escherichia coli
lipopolysaccharide (serotype O55:B5 , Sigma Aldrich) and mouse recombinant IL-4
(eBioscience) to a final concentration of 20 µg/mL and 25 ng/mL, respectively.   After 4 days 
of activation, cells were harvested for cell cycle analysis.
Patient studies
A homozygous hypomorphic mutation in the DNA polymerase epsilon gene has been 
reported within a large French family (Pachlopnik Schmid et al., 2012). 10 ml of blood were 
obtained from a 13.5 years old affected member after informed consent, and somatic 
mutations were determined in the JH4-JH5 intronic sequence flanking rearranged VH genes of 
sorted IgD
-
CD27
+
and IgD
+
CD27
+
B cells, as described previously (Weller et al., 2008). PCR 
conditions were as follows: 40 cycles of 98°C for 10 seconds, 60°C for 20 seconds, and 72°C 
for 20 seconds. The resulting JH4-JH5 PCR products were gel purified and cloned with Zero 
Blunt PCR Cloning kit (Invitrogen). Sequences were run in an ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems). Mutation frequencies were calculated by comparing the 
sequences obtained with germline intronic JH4-JH5 sequences over 284 bp, starting at the 3’ 
border of the JH4 gene segment.
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Figure legends.
Figure 1. Cell cycle restricted expression of AID in transduced hematopoietic stem cells.
Retroviral constructs expressing the G1-restricted form of AID fused to the mKO2 
fluorescent reporter (AID-mKO2-G1) and its cell cycle control mutant (represented by a red 
spark), the S/G2/M-restricted from (AID-Cherry-S/G2/M) and its cell cycle control mutant 
(same symbol), with an IRES EGFP reporter were used to transduced Lin
-
hematopoietic stem 
cells. Cell cycle analysis was performed three days after transduction, using Hoechst staining 
to estimate of the cell DNA content. The cell cycle profile of EGFP
+
cells (bottom row) and 
of mKO2-EGFP or mCherry-EGFP double positive cells (upper row) is indicated, with 
distribution within the different phases of the cell cycle estimated by the FlowJo software. 
Figure 2. Restoration of peripheral B and T cells by HSC transduced with AID-expressing 
vectors.
(A) Percentage of transduced EGFP
+
cells among Aicda
-/-
Lin
-
hematopoietic stem 
cells used to restore the Rag2-deficent mice analyzed in (B) and (C), and analyzed three days 
after transduction. (B) Relative B cell and CD4
+
and CD8
+
T cell distribution among total 
spleen cells, two to three months after restoration with Aicda
-/-
transduced HSC. Analysis of 
wt mice and of animals restored in parallel with mock-transduced Aicda
-/-
HSC is shown for 
comparison. (C) Proportion of EGFP
+
cells, transduced with the different AID expression 
vectors, among total spleen cells (top), CD4
+
and CD8
+
T cells and B cells (bottom row). 
AID
G1
and AID
S/G2/M
: AID restricted in G1 or S/G2/M by fusion with the hCDT1 or Geminin 
degron, respectively; AID
G1-MUT
and AID
S/G2/M-MUT
: mutated version of the same AID fusion 
proteins, in which amino acids responsible for cell cycle control have been mutated or 
deleted.
Figure 3. Cell cycle restricted expression of AID in LPS blasts from reconstituted animals.
Same as Figure 1, but performed on naive splenic B cells from restored animals, three 
days after LPS + IL4 stimulation. Activations were performed on sorted EGFP
+
B220
+
GL7
-
PNA
low
B cells, except for mutated AID-mKO2-G1, for which activation was performed on 
total naive B cells, and gated on EGFP
+
cells for cell cycle analysis. 
Figure 4. Mutation profile of germinal center B cells from mice reconstituted with cell cycle-
restricted AID-expressing HSC. Base substitution pattern (A) and mutation frequency (B) in 
JH4 intronic sequences from Rag2-deficient animals restored with Aicda
-/-
HSC transduced 
with the different AID-expressing vectors. The mutation profile of mice restored with 
AID
S/G2/M
is not shown, since it concerns a total of 8 mutations. Representation of mutation 
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frequencies for the different animals studied (C) and of the relative G/C and A/T ratio among 
total mutations obtained for the four different AID constructs (D).
 
Figure 5. Ig gene mutation profile of patients with a homozygous hypomorphic mutation in 
DNA polymerase epsilon. Base substitution pattern (A) and mutation frequency (B) in JH4-
JH5 intronic sequences from peripheral memory B cells (IgD
+
CD27
+
and IgD
-
CD27
+
) of a 
patient presenting an hypomorphic mutation in the DNA epsilon gene. The control sample 
values are taken from Faili et al. (Faili et al., 2009), with the range of variation among the 6 
individuals studied.
 
 
 
!"#$
%
&
'
(
$
!"#$
%
)
*
+
,
,
-
$
./0$1234+34$562+1*74$8889(:$
!;<$=>?@A$
B<$8C>;A$
!(<$C>DA$
!;<$9@>8$A$
B<$9D>CA$
!(<$;D>DA$
!;<$9E>8A$
B<$9C>8A$
!(<$9>8A$
!;<$=(>($A$
B<$9(>;A$
!(<$=>EA$
!;<=D>F$A$
B<$9=>;A$
!(<$9>8A$
!;<$9=>EA$
B<$99>FA$
!(<$@>FA$
!;<$C=>DA$
B<$;9>@A$
!(<$C>;A$
!;<$C>DA$
B<$CE>;A$
!(<$;=>DA$
!"#$ %&'($ )*#+,$ !"#$ %*)-../$ 0-%1212$
"GHI,+$;$
!"#$ %&'($ )*#+,$
3$
!"#$ %*)-../$ 0-%1212$
3$
 
!"
#$%&'(")"
*
+
N.A. 
 
!"#$
%
&
'
(
$
!"#$
%
)
*
+
,
,
-
$
./0$1234+34$562+1*74$8889(:$
!;<=8>8$?$
@<$(8>9?$
!(<$8>8?$
!;<AB>8$?$
@<$8;>9?$
!(<$8>8?$
!;<$=(>C?$
@<$((>B?$
!(<$B>A?$
!;<=(>;$?$
@<$(8>;?$
!(<$9>=?$
!;<$=(>9?$
@<$((>(?$
!(<$B>9?$
!;<$=(>C?$
@<$(8>;?$
!(<$9>D?$
!;<$D(>A?$
@<$B>B?$
!(<$;>E?$
!;<;(>D$?$
@<$AB>A?$
!(<(;>B?$$
"FGH,+$8$
!"#$ %&'($ )*#+,$ !"#$ %*)-../$ 0-%1212$!"#$ %&'($ )*#+,$
3$
!"#$ %*)-../$ 0-%1212$
3$
 
!"
"
"
"
#"
"
$" " " " " " %"
"
"
"
"
&'()*+",
"
"
"
! -'./'0"12$" -'./'0"!23"
" .*405'.'605" .*4057+*5'605" .*405'.'605" .*4057+*5'605"
"
12$"8"!23" .*405'.'605"8"
.*4057+*5'605" 1".6"!"
$".6"3"
1".6"3"
$".6"!"
1".6"$"
$".6"1"
!".6"1"
3".6"$"
!".6"3"
3".6"!"
!".6"$"
3".6"1"
!9%
1:
" ;<=>"8",?=:" @;=>"8"A,=:" @<=@" A=B" A:=?" @;=B" @=C" :@=A"
!9%
1:DE).
" ;C=<"8",:=," <C=B"8?A=B" C<=<" <=C" <=<" ,:=<" ,:=;" :<=>"
!9%
F21A2E
" G=%=" G=%=" G=%=" G=%=" G=%=" G=%=" G=%=" G=%="
!9%
F21A2EDE).
" ;B=,"8,>=<" <?=>"8?<=:" @C=C" ,=@" :<=;" ,C=@" AA=B" A>=?"
" !9%
1:
" !9%
1:DE).
" !9%
F21A2E
" !9%
F21A2EDE).
"
G)HI+*"6J"H'K+" ?" ," ;" A"
G)HI+*"6J"5+L)+0K+5" AA<" A>:" A?A" :?B"
36.4M"M+0(./"5+L)+0K+N"OIPQR" :B?S@?," :??S;<>" :B<S@AB" <,S?;B"
T0H).4.+N"5+L)+0K+5"OP+*K+0.Q" <<" @@" >@" @<"
36.4M"0)HI+*"6J"H).4.'605" CA" ?:," C" ,A"
ON+M+.'605"40N"'05+*.'605Q" O?Q" O?Q" OBQ" OAQ"
E).4.'60"J*+L)+0KU"P+*".6.4M"5+L)+0K+5"OP+*":BB"IPQ" B=BC:>" B=A?@?" B=BB@;" B=B@?@"
E).4.'60"J*+L)+0KU"P+*"H).4.+N"5+L)+0K+5"OP+*":BB"IPQ" B=?;<:" B=@B,@" B=A,>B" B=?B>A"
 
!"
"
"
#"
"
"
"
"
" " " " " " "
"
" " " " " " " " " " " $%&'()"*
"
"
"
! ! ! +%,-%."/01" +%,-%."!02"
" ,(3.4%,%5.4" ,(3.46)(4%5.4" ,(3.4%,%5.4" ,(3.46)(4%5.4"
"
/01"7"!02" ,(3.4%,%5.4"7"
,(3.46)(4%5.4" /",5"!"
1",5"2"
/",5"2"
1",5"!"
/",5"1"
1",5"/"
!",5"/"
2",5"1"
!",5"2"
2",5"!"
!",5"1"
2",5"/"
81"
!"#$%&'(
*9:9"7"*9:9"
!)*+,-.,+/(0()*+1-.,+)'(
*;:<"7"=>:?"
!)2+1-.3+)(0()2+,-.3+/'"
*;:9"
!),+/-.)+,'"
;@:A"
!/3+4-35+)'"
<A:>"
!*5+)-*,+4'"
*;:@"
!)1+3-.2+.'"
A;:>"
!/2+5-3.+/'"
A@:@"
!3*+3-31+.'"
B5C"D" =@:*"7"*<:*" =?:>"7"*A:A" =E:<" ;=:E" <*:>" =@:<" A>:E" A=:?"
" 81"
F&G
H
1GA?
H
"
81"
F&G
I
1GA?
H
"
B5C"D"
F&G
H
1GA?
H
"
B5C"D"
F&G
I
1GA?
H
"
J'KL)("5M"4)N').O)4" ;<?" ;A=" ;=" ;A"
25,3C"C).&,-"4)N').O)P"QLRST" <>U??;" <*U9EA" =?@9" =9>9"
V.K',3,)P"4)N').O)4"QR)(O).,S" =" A" A;" >"
25,3C".'KL)("5M"K',3,%5.4" ;;?=" A;<@" EE" ;>A"
QP)C),%5.4"3.P"%.4)(,%5.4S" Q*=S" Q;;=S" Q=S" Q@S"
W',3,%5."M()N').OX"R)(",5,3C"4)N').O)4"QR)(";99"LRS" <:9<" @:9E" A:;@" =:@;"
W',3,%5."M()N').OX"R)("K',3,)P"4)N').O)4"QR)(";99"LRS" <:;=" @:;E" A:?*" *:9<"
 
Zivojnovic Marija –L’hypermutation somatique des gènes des immunoglobulines -2013
177 | P a g e
Part Three: Unpublished research project  
Cell cycle-restricted PolɄ fusions fail to 
complement in vivo Ʉ
hypermutation 
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Design of Pol Ʉ fusions and the quality of restricted Pol Ʉ 
expression 
After AID expression was successfully confined to the G1 phase in AID-mKO2-
hCDT1:30/120-expressing 3T3 fibroblasts, we set out to replace the fluorochromes from the 
original constructs (pFucci Orange G1: mKO2-hCDT1:30/120, pFucci-Green S/G2/M: mAG-
*HPLQLQZLWKP&KHUU\6LQFHWKHILQDOIXVLRQSURWHLQZLWKPRXVHSRO\PHUDVHȘZDVWR
be expressed from pMigR1 construct containing IRES-GFP reporter gene, the need to replace 
Azami Green (mAG) was obvious. As for pFucci-Orange whose original fluorochrome 
mKO2 is retained for cloning of AID
G1
fusion, we sought to replace it with a fluorochrome 
whose emission signal is better captured with the laser configuration of our flow cytometer. 
Degradation driven by hCDT1:30/120 degron was shown to be sensitive to the nature of the 
other fusion partner, whereas Geminin:1/110 was shown to be more permissive (Sakaue-
Sawano et al., 2008). However, both degrons governed very successfully the cell-cycle 
specific degradation of mCherry in NIH 3T3 cells transduced with pMigR1 vectors coding for 
mCherry fusions (Figure 1). The degradation profile was similar to the one of fusions 
expressed from the original constructs in HeLa cells.  The GFP+mCherry+ population was 
clearly demarcated from GFP only expressing cells in both cases and was highly enriched in 
the accumulation-permissive phase. Nonetheless, none of the fusions was spared from a minor 
leakage of around 15% of GFP
+
mCherry
+
cells into phases where the fusion is susceptible to 
degradation. The majority of “leaky” GFP
+
mCherry
+
accumulated at G1/S phase transition, 
reproducing the pattern of yellow HeLa cells expressing the dual Fucci system in which 
fluorescence from pFucci Orange G1 and pFucci-Green S/G2/M overlaps at G1/S transition. 
Mouse Polh cDNA was fused C-terminally to mCherry
G1
and mCherry
S/G2/M 
fusions. 
Fusion to Cherry portion was carried out in frame, but lacked the flexible linker that separated 
AID-C terminus from the fluorochrome in AID constructs. Furthermore, we created control 
3ROȘ-mCherry fusions with mutated degrons to verify whether the bulky mCherry-degron tail 
preventV 3RO Ș IURP SURSHU IROGLQJ RU IXOO activity. We deleted the Geminin:1/110 portion 
containing residues for APC/C-mediated ubiquitinylation (degron S/G2/M-Mut) and mutated 
the PARRRLRL motif of hCDT1:30/120 governing SCF/Skp2 (degron G1-Mut), thus 
abrogating the cell cycle restriction of corresponding fusions. When the cell cycle profile of
SV40T-transformed 3RO Ș GHILFLHQWmouse embryonic fibroblasts (MEF-T) transduced with 
vectors expressing 3ROȘ-Cherry-degronMut was assessed, the GFP+mCherry+ population
displayed a cell cycle profile similar to the one of non-transduced cells (Figure 2). For the 
VDNHRI FODULW\3RO Ș-mCherry-degron/mutated degron fusions will be named from now on 
3ROȘ-G13ROȘ-G1-Mut3ROȘ-S/G2/M DQG3ROȘ-S/G2/M-Mut in further text.
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Figure2. mCherry cell cycle-regulated expression in NIH 3T3 mouse fibroblasts.  
pMigR1 retroviral constructs express from the LTR promoter: G1- and S/G2/M-restricted form of 
mCherry and the cell cycle mutant mCherry-S/G2/M-Mut (represented with a red sparkle) 
concomitantly with GFP from the pMigR1 IRES.  Staining with Hoechst was used to estimate DNA cell 
content. The cell profile of uninfected cells (bottom row) and of GFP
+
mCherry
+
 cells (upper row) is 
indicated, with distributions within different phases of the cell cycle estimated by the Flow Jo 
software. 
Leakiness of MEF-T Polh
-/FHOOVH[SUHVVLQJ3ROȘ-mCherry fused to functional degrons 
was comparable to percentages of GFP-mCherry double positive cells in NIH 3T3 expressing 
the respective mCherry-only fusions  (around 15% in phases prone to degradation). However, 
the level of P&KHUU\IOXRUHVFHQFH LQ*)3P&KHUU\SRSXODWLRQVRI3ROȘ-transduced MEF 
differed markedly from the one of the restricted mCherry  fusions. Despite the fact that the 
H[SUHVVLRQRIP&KHUU\IXVLRQVZLWKRUZLWKRXW3ROȘZDVGULYHQE\WKHVDPHUHWURYLUDO/75
promoter and that in all cases multiplicity of infection (MOI) was in the same order of 
magnitude, mCherry mean fluorescence intensity (MFI) of GFP
+
mCherry
+
population for Pol 
ȘIXVLRQVZDVFRQVLGHUDEO\ORZHUFRPSDUHGWRIXVLRQVZLWKVROHP&KHUU\. This was observed 
IRU DOO 3RO Ș IXVLRQ LQ ERWK 0() Polh-/-and hematopoietic stem cells, irrespective of the 
restriction profile (Figures 2 and 5).
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In vitro activity of PolɄ in fusion with mutated degrons 
To check for a potential alteration of PROȘ DFWLYLW\GXH WR LWV HPERGLPHQWZLWKLQ D
IXVLRQDQGLQGHSHQGHQWO\RIWKHFHOOF\FOHUHVWULFWLRQFRQWH[WZHWHVWHGWKHDFWLYLW\RI3ROȘ
fused to mutated degrons in MEF-7 FHOOV GHILFLHQW IRU 3RO Ș  89 LUUDGLDWLRQ OHDG WR WKH
formation of repair foci in which Ub-PCNA and Pol eta cluster (Kannouche et al., 2004b) .
:HVHWRIIWRWHVWWKHDELOLW\RI3ROȘ-mCherry fusions to accumulate in UV-induced foci in 
irradiated MEFs. A C-WHUPLQDOIXVLRQRI3ROȘZLWK(*)3H[SUHVVHGIURPDS0LJ5YHFWRU
lacking IRES-GFP portion was used as a positive control (Figure3). In non-irradiated cells, 
mCherry was diffusely distributed throughout the nuclei of both 3ROȘ-G1-Mut and 3ROȘ-S/G2/M-
Mut
- transduced cells. Six hours post-irradiation, mCherry fluorescence of both constructs 
segregated into distinct focal points. The same accumulation pattern was unambiguously 
UHSURGXFHGE\3ROȘ-EGFP fusion.
Figure3 Cell cycle restricted expression of Pol ɻ in SV40 T-transformed MEF Polh-/- cells.  
pMigR1 retroviral constructs expressing the G1-restricted form of Pol ɻ fused to the mCherry 
fluorescent reporter (Pol ɻ-mCherry-G1) and its cell cycle control mutant (represented by a red spark), 
the S/G2/M-restricted from (Pol-Cherry-S/G2/M) and its cell cycle control mutant (same symbol), with 
an IRES EGFP reporter. Cell cycle analysis was performed using Hoechst staining to estimate the cell DNA 
content. The cell cycle profile of EGFP
+
 cells (bottom row) and of mCherry-EGFP double positive cells 
(upper row) is indicated, with distribution within the different phases of the cell cycle estimated by the 
FlowJo software.  
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Figure3  Subnuclear organization of Pol ɻ-EGFP fusion and Pol ɻ-mCherry fusions with mutated degrons 
(Pol ɻ-G1-Mut and Pol ɻ-S/G2/M-Mut). Transduced and GFP+ sorted non-irradiated MEF Polh-/- (left panel 
including DAPI/GFP/mCherry columns) or UV-irradiated with 10 J/m
2
  (right panel) were fixed  6h post-
irradiation and mounted on coverslips. Post-acquisition treatment of micrographs was carried out in 
ImageJ software. 
Figure 4 Survival of WT MEFs, Poh
-/-
 MEF-T mock-transduced and transduced with pMigR1 constructs 
expressing Pol ɻ fusions with abrogated cell cycle restriction.  
Survival was measured with a colorimetric assay 72h post-UV irradiation for non-irradiated, 6 J/m
2
 
and 10 J/m
2
-irradiated cells  after recovery in culture supplemented with 1mM caffeine. Data points 
were acquired in triplicates, averaged and subtracted for the values of background emission. 
Displayed error bars represent SD. Data were analyzed and plotted in GraphPad Prism software. 
J/m
2
% survival
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During the last years, an increasing body of evidence supports a temporal separation 
between the visible accumulation of TLS polymerases into subnuclear foci and the mere act 
of loading them onto DNA and performing lesion bypass (Gueranger et al., 2008; Soria et al., 
2009) :H SXUVXHG RXU WHVWLQJ RI 3RO Ș DFWLYLW\ LQ IXVLRQ EH\RQG UHFUXLWPHQW WR WKH 89-
induced foci by measuring the capacity of  3RO Ș-G1-Mut and 3RO Ș-S/G2/M-Mut fusions to 
complement the UV light sensitivity of MEF-T Polh
-/-
. To do so, we subjected previously 
transduced and sorted GFP
+
cells to two different doses of UV irradiation (6 and 10 J/m
2
), 
allowed them to recover in complete medium supplemented with 1mM caffeine for 72h, 
followed by the quantification of post-UV irradiation survival. Non-irradiated transduced 
MEFs were treated simultaneously with irradiated cells (Figure 4).
3RO Ș-deficient MEFs expressing 3RO Ș-G1-Mut and 3RO Ș-S/G2/M-Mut were efficiently 
rescued from cell death due to the replication fork collapse (observed for Polh
-/-
MEF-T) 
already at 6 J/m
2
of UV irradiation. This efficiency was close to the success rate of 
HQGRJHQRXVO\ H[SUHVVHG :7 3RO Ș DW  -P2. These results indicate that stable ectopic 
expression of 3ROȘ-G1-Mut and 3ROȘ-S/G2/M-Mut fusions driven by retroviral promoters is able to 
complement the UV sensitivity of Polh
-/-
deficient MEFs. However, one should refrain from 
FRQFOXGLQJWKDWDVLQJOH3ROȘ-IXVLRQPROHFXOHLVDEOHWRVXEVWLWXWHIRUIXOO:73ROȘDFWLYLW\
due to the difficult-to-FRQWURO 3RO Ș RYHUH[SUHVVLRQ IURP/75 SURPRWHU DQG IURPPXOWLSOH
integration sites. 
Adoptive transfer of Polh-/- hematopoietic cells expressing 
cell-cycle restricted Pol Ʉ 
We proceeded to generate retrogenic mice with adoptively transferred hematopoietic 
stem cells (HSC) expressing 3ROȘ-G13ROȘ-G1-Mut3ROȘ-S/G2/M DQG3ROȘ-S/G2/M-Mut- fusions in 
the same manner as for cell cycle-restricted AID expression. The phase-restricted cell cycle 
profiles of GFP
+
mCherry
+
Lin
-
cells expressing 3ROȘ-G1 and 3ROȘ-S/G2/M constructs strictly 
reproduced those of mCherry
G1
and mCherry
S/G2/M 
fibroblasts, respectively. Transduced HSC 
cells were more efficient in limiting GFP
+
mCherry
+
cells leakage to degradation-prone phases 
(Figure 5). 
Interestingly, if one compares mCherry MFI of the GFP
+
mCherry
+
cells in, for 
example,  AID
S/G2/M DQG 3RO ȘS/G2/M Lin- cells for a given value of GFP fluorescence, it 
EHFRPHV FOHDU WKDW 3RO Ș-mCherry fusion starts to visibly accumulate only in GFPhi cells. 
Values of accumulated AID-mCherry in AID
S/G2/M
cells closely matched the quantity of GFP 
SHU FHOO 7KHVH SURSHUWLHV RI 3RO Ș-mCherry accumulation and expression underline the 
H[LVWHQFHRIDGGLWLRQDOFHOOXODUPHFKDQLVPVWKDWDFWLYHO\UHJXODWHWKHDYDLODEOH3ROȘSRROLQ
the cell. 
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Figure5. Cell cycle restricted expression of WŽůɻ in transducedPolh-/-hematopoietic stem cells. 
Retroviral constructs expressing G1- and S/G2/M-ƌĞƐƚƌŝĐƚĞĚĨŽƌŵƐŽĨWŽůɻĂůŽŶŐǁŝƚŚWŽůɻ-mCherry fused to mutated G1 
degron (represented by a red spark), ǁŝƚŚĂŶ/Z^'&WƌĞƉŽƌƚĞƌǁĞƌĞƵƐĞĚƚŽƚƌĂŶƐĚƵĐĞĚ>ŝŶ- hematopoietic stem cells. 
Fusion ŽĨWŽůɻƚŽĐĞůůĐǇĐůĞŵƵƚĂŶƚĨŽƌ^ͬ'ϮͬD-ĐŽŶĨĞƌƌĞĚƌĞƐƚƌŝĐƚŝŽŶǁĞƌĞŶŽƚĂǀĂŝůĂďůĞĨŽƌĐĞůůĐǇĐůĞĂŶĂůǇƐŝƐ͘ Cell cycle 
ĂŶĂůǇƐŝƐ ǁĂƐ ƉĞƌĨŽƌŵĞĚ ƚŚƌĞĞ ĚĂǇƐ ĂĨƚĞƌthe last transduction cycle, using Hoechst staining to estimate the cell DNA 
content. The cell cycle profile of non-transduced ĐĞůůƐ ;ďŽƚƚŽŵƌŽǁͿĂŶĚŽĨŵŚĞƌƌǇ-EGFP double positive cells (upper 
ƌŽǁͿŝƐŝŶĚŝĐĂƚĞĚ͕ǁŝƚŚĚŝƐƚƌŝďƵƚŝŽŶǁŝƚŚŝŶƚŚĞĚŝĨĨĞƌĞŶƚƉŚĂƐĞƐŽĨƚŚĞĐĞůůĐǇĐůĞĞƐƚŝŵĂƚĞĚďǇƚŚĞ&ůŽǁ:ŽƐŽĨƚǁĂƌĞ͘ 
 
In spite of high transduction levels, PoOȘ-G1(67% GFP+ cells) and 3ROȘ-G1-Mut (61.4% 
GFP
+
cells) poorly reconstituted the B and T-cell pool of irradiated Rag2-deficient receivers. 
Extremely low percentage of PNA
hi
GFP
+
B-cells in spleens of immunized 3ROȘ-G1 and3ROȘ-
G1-Mut
-reconstituted mice prevented us from amplifying the JH4 intronic region with direct 
PCR strategy. We temporarily abandoned the plan of restricting of 3RO Ș to G1 phase and 
pursued the analyses of the 3RO Ș-S/G2/M DQG 3RO Ș-S/G2/M-Mut-restored mice, which were 
supposed to yield more informative readout to test our hypothesis of a cell cycle-coordinated 
SHM process (Figure 28, Chapter III.3).
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Pol ɄS/G2/M-Mut germinal center B-cells have mutation 
profile identical to Pol Ʉ-deficient mice 
B and T-cell pools were successfully reconstituted upon the transfer of 3ROȘ-S/G2/Mand 
3ROȘ-S/G2/M-Mut–expressing Lin- cells in irradiated Rag2-/- mice (3 mice/ group). Levels of B-
and T-cells were comparable to reconstitution with AID-coding constructs (not shown). 
Immunizations with sheep red blood cells triggered a robust response, allowing us to sort up 
to 50,000 B220
+
PNA
hi
GFP
+
cells per mouse in the S/G2/M-restricted group (representing a 
mean of 0.5% of total live spleen cells) and successfully perform VH-D-JH4 intron
amplification and sequencing. However, only in one 3RO Ș-S/G2/M-Mut mouse could an 
amplification with sufficient clonal junctional diversity be obtained (Figure 6).
0XWDWLRQSURILOHRI3ROȘS/G2/M PLFHFORVHO\UHVHPEOHGWKHRQHRI3ROȘGHILFLHQWPLFH
(data taken from (Delbos et al., 2007). Such a profile, biased for A to C and T to G 
transversions harbors the signature of PolN, which substitute for Pol K in its absence (as seen 
in Figure 6D). However, the same held true for the single 3ROȘ-S/G2/M-Mut mouse analyzed. 
Albeit satisfactory UV sensitivity complementation in Polh
-/-
MEFs and successful recruitment 
to subnuclear foci were observed, 3ROȘ fused with mutated S/G2/M degron and henceforth 
H[SUHVVHGWKURXJKRXWWKHFHOOF\FOHRQD3ROȘ-deficient background, failed to restore the in 
vivo :73ROȘPXWDWLRQSDWWHUQLQJHUPLQDOFHQWHU%-FHOOV:HFRQFOXGHGWKDW3ROȘIXVHGLQ
C-terminal configuration with mCherry and mutated Geminin:1/110ǻ degron severely 
impaired the enzyme’s in vivo efficiency to be recruited to Ig genes or to perform A:T 
mutagenesis in somatic hypermutation and prevents us from concluding about its possible in 
vivo restriction to a specific phase of the cell cycle.
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A
B
 WŽůɻS/G2/M WŽůɻS/G2/M-Mut 
Number of mice 3 1 
Number of sequences 129 56 
Total length sequenced (bp) 32,859 35,391 
Unmutated sequences (percent) 23 6 
Total number of mutations 184 174 
(deletions and insertions) (1) (0) 
Mutation frequency per total sequences (per 100 bp) 0.70 0.58 
Mutation frequency per mutated sequences (per 100 bp) 1.18 0.62 
C D
Figure 6. Mutation pattern of JH4 intron of splenic GFP+ GC B-ĐĞůůƐĨƌŽŵŚŽƐƚŵŝĐĞǁŝƚŚĂĚŽƉƚŝǀĞůǇƚƌĂŶƐĨĞƌƌĞĚWŽůɻ-G1-Mut 
ĂŶĚWŽůɻ-S/G2/M-Mut-expressing hematopoietic stem cells. 
ͿWĂƚƚĞƌŶŽĨŶƵĐůĞŽƚŝĚĞĐŚĂŶŐĞƐŝŶWŽůɻ-ĚĞĨŝĐŝĞŶƚŵŝĐĞ;ĚĂƚĂƐĞƚƚĂŬĞŶĨƌŽŵ;ĞůďŽƐ͕ϮϬϬϳͿͿ͕WŽůɻ-S/G2/M ĂŶĚWŽůɻ-S/G2/M-
Mutretrogenic host mice. B) Summary of analyzed sequences and pooled mutation rates per reconstituted host group. C) 
Graphic representation of relative frequencies for A:T and G:C mutations in JHϰŝŶƚƌŽŶŽĨ'&Wн'ĐĞůůƐĨƌŽŵWŽůɻ-G1-Mut 
ĂŶĚ WŽů ɻ-S/G2/M-Mut-expressing retrogenic mice (values from A). D) Graphic representation of relative frequencies for 
ƚƌĂŶƐŝƚŝŽŶƐĂŶĚƚƌĂŶƐǀĞƌƐŝŽŶƐĂƚ͗dďĂƐĞƉĂŝƌƐŝŶWŽůɻ-/-͕WŽůɻ-G1-Mut ĂŶĚWŽůɻ-S/G2/M-Mut,  
 within G/C within A/T 
 G/C : A/T transitions : 
transversions 
transitions transversions transitions transversions 
 
G to A 
C to T 
G to T 
C to A 
G to C 
C to G 
A to G 
T to C 
A to T 
T to A 
A to C 
T to G 
WŽůɻ-/- 84.4 :15.6 53 :47 59.3 11.7 29.0 18.8 24.7 56.5 
WŽůɻS/G2/M 80.3 :19.7 49 :51 54.5 10.0 35.5 26.5 20.5 53.0 
PolɻS/G2/M-Mut 70.4 :29.6 53 :47 67.1 11.6 21.4 19.7 29.6 50.7 
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Materials and methods 
Construction of retroviral vectors.
Mouse Polh gene, previously amplified from mouse cDNA and cloned into an intermediary 
vector, was amplified using the following PCR primers: forward (mPol eta BamHI For) and 
corresponding assembly reverse primers.
In the following course of experiments, we amplified separately the fragments of mCherry, 
hCDT1_30-120aa and hGeminin_1-110aa degrons from commercially available cloning 
vectors: pmCherry (Clontech), pFucci-G1 Orange and pFucci –S/G2/M Green (MBL 
International), respectively.  POLH gene were fused to mCherry and degrons in successive 
steps of assembly PCR reactions using Phusion polymerase (New England Biolabs), 
individual fragments as templates and following cycling conditions: first 10 cycles without 
assembly primers : 10 sec 98°C / 30 sec  55°C / 60-90 sec  72°C and 20-25 cycles with same 
conditions except for annealing temperature (60°C) in the presence of assembly primers.
G1 degron (hCDT1_30-120) in mCherry
G1-Mut
moiety was generated by PCR mutagenesis by 
mutating RRL to AAA in the PARRRLRL motif responsible for its degradation. 
mCherry
S/G2/M-Mut
was generated by PCR site-directed mutagenesis as an in-frame deletion of 
the destruction box sequence (RRTLKVIQP) that begins at amino acid 33 in hGeminin_1-
110aa degron and that abolishes APC-mediated ubiquitination at M/G1 transition.
Pol eta-GFP fusion was generated by successive assembly PCR steps using Ass Pol eta-EGFP 
For and Ass Pol eta-EGFP Rev.
pMigR1 (MSCV: IRES-EGFP (Pear et al., 1998), courtesy of O.A.-C.) retroviral vector was 
used as a backbone for cloning of finalized phase-restricted fusions: Pol eta-mCherry
G1
, Pol 
eta-mCherry-
G1Mut
, Pol eta-mCherry-
S/G2/M
, Pol eta-mCherry-
S/G2/M-Mut
.In order to express Pol 
eta-GFP fusion, IRES-GFP fragment was subsequently deleted by cutting it out from 
pMigR1: Pol eta-GFP finalized vector. All constructs were verified by DNA sequencing.
 
Production and titration of ecotropic retroviral particles.
Cf. Same chapter in Part I, article “AID expression restricted to the G1 phase of the cell cycle 
recapitulates the mutation spectrum of immunoglobulin genes”
 
Cell lines and transduction conditions. 
NIH 3T3 cells were cultured in DMEM 10% bovine calf serum (HyClone). In-house isolated 
and SV40T-transformed mouse embryonic fibroblasts (MEF-T) Polh
-/-
were grown in DMEM 
10% FCS (Hyclone) with 1mM sodium pyruvate.  All mouse cell lines were transduced in the 
same conditions: briefly, cells plated in suboptimal confluence were incubated with 5 
µg/mLpolybren in PBS (Sigma Aldrich) for 1h, supplemented with HEPES 10mM 
(Invitrogen Life Technologies) and inoculated with retroviral particles at MOI varying from 
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1-3. Cell plates were centrifuged for 1h30 at 600g 25°C and allowed to incubate with virus for 
24h, after which the medium was replaced.      
Confocal microscopy. 
Adherent cells (MEF-T Polh
-/-
) were seeded in 24-well plates containing glass coverslips 
previously coated with poly-L-lysine 0.01% w/v solution in water (Sigma Aldrich) and 
allowed to adhere overnight. The next day, medium was carefully removed from the wells and 
cells were fixed with 4% paraformaldehyde (Electron Microscopy Sciences) solution in PBS 
for 15 min. After washing with PBS, coverslips were mounted in Vectashield DAPI (Vector 
Laboratories) on glass slides. Micrographs were acquired with Leica TCS SP5 confocal 
microscope (Leica Microsystems, Necker/Broussais imaging facility). All images were 
treated with ImageJ 1.46r software (NIH). 
 
3ROȘFRPSOHPHQWDWLRQDVVD\IRUWKHVXUYLYDORIWUDQVGXFHG0()-T Polh-/-.
MEF-T Polh
-/-
cells were plated at 2x10
4
cells/cm
2
and transduced with pMigR1: Poleta-
expressing vectors as described previously. Seventy-two hours post-transduction, cells were 
trypsinized, counted, washed and sorted for GFP fluorescence. GFP
+
transduced MEF-Ts 
were grown and checked for GFP expression for a week then plated at 1x10
4
cells per well in 
96-well white plates (Nunc) in triplicate. 24 hours after plating, wells were washed with PBS 
and let dry while irradiating with UVC light (253,7nm)at 0, 6 and 10 J/cm
2
using the UV 
irradiator at Institut de Recherche Integrée en Cancerologie Gustave Roussy, Villejuif 
(provided kindly by S. Aoufouchi, UMR CNRS 8200). Immediately after irradiation, MEF-T
culturing medium supplemented with 1mM caffeine (Sigma-Aldrich) was added to irradiated 
wells. Seventy-two hours post-UV irradiation, cells were trypsinized and tested for viability 
by using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Colorimetric 
measurements were carried out with VICTOR X4 2030 Multilabel plate reader (Perkin 
Elmer), with each plate read three times with 1min interval in between. 
 
3ROȘIRFLIRUPDWLRQLQWUDQVGXFHG0()-T Polh-/-.
After transducing and sorting, GFP
+
MEF-T Polh
-/-
cells were grown and checked for GFP 
expression for a week, then plated at 2x10
4
cells/well on sterile round glass coverslips 
deposed in wells of a 24-well plate and previously coated with polylysine solution in PBS. 
Cells were grown on coverslips for 24h, and then irradiated with 254 nm UVC light at 0 and 
10 J/cm
2
by using UV-sterilization lamps (output: 13.4 W). Six hours post-irradiation, 
coverslip-grown MEFs were fixed in paraformaldehyde and mounted.   
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Mouse strains.
Polh
-/-
C57BL/6 mice were maintained in specific pathogen-free conditions in mouse facility 
of Service de l’Expérimentation Animale et Transgénèse, CNRS Villejuif. RAG2-deficient 
mice were maintained in specific pathogen-free conditions in Laboratoire d'Expérimentation
Animale et Transgénèse, Faculté de Médecine Necker and Broussais mouse facility. All 
experiments and procedures were approved by the French Ministry of Agriculture. 
Hematopoietic stem cell transduction and adoptive transfer experiments.
Cf. Same chapter in Part I, article “AID expression restricted to the G1 phase of the cell cycle 
recapitulates the mutation spectrum of immunoglobulin genes”
 
Cell cycle analysis.
Cf. Same chapter in Part I, article “AID expression restricted to the G1 phase of the cell cycle 
recapitulates the mutation spectrum of immunoglobulin genes”
 
Other flow cytometry analysis.
Cf. Same chapter in Part I, article “AID expression restricted to the G1 phase of the cell cycle 
recapitulates the mutation spectrum of immunoglobulin genes”
 
Immunization, sorting strategy, genomic DNA extraction and sequence analysis.
Cf. Same chapter in Part I, article “AID expression restricted to the G1 phase of the cell cycle 
recapitulates the mutation spectrum of immunoglobulin genes”
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Supplementary Figure 1.Oligonucleotide panel used in this study
V1-FR3 GAGGACTCTGCRGTCTATTWCTGTGC 
V5-FR3 GAGGACACRGCCATGTATTACTGTGC 
V3-FR3 GAGGACACACCCACATATTACTGTGC 
V7-FR3 GAGGACAGTGCCACTTATTACTGTGC 
V9-FR3 ATGAGGACATGGCTACATATTTCTGT 
Jh4 nested 2 CACCAGACCTCTCTAGACAGC 
Jh4 AS 2620 TCCCTCCAGCCATAGGATTG 
hCdt1EcoRI-PacI Rev AAG AAT TCT TAA TTA AAT GGT GTC CTG GTC CTG C
hCdt1mut For GCC CGC GCG GCA GCG CGG CTG TCG GTG GAC GAG
hCdt1mut Rev CAG CCG CGC TGC CGC GCG GGC CGG TGG CCT GGC
Ass mCherry-hCdt1 For CTG TAC AAG GGA TAT CCA TCA CAC TGG CG
Ass mCherry-hCdt1 Rev GAT GGA TAT CCC TTG TAC AGC TCG TCC ATG C
EGFP-PSLD BglII For AAA GAT CTG CCG CCA CCA TGG TGA GCA AGG GCG A
EGFP-PSLD BamHI-PacI For AAG GAT CCT TAA TTA AGT TTC TTG ATT ATC GGT G
mPol eta BamHI For AAG TCG AGG ATC CGC CAC CAT GGC TCC TGG GCA GAA TCG A
Ass Pol eta-EGFP For ACT GAC ACA TGT GAG CAA GGG CGA GGA
Ass Pol eta-EGFP Rev CCT TGC TCA CAT GTG TCA GTG GCT TAA A
hGemEcoRI-PacI Rev AAG AAT TCT TAA TTA AAG CGC CTT TCT CCG TTT TTC
hGemmut For TTC TGT CCC ATC TGC ATC TGG ATC TCT TGT TG
hGemmut Rev CAG ATG CAG ATG GGA CAG AAC TAT TCT TTA TA
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Summary 
A/T mutations at the immunoglobulin loci are introduced by DNA polymerase eta (Polh), during an 
Msh2/6-driven repair process resulting in As being two-fold more mutated than Ts. This patch 
synthesis is initiated by a DNA incision event, the origin of which is still obscure. We report here the 
analysis of A/T oligonucleotide mutation substrates inserted at the heavy chain locus, including or not 
internal Cs or Gs. Surprisingly, the template composed of only As and Ts was highly mutated over its 
entire 90-bp length, displaying a 2-fold decrease in mutation from 5' to 3' and a constant A/T ratio of 
4. These features implied that Polh synthesis was initiated from a break in the 5'-flanking region of the 
substrate and proceeded over its entire length. The A/T bias was strikingly altered in an Ung-/- 
background, thus providing the first experimental evidence supporting the proposition of Schanz et al. 
(1) of a concerted action of Ung and Msh2/6 pathways to generate mutations at A/T bases. New 
analysis of Pms2-/- animals provided a complementary picture, revealing an A/T mutation ratio of 4. 
We thus propose that Ung and Pms2 provide mutual back-up function for the DNA incision that 
promotes synthesis by Polh. 
 
Introduction
 
 Somatic hypermutation of immunoglobulin genes is a locus-specific mutagenesis, triggered by 
an initial deamination event performed by the lymphoid-restricted enzyme, AID (activation-induced 
cytidine deaminase) (2, 3). Such a process which mostly, but not exclusively, takes place in B cells 
engaged in an immune response, allows the unique adaptive biological process by which the immune 
system fighting a pathogen improves the specificity and efficiency of its recognition and, as a 
consequence, its control and its elimination. 
 The paradoxical feature of hypermutation is the mutagenic outcome of the processing of this 
ordinary lesion, uracils generated by cytidine deamination or dUTP incorporation during replication 
being normally efficiently and faithfully removed from the genome. This mutagenesis appears to 
result from a combined process of lesion ignorance, incomplete processing or diverted repair, 
mobilizing as mutagenic partners actors with a major function in genome maintenance and mutation 
avoidance: uracil glycosylase and mismatch repair (4). 
 Uracils can remain unprocessed, generating transitions at G/C bases upon the next replication 
step. They can also be partially processed by uracil glycosylase, giving rise to abasic sites that will be 
bypassed by translesion DNA polymerases, among which Rev1 is the only one unambiguously 
identified (5, 6). This process generates transversions, but also transitions at the deamination site. A 
fraction of uracils can be processed further, resulting in DNA incision. Such nicks constitute a key 
step in class switch recombination, a second molecular alteration driven by AID at the switch regions  
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of the Ig locus that involves the rejoining of two double-strand breaks generated at distant sites and 
that exchanges the constant domain of the heavy chain, allowing the B-cell to acquire new effector 
capacities. Nicks in DNA also take place in the V region, resulting, in a fraction of events, in classical, 
error-free base excision repair. 
 Uracils can also be recognized as mismatches by Msh2-Msh6, which, together with ExoI 
triggers a long patch error-prone DNA synthesis that relies on DNA polymerase eta (PolȘ) and 
ubiquitination of PCNA (7, 8). This pathway generates mainly mutations at A/T bases, at distance 
from the initial deamination sites, due to the specific misincorporation of PolȘ that has low fidelity 
when copying Ts. This patch repair is unusual in that the second part of the mismatch repair complex, 
MutLa, composed of Pms2 and Mlh1, appears dispensable, and relies on the sole Msh2-Msh6 complex 
(MutSa), together with Exonuclease I (ExoI) (9, 10). It is thus totally unclear which endonuclease 
activity provides the DNA incision required to initiate the error-prone synthesis.  Moreover, the 
mutation pattern of Ig genes displays an average two-fold higher targeting at A bases than at T bases, 
suggesting a preferred PolȘ synthesis of the coding strand.  
 To understand the process directing the strand choice, Uniraman and Schatz (2007) designed 
transgenic light chain substrates in which they inserted a 100-bp oligonucleotide uniquely composed 
of alternate As and Ts except for one central C or G as AID target. The aim was to correlate the strand 
bias observed in the mutation pattern with the strand targeted for deamination, either the coding (top) 
or the transcribed (bottom) strand. In spite of its elegance, this approach had major weaknesses and 
some inconsistencies: first, the transgene mutation load was very low, 22 mutations being collected in 
total for the transgene including one C, and almost none for the one containing G. It was thus 
concluded that only the top strand can be targeted by AID, whereas mice deficient for both uracil 
glycosylase and mismatch repair (Ung-/-Msh2-/-), a configuration that reveals the unprocessed footprint 
of AID-mediated deaminations, have shown a mutation profile with only a minor bias of C over G 
targeting (4, 9). Lastly, the mutation pattern observed, biased towards T mutations, was not consistent 
with the mutagenic outcome of PolȘ copying the transcribed strand.  
 Transgenic mutation substrates are notoriously variable in their capacity to become efficiently 
targeted, making comparisons between mouse lines with unrelated insertion sites difficult. We decided 
therefore to perform a similar study by using knock-in strategies at the IgH locus, allowing the 
collection of large mutation databases and the direct comparison of different substrates. Such a 
strategy gave a rather different picture of PolȘ performances at the Ig locus, with a long patch length 
and a different strand bias in Ung-proficient or -deficient backgrounds. 
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Materials and Methods 
 
In vitro PolȘ polymerization assay. 
The two oligo-C/oligo-G oligonucleotides were annealed and inserted by blunt-end cloning in the 
EcoRI site of the M13mp18 vector with an orientation resulting in the presence of the oligo-G 
sequence in the single stranded DNA form. E. coli JM109 competent cells (Promega) were used for 
transformation, production of bacteriophage stocks and mid-size single-stranded DNA preparation. A 
polymerization initiation primer (ATTTAGGTGACACTATAGTGTAAAACGACGGCCAGT) was 
designed that includes an SP6 sequence (underlined) and an M13 forward sequence priming 60 bp 
downstream of the oligo-G cloning site. Purified human PolȘ (80 nM, Enzymax) was used to elongate 
this primer in presence of 40 fmol (100 ng) single-stranded M13mp18-oligo-G vector in 
polymerase:primer:template molar proportions of 50:10:1 in 25 µl of the polymerization mixture 
containing 250 µg/ml bovine serum albumin (BSA, MP), 40 mM Tris-HCl pH 8.0, 60 mM KCl, 10 
mM MgCl2, 10 mM dithiotreitol, 2.5% (v/v) glycerol (Sigma) and 100 µM total dNTP (Eurogentec). 
Following incubation for 1h at 37°C, PolȘ was heat-inactivated for 20 min at 65°C, double-stranded 
polymerization products were denatured at 95°C for 10 min and purified on Nucleospin Gel Extract II 
column with NTC buffer (Macherey-Nagel). A reaction including a32P-dATP was run in parallel to 
check for the efficiency of the polymerase extension by electrophoresis on denaturing gels. 
Polymerization products that were fully elongated beyond the 5’ end of oligo-G were amplified by 
PCR reaction with Phusion polymerase (New England Biolabs) (10 s 98°C, 30 s 55°C, 75 s 72°C, 25 
cycles) using SP6 as a forward primer (ATTTAGGTGACACTATAG) and a reverse primer 
complementary to the 5’ flanking region of oligo-G (GGTTAAAATAAAGACCTGGAG). 250-bp 
PCR products were gel-purified, cloned into ZeroBlunt cloning vector (Invitrogen) and sequenced 
with M13 reverse universal primer as described below. 
 
Construction of mutation substrates 
A 4.1 kb segment containing the DQ52-JH locus and extending 510 bp downstream from the end of 
JH4 was amplified from E14.1 ES cell DNA and cloned in the pCR-TOPO-XL vector (Invitrogen) and 
a ClaI site was inserted 41 bp downstream of the JH4 splicing site by PCR-based mutagenesis. A 2.3 
kb fragment adjacent in 3' was amplified similarly, before insertion of both fragments on either side of 
the floxed NeoR cassette of the pLNTK vector. The following oligonucleotides: Oligo-G, 
CG(TATTATTAA)4GTATTATTAAGTATTATTAAG(TATTATTAA)4  and oligo-C, 
CG(TTAATAATA)4CTTAATAATACTTAATAATAC(TTAATAATA)4 were annealed before 
insertion in the ClaI restriction site, generating the oligo-G or oligo-C constructs depending upon the 
orientation of the insertion, named in reference to the presence of G or C in the coding strand. 
Annealing of the oligo-noG, oligo-noC oligonucleotides (same sequence except for the absence of the 
three Gs or Cs) and cloning generated similarly the oligo-noG and oligo-noC constructs. Transfection  
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of E14.1 ES cells, screening of clones and Cre-mediated excision of neoR gene was performed as 
described (PCR primers available upon request) (11). Injection of targeted ES clones into C57Bl/6 
blastocysts was performed to generate the four mouse lines: Tg-G, Tg-C, Tg-noG, Tg-noC (Service 
d'Expérimentation Animale et de Transgénèse, Villejuif) 
 
Mouse line and breeding 
Screening of knock-in mice was performed using PCR primers flanking the loxP site for the 4 
different lines: forward primer, TGGAAGGAGAGCTGTCTTAG and reverse primer, 
TGAGTACTTGAAAACCCTCTCAC (30 s 94°C, 30 s at 59°C, 90 s 72°C, 35 cycles with GoTaq 
polymerase, Promega). Knock-in lines were backcrossed with C57Bl/6 mice, and analyzed 
indifferently in heterozygous or homozygous configuration.  Tg-G and Tg-C lines were bred with 
Ung-/- mice (kindly provided by Dr Deborah Barnes) to generate Ung-/- Tg-G and Tg-C lines. Pms2-
deficient animals were kindly provided by Michael R. Liskay. Animal experiments were done in 
compliance to guidelines of the Institut National de la Santé et de la Recherche Médicale. 
 
Immunization, cell sorting, genomic DNA extraction and sequence analysis. 
 For each genotype, 3 to 6 mice were sacrificed for either Peyer's patches or spleen cell isolation. 
Fourteen days prior to spleen isolation, mice were immunized by intra-peritoneal injection of 5x109 
sheep red blood cells (SRBC, Eurobio) resuspended in 500 µl PBS. Spleen and Peyer's patch cells 
were labeled with an anti-B220 antibody and PNA (phycoerythrin-conjugated anti-B220 
(eBiosciences), PNA-FITC (Vector)) for sorting on FACS Aria I (Becton Dickinson). Sorted 
B220+PNAhigh cells were heat-lysed at 95°C for 10 min and proteins were digested 30 min at 56°C 
with proteinase K (Roche). Three to four aliquots of 104 cells were used as a genomic DNA template 
for amplifying the rearranged VDJ locus and adjacent JH4 intron. Five forward primers amplifying 
VH1, VH5, VH3, VH7 and VH9 gene families, at a ratio of 6:3:1:1:1, respectively (12), and a reverse 
primer in the JH4 intron (CTTGGATATTTGTCCCTGAGGGA) were used with Phusion polymerase 
(15 sec at 98°C, 30 sec at 64°C, 30 sec at 72°C, 40 cycles). 300 bp-long PCR products were gel 
purified, A-tailed with Taq polymerase (New England Biolabs) and ligated into pCR2.1 cloning vector 
(Original TA Cloning Kit, Invitrogen). Plasmid DNA was extracted by Millipore 96-well Miniprep 
system. Sequencing was carried out in ABI Prism 3130xl Genetic Analyzer. The diversity of VDJ 
junctions, mutations within 90/93 bp of oligonucleotide transgenes and 64 bp of JH4 intron were 
analyzed with CodonCode Aligner software. 
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Results 
An A/T rich mutation substrate inserted at the IgH locus 
 We designed an oligonucleotide to be used as a hypermutation substrate after its insertion 
within the heavy chain locus, which includes alternate A and T bases as well as 3 Gs or Cs located in 
its central part. Since PolȘ has a preferred misincorporation pattern opposite T bases, the A/T targeting 
is anticipated to reveal the strand bias of the patch of PolȘ-mediated DNA synthesis during 
hypermutation. This 93 base pair long oligonucleotide includes ten repeats of the 9-mer 
TATTATTAA motif, with three G intercalated within the central repeats ("oligo-G", Fig. 1). Each of 
these G is thus located within an AID RGYW (R: purine; Y: pyrimidine and W: A or T) mutation 
hotspot, AGTA. Moreover, since WA (A being the mutated base) is, on one strand or the other, the 
major PolȘ mutation hotspot at the Ig locus, each A or T of the oligonucleotide, including those 
flanking the Gs, are thus embedded in such a motif. The knock-in construct consisted in a 6.4 kb 
fragment of the mouse JH4 genomic locus in which a ClaI site was generated by mutagenesis, 41 bp 
downstream of the JH4 splicing site, a restriction site where the oligonucleotide was inserted. These 
constructs were used to generate knock-in ES cell line, in which the floxed neoR gene present 500 bp 
downstream of the JH4 intron border was excised. The recombinant mouse line obtained is named 
"transgene G" (Tg-G). 
 Three other mouse strains were generated: the "transgene C" (Tg-C) line in which the same 
oligonucleotide was inserted in reverse polarity, and the "transgene no-C", "transgene no-G" lines, in 
which the three C or G were absent from the same 90 nucleotide A/T backbone. 
 
In vitro assay of PolȘ mutagenicity on an A/T rich substrate 
 Prior to the analysis of mutations generated in B cells harboring the various transgenes, the 
profile of mutations generated during PolȘ DNA synthesis was determined in an in vitro assay, upon 
copy of the oligo-G sequence inserted in a single-stranded M13mp18 vector. Since the mutation 
frequency induced by PolȘ exceeds by several orders of magnitude the one of Phusion DNA 
polymerase, we designed a PCR assay of the PolȘ synthesized products to assess the mutagenicity of 
the enzyme. This PCR was based on an SP6 sequence included in the DNA synthesis primer, and thus 
unique to the DNA produced in the reaction, and a primer complementary to complete products that 
extended in 3' within the M13 vector (Fig. 2A). PCR products of the correct size were gel purified and 
cloned for sequence analysis.  
 112 sequences were determined and 54% of them were mutated, harboring between 1 and 8 
mutations, thus confirming the correct restriction of the PCR amplification to the newly synthesized 
product (Fig. 2B). Moreover, no mutations were obtained when Klenow was used instead of PolȘ as 
control (not shown). The 239 mutations collected displayed a mutation bias similar to the one 
described when PolȘ fidelity was assessed on the beta-galactosidase sequence in the blue/white  
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complementation assay, or  on the Vkox light chain sequence (13, 14). It should be noted that in these 
two approaches, the mutation pattern was determined after transformation in E. coli of mismatch-
containing M13 substrates, as opposed to the direct PCR strategy used here.  The two most frequent 
misincorporations resulted in A to G followed by T to A mutations (read in the synthesized strand), in 
agreement with the preferred G misincorporation of PolȘ opposite T, and of A opposite A in vitro. An 
overall A/T ratio of 3 was observed, after correction for base composition (the oligo-G including 50 T 
and 40 A) (Fig. 2C, D).  The unusual base composition of the oligonucleotide does not appear 
therefore to impact the misincorporation specificity of PolȘ.  
 
The control transgene substrates reveal a DNA polymerase patch synthesis exceeding the 
oligonucleotide length 
 Mutation profiles were determined for the two G and C transgenes as well as for the two 
controls (Tg-noG, Tg-noC).  These controls were included to define a core domain within the 90 bp 
oligonucleotide that would be spared by mutations initiated from either side.  
 The oligonucleotide transgenes were surprisingly highly mutated, which led us to restrict our 
analysis to Peyer's patch PNAhigh B cells from young mice (2 months of age), or, if young mice were 
not available, to splenic PNAhigh B cells isolated 14 days after immunization with SRBC (Table 1). 
Even so, transgenes accumulated up to 17 mutations, a complex situation since such mutations 
generated additional G and C bases, and thus new and uncontrolled AID targets. The insertion site, at 
the beginning of the JH4 intron is indeed located within a highly mutated domain, downstream of the 
CDR3 region that is a major focus of hypermutation. As control, mutations were determined for each 
mouse line in 64 bp of flanking sequences (41 upstream and 23 downstream of the ClaI insertion site), 
and this region displayed an average mutation frequency approximately 2-fold lower than the adjacent 
oligonucleotide transgene for all constructions (Table 1). The high mutation frequency of the different 
transgenes does not appear therefore abnormal, considering the high density of PolȘ mutation hotspots 
they contained, and which might be efficiently targeted once the patch synthesis is initiated. 
 We divided the sequences analyzed in two categories, total sequences and sequences including 
1-3 mutations, which could be considered as a sample resulting from a single (or a small number of) 
mutation hits (Table 2). Even within the 1-3 mutation sample, control transgenes harbored mutations 
throughout the 90 bp oligonucleotide, thus precluding the identification of a core region in which the 
impact of the three Cs or Gs could be assessed (Fig. 3). As discussed in the next chapter, the patch of 
DNA synthesis performed by PolȘ appears indeed to exceed the length of the 90 bp A/T substrate. 
 
In vivo mutation profile of DNA polymerase eta. 
 These control transgenes provide nevertheless a unique opportunity to study the mutagenic 
properties of PolȘ in vivo, in a context of a balanced and symmetrical number of WA (TW) mutation 
hotspots that is not encountered in natural DNA templates.  572 mutations were collected for the Tg- 
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noG line from 8 different mice, with 319 mutations in sequences in the 1-3 mutation range. For the 
Tg-noC control, no germline transmission was obtained. Two founder mice with high chimerism were 
therefore studied (Table 2).  
 Mutation distribution was analyzed along the 90 bp of Tg-noC and Tg-noG templates, and 
results were grouped in three different segments, in order to represent mutation samples of sufficient 
size: the 5'-part corresponding to the first three repeats, the 3'-part corresponding to the last three, and 
the core region corresponding to the internal four repeats (i.e. a region including one repeat on each 
side of the central Cs and Gs in the Tg-C and Tg-G constructs, see Fig. 1). Mutation frequencies were 
corrected for the sequence length of each segment, as well as for the base composition of each 
transgene in case of mutations at As or Ts, the Tg-noC displaying, as mentioned above, 5 A and 4 T in 
each repeat, and the Tg-noG the reverse base composition. 
 In the case of Tg-noC, the distribution of mutations in the 1-3 mutation sequence sample was 
regular throughout the sequence length, whereas a clear decline was observed towards the 3' part of 
the Tg-noG template, with still a high mutation load up to its 3' end (Fig. 3). The trend was similar 
when all sequences were analyzed, thus indicating that it is not a difference due to the smaller 
mutation sample size collected for Tg-noC (not shown). This would therefore suggest that, in spite of 
their similarity, these A/T sequences present differences, possibly in the secondary structure adopted, 
which could impact elongation of PolȘ DNA synthesis.  
 Interestingly, a similar A/T mutation ratio was observed for both control transgenes in each of 
the three segments analyzed, indicating a constant strand bias over the 90-nucleotide substrate. The 
average A/T ratio on the complete sequence was quite high, around 4 for Tg-noC and Tg-noG, 
respectively (around 3 when all mutated sequences are considered) (Fig. 3 and 4B). This strand bias is 
approximately twice as high as the one observed at the Ig locus. The mutation pattern was accordingly 
biased towards A to G, A to T and A to C mutation with decreasing frequency, with A to G being the 
most prevalent mutation. Complementary mutations at T bases were lower by an approximate 3- to 4-
fold ratio (Fig. 4A). This mutation pattern obviously differs from the one observed in vitro, a pattern 
according to which, since A to G predominates, one would expect T to A to be the second most 
frequent one.  Nevertheless, the mutation pattern mirrors the one at the Ig locus in vivo, which shows a 
similar bias, albeit less pronounced, with prevalent mutations at A showing the same decreasing 
frequency from G, T to C, and a two-fold difference for complement mutations at T positions (from C, 
A and G). 
 WA has been described as the main PolȘ hotspot at the Ig locus in vivo. When corrected for its 
frequency within the oligonucleotide, TA mutates twice more frequently than AA, whether in the 
TAA or TAT motif (Fig. 5A). As reported by Spencer and Dunn-Walters, the tri-nucleotide context of 
the mutated base appears to impact the type of mutation generated (15). Our transgene provides only 
three tri-nucleotide contexts due to its peculiar sequence, AAT, TAA and TAT, when considering 
mutations at A bases (and the reverse ATT, TTA and ATA for mutations at Ts). A to T mutations  
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appear specifically disfavored in the TAA context, and the same holds true for the reverse complement 
motif TTA, an effect apparently contributed by both the 5' and 3' surrounding bases (Fig. 5B).  
 A reverse complementarity was thus strikingly observed for the overall A and T mutation 
pattern, including in terms of relative hotspot frequency and nucleotide context. This could be 
interpreted in two ways: first, PolȘ could be mutagenic when copying T only (or with several orders of 
magnitude in nucleotide incorporation infidelity), the 4-fold ratio observed corresponding to the 
relative proportion of synthesis of each DNA strand, i.e. 80% for the coding strand and 20% for the 
transcribed strand. Alternatively, PolȘ could be targeted only to coding strand synthesis, with a four-
fold higher mutation frequency when copying Ts than when copying As. The mutation profile of Tg-
noC (constant distribution of mutations and A/T ratio along the sequence) does not allow us to 
discriminate between these two propositions. In contrast, the mutation pattern of Tg-noG is only 
compatible with the second possibility: the distribution shows indeed a 5' to 3' gradient in mutation 
frequency while keeping the A/T ratio fairly constant in the whole 90-nucleotide template, thus 
precluding a contribution in the reverse direction that would markedly bias mutations towards Ts on 
the 3' side (Fig. 6A, B).   This indicates accordingly that our transgenic substrate is targeted on the top 
strand only, with a patch of PolȘ synthesis that is initiated by a DNA break in the 5' flank of the 
oligonucleotide transgene and which can proceed over its total length and even extend beyond its 3' 
end. 
 
A strand bias reversed by Ung deficiency: a role for the complete mismatch repair complex? 
 When mutation profiles of Tg-G and Tg-C are confronted with the one of their A/T-only 
backbone, no major differences are observed, either in terms of mutation distribution along the 
sequence, A/T ratio or mutation pattern. Whereas Gs and Cs are clearly targeted by AID, their 
capacity to trigger an Msh2-driven repair process appears thus minor compared to the contribution of 
sites external to the sequence. 
 The Tg-G and Tg-C lines were bred into an Ung-/- background, in order to more clearly isolate 
mutations contributed by the Msh2-Msh6 pathway. The most striking alteration was a diminution in 
the overall A/T bias, to 2.5 and 2.2 for Tg-G and Tg-C, respectively. This reduction was strikingly 
more pronounced in the 3' part of the oligonucleotide template (Fig. 3 and 4B). It thus appears that 
Ung deficiency promoted the alternate use of entry points 3' to the oligonucleotide transgene, 
triggering PolȘ synthesis in reverse orientation, over a short part only of the oligonucleotide sequence, 
the 5' segment conserving a high A/T ratio.  
 Uracil glycosylase can trigger error-free repair of uracils at the Ig locus, at a frequency that is 
still a debated issue, but which represents a fraction only of the deamination events leading to 
mutations at G/C bases. Such error-free processing involves the incision of the DNA chain, and has 
been proposed to provide an entry point for the Mhs2-Msh6 driven long patch DNA synthesis (1). 
This process, which requires the simultaneous formation of two nearby uracils, is more likely to take  
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place in regions highly targeted for mutation, and on the coding strand exposed by transcription. In its 
absence, the Pms2-Mlh1 endonuclease could provide nicks in DNA with a looser strand bias, typically 
associated with a non-canonical mismatch repair process that lacks directionality (see discussion).  We 
think that our observations provide the first set of data comforting this proposition, even though they 
pertain to an artificial substrate. We indeed interpret the strand bias observed in our transgenes as 
being generated by a uracil glycosylase-induced incision in 5' of the oligonucleotide transgene, 
coincident with recognition by the Msh2-Msh6 complex of another deamination event downstream of 
it in this highly mutated region of the Ig locus, and promoting a long patch of PolȘ mutagenic 
synthesis. In the uracil glycosylase-deficient context, access to the non-coding strand would be 
provided by Mlh1-Pms2, thus re-equilibrating the A/T ratio towards values observed in Ig genes in 
vivo (Fig. 6D).  
 An additional difference observed in the Ung-deficient background concerns the targeting of 
the G and C bases. We evaluated the mutation frequency at these three bases compared to the rest of 
the transgene, corrected for their representation (3 G/C for 90 A/T, i.e. a ratio of 30). Gs were 3-fold 
more mutated than the neighboring A/T bases in both the wt and Ung-/- context, for sequences with 1-3 
mutations.  Cs were slightly more mutated than G in the Ung-/- background, confirming an efficient 
targeting of both DNA strands. But, in contrast, mutations at Cs were 5-times less frequent in wt than 
in Ung-/- animals (Fig. 4C). This can be interpreted again as an error-free repair coupled with U/G 
mismatch recognition, providing entry sites within the transgene and favored, like for external 
incisions, on the coding strand (Fig. 6C). Their overall number is however too modest to impact the 
global A/T mutation pattern, thus precluding the assessment that was initially intended in the design of 
the transgenes of a differential effect between the Tg-C and Tg-G configurations.  
 
Increased strand bias of A/T mutations in Pms2-deficient background. 
 Pms2 or Mlh1 inactivation has been previously reported to have no discernable impact on 
somatic hypermutation, suggesting that the MutLa complex is not involved in triggering the MutSa-
driven error-prone repair. However these data are either based on small mutation samples, or used 
tools for their analysis that minor the contribution of recurrent hotspot mutations (see discussion).
 We therefore readdressed the question of a possible role of MutLa, by determining a large 
mutation database from both Pms2 and Ung-deficient backgrounds (Fig. 7). The most obvious 
difference between the wt and the Pms2-/- pattern was the large increase in the A over T mutation ratio, 
which reached an average value of 4 (Fig. 7C). No such bias was observed in Ung-/- mice. Like for the 
transgene in the Ung-deficient background, this would suggest that the MutLa complex is mainly 
producing the endonuclease incision required for initiation of PolȘ synthesis, an incision with a more 
moderate strand bias. In its absence, Ung would compensate for this function, with a heavier bias 
towards the non-transcribed strand in which multiple deamination events might be more likely to  
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occur. The transgene would only be different in that its "default" MutSa pathway would rely on breaks 
generated by Ung. 
Discussion 
 
 We report here the analysis of oligonucleotide mutation substrates inserted by knock-in at the 
IgH locus, to study the strand bias characteristics of the MutSa-driven error-prone repair synthesis 
taking place during somatic hypermutation in germinal center B cells.  This mechanism represents the 
only developmental process in which the outcome of DNA polymerase eta polymerization on 
undamaged DNA templates can be assessed.  
 These oligonucleotide substrates consisted in 10 repeated motifs of the TATTATTAA 9-mer, 
inserted in both orientations and including or not Gs and Cs in their central part. They were initially 
designed to determine the impact on the strand choice of the error-prone DNA synthesis process of 
AID targets embedded in a 90 bp backbone of alternate WA hypermutation hotspots, with substrates 
lacking such G/C internal entry points as controls. Surprisingly however, both G/C and control 
substrates were similarly targeted, indicating that the internal sites failed to add significantly to the 
mutations generated by the vigorous error-prone synthesis promoted by flanking sequences. The 
substrates were indeed inserted downstream of the JH4 segment, i.e. in a genomic region flanking 
CDR3 and highly targeted for hypermutation, which may account for the unexpected inefficiency of 
the AID hotspots that were designed.  
 The control substrates allowed us to define the PolȘ misincorporation profile on targets 
offering a symmetrical distribution of WA and TW motifs. Mutations were four times more frequent 
at As than at Ts, with decreased frequency from A to G, A to T and A to C. Reverse complementarity 
was observed for the mutation pattern at Ts. This stands in marked contrast with the PolȘ error 
specificity determined in vitro, in which, if G misincorporation opposite T is the most frequent error, 
the second most frequent one is A opposite A (13, 14). We controlled that this difference was not 
contributed by the biased nucleotide composition of our transgene, by establishing its mutation profile 
when copied in vitro by PolȘ, and found the same types of errors as the ones reported in other in vitro 
studies. PolȘ contribution in hypermutation is obviously taking place in a different context, involving 
factors like ubiquitinated PCNA whose role is not reproduced in in vitro assays, and which may 
notably affect its elongation after a misincorporated base (8). 
  The whole 90 bp length of the A/T mutation substrates appeared targeted along a repair patch 
initiated in its flanking region. Interestingly, if both substrates devoid of G/C (Tg-noG and Tg-noC) 
behaved slightly differently, Tg-noG displayed a very informative pattern: mutation frequency 
decreased by two-fold between the 5' and 3' sides of the 90 bp substrate, while the A/T ratio remained 
constant, around 4. This can only be interpreted as the result of a synthesis initiated exclusively from 
the 5' flank, since a decreasing progression from 5' to 3' and a backward synthesis initiated from the 3'  
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side would obviously affect the A/T ratio according to the relative contribution of synthesis 
proceeding from each side (schematized in Fig. 6). We can therefore conclude that our control 
transgenes reveal the PolȘ misincorporation profile upon a synthesis only performed on the coding 
strand, a configuration possibly resulting from their specific location and specific base composition. 
This represents accordingly a surprisingly long patch of DNA, exceeding 90 bases, which can be 
copied by PolȘ from a single initiation event. The 2-fold A over T bias observed in vivo in Ig genes 
would thus result from an error-prone synthesis proceeding in an approximate 3 to 1 ratio on the 
coding and non-coding strand, respectively. Such ratio can either result from a similar frequency of 
initiation on each strand, or from a difference in the length of the patch produced (or both). 
 The second observation contributed by these mutation substrates pertains to the question of the 
still elusive activity that triggers DNA incision after recognition of the U:G mismatch by the MutSa 
complex. Jiricny and colleagues proposed that uracil glycosylase may provide such nicks, in a 
configuration in which two nearby uracils (tested within a 300 bp distance) are generated and 
processed, the 5' one providing an incision mediated by Ung that would allow exonucleolytic 
processing with 5' to 3' directionality, triggered by Msh2-Msh6 bound to the U:G mismatch in 3' (1). 
The relevance of this proposition can be questioned, since Ung-deficiency has limited impact on A/T 
mutagenesis (5). Moreover, if the processive action of AID has been described in the switch regions 
that harbor a high density of AID hotspots (16), one should mention that hypermutation around the V 
region is estimated around 10-3 per base pair and per cell cycle, making simultaneous deamination 
events unfrequent, and possibly restricted to the most highly targeted regions, along the transcription 
bubble that provides accessibility to AID.  
 Our transgenic substrates provide the first experimental support for this proposition. They 
indeed appear to be targeted for A/T mutagenesis exclusively from nicks introduced in the 5' flanks of 
the transgene and generating a four-fold A over T mutation ratio reflecting the performances of PolȘ. 
When backcrossed into an Ung-deficient background, these transgenes showed, in contrast, a reduced 
A/T mutation ratio, with a marked decrease towards their 3' end, reflecting a synthesis initiated from 
the 3' flanking sequence and proceeding over shorter distance in the reverse orientation. Our 
interpretation of these striking changes is through the involvement of the endonuclease activity of the 
MutLa complex, acting instead of Ung, and generating a less pronounced strand bias, as anticipated 
for a mismatch repair process acting outside replication and lacking the directionality provided by the 
discontinuities of the replication fork (17). 
 Like for Ung, Pms2 and Mlh1 deficiencies have been reported to have no impact on A/T 
mutagenesis (10). More recent data, using catalytic knockin mutants, have further addressed the 
specific contribution of the endonuclease activity of Pms2 and did not report any major impact of its 
inactivation on Ig gene hypermutation (18). We however think that the specific analysis performed by 
the authors may preclude subtle changes to be monitored. The first reason is the multiplicity of the 
templates analyzed, and the predominance of mutations collected in a functional, selected VH  
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sequence. Second, and more importantly, mutations were analyzed using the SHMTool program, 
which only records a single mutation of each type at each nucleotide position (19). Such an analysis 
will obviously minor the contribution of recurrent changes observed at mutation hotspots. 
 A new mutation database from JH4 intronic sequences from Pms2-deficient B cells was 
generated and revealed a marked A/T strand bias, with a ratio of 4, suggesting, like for the transgene, 
that DNA incision promoting A/T mutagenesis may be mainly provided by Ung and targeted to the 
coding strand. The absence of impact of single Pms2 or Ung deficiencies on the A/T mutation 
frequency would thus be explained by the reciprocal backup they exert on each other. Whereas the 
function of the MutLa complex may predominate at the natural Ig locus, Ung appears to be the 
primum movens in the transgene context, possibly due, as mentioned above, to its specific location 
and/or base composition.  
 Our transgenic substrates thus allowed a thorough description of the profile of PolȘ-mediated 
mutagenesis, showing a long patch size and a mutation profile distinct from the one described in in 
vitro assays. Interestingly, a PolȘ signature has been recently defined among cancer cell lines, 
predominantly in B-cell lymphomas, and it would be interesting to confront it with the profile 
described in this study (20). Together with the analysis of mutation in the Pms2-deficient background, 
our transgenes also allowed us to propose a mutual back-up function between Ung and MutLain the 
DNA incision step promoting A/T mutagenesis, with distinct strand preference. Combined gene 
inactivations will obviously be required to establish whether other factors may contribute as well in 
the targeting of this error-prone repair process. 
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Figure legends 
 
Figure 1. A knock-in strategy for the generation of A/T rich oligonucleotide mutation substrates. 
Oligonucleotide mutation substrates were inserted by knock-in at the heavy chain locus, 41 bp 
downstream of the JH4 segment. A schematized view of mutation distribution within 490 bp of the JH4 
intron is represented, to highlight the mutation density around the oligonucleotide insertion site. These 
oligonucleotides consist in 10 repeats of a 9-mer sequence, TATTATTAA, with four repeats flanking 
on either sides three Gs separated by the same 9-mer sequence (oligo-G). Oligo-C represents the same 
sequence inserted in reverse orientation. Oligo-noG and oligo-noC consist in the same A-T backbone 
from which Gs or Cs are omitted. The three segments of the oligonucleotide transgene used in 
subsequent mutation analysis are represented: 5' segment, core region, and 3' segment.  
Figure 2. Pattern of PolȘ synthesis in vitro on an A/T-rich oligonucleotide substrate. 
A) Scheme of the strategy used for amplification of in vitro PolȘ DNA synthesis products. Oligo-G 
was inserted in a single-stranded M13 template and subjected to PolȘ-mediated DNA synthesis. The 
primer sequence includes an SP6 sequence that allows the selective amplification of complete in vitro 
synthesized products. B) Total mutations generated during in vitro PolȘ synthesis of the oligo-G 
template. C) Pattern of mutations at A/T bases generated by PolȘ in vitro after correction for base 
composition and reported to the synthesized strand. D) Graphical representation of the mutation 
profile with indication of the dNTP misincorporated opposite the template base. 
 
Figure 3. Distribution of mutation and A/T ratio along the oligonucleotide sequence. 
Mutation frequency (corrected for relative nucleotide length and normalized to 100 for the 5' segment) 
and A/T ratio (corrected for relative A/T composition) is represented for sequences including 1-3 
mutations and analyzed along the three segments of the oligonucleotide transgenes defined in Fig. 1: 5' 
part, core segment and 3' part. 
 
Figure 4. Mutation profile at A/T and G/C bases for the different oligonucleotide substrates. 
A) Distribution of mutations were represented for each transgenic substrate and analyzed in two 
categories: total sequences and sequences with 1-3 mutations over the 90 or 93 bp oligonucleotide 
template, and corrected for base composition B) Average A/T mutation ratio for the different 
transgenes C) Relative mutation frequency at Cs and Gs vs. the A/T backbone in the wt and Ung-
deficient contexts (corrected for their 30-fold lower representation). 
 
Figure 5. Symmetrical targeting of WA and TW motifs. 
(A) Mutations were analyzed for each three-nucleotide context, with reference to the central mutated 
position. (B) Distribution of mutation outcome at the central nucleotide position is represented for  
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each three-nucleotide context. Analysis of mutations is restricted to Tg-noG for which a larger 
database was assembled. 
 
Figure 6. A putative scheme of Ung/Pms2 strand targeting at the A/T oligonucleotide substrate.   
A) A schematic impact on A/T mutagenesis of the two possible PolȘ synthesis profiles accounting for 
the observed A/T ratio of 4. Scenario 1: an 80/20 A/T mutation profile on top strand synthesis; 
scenario 2: a 100% A mutation profile with 80% of synthesis on the top strand and 20% on the bottom 
strand. Only the first proposition corresponds to the pattern observed in Tg-noG, the profile of 
mutations at Tg-noC (not represented) being compatible with both (see Fig. 3). B) Ung-triggered DNA 
incision at uracils (represented by orange scissors) is proposed to cooperate with U:G mismatch 
recognition by Msh2/Msh6 to promote initiation of PolȘ-mediated error-prone DNA synthesis at the 
nicks generated (1). Nearby deamination events are more likely to occur on the non-transcribed, 
exposed strand. C) Initiation of DNA synthesis at internal Cs of the Tg-C substrate triggered by Ung, 
accounting for the reduced C mutation frequency in the wt vs. the Ung-deficient background (Fig. 4C). 
D) Reduced A/T ratio in the Ung-/- context, due to a more moderate strand bias of the non-canonical 
mismatch repair involving the Pms2-Mlh1 endonuclease activity (blue scissors). The recruitment of 
the complete mismatch repair complex (MutSa and MutLa) is proposed to be the default pathway at 
the Ig locus, but Ung would take over the provision of DNA incisions in the specific context of the 
oligonucleotide substrate, or in a Pms2-deficient context (see discussion). 
   
Figure 7. An A/T bias linked with Pms2 deficiency. 
A) Analysis of mutations in JH4 intronic sequences from wt, Ung
-/- and Pms2-/- mice. B) Mutation 
profile of wt, Ung-/- and Pms2-/- mice. C) A over T mutation ratio. P-value = 0.012 (two-tailed Mann 
Whitney test). 
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Table 1. Relative mutation frequencies in oligonucleotide transgenes and adjacent JH4 sequences. 
 
   JH4 intron mutations Transgene mutations Mutation ratio 
Transgenic mouse Age 
(month
s) 
Organ Total 
number 
Frequency 
(%) 
Total 
number 
Frequency 
(%) 
Transgene/ 
JH4 intron 
Tg-noG 2  IPP 18 0.55 110 1.91  
 2  IPP 43 0.50 92 2.42  
 5  Spleen 25 0.56 58 0.92  
 6  Spleen 31 0.54 127 1.60  
 6  Spleen 15 0.29 74 1.03  
 6  Spleen 18 0.34 64 0.81  
 6  Spleen 21 0.44 54 0.82  
Total   171  579  2.41 
Tg-noC 5  Spleen 57 0.84 128 1.38  
 10  Spleen 24 0.64 74 1.43  
Total   81  202  1.77 
Tg-G 2  IPP N.A. N.A. 20 0.58  
 2  IPP N.A. N.A. 43 1.26  
 2  Spleen N.A. N.A. 65 1.80  
 2  Spleen N.A. N.A. 35 1.06  
 5  Spleen 21 0.69 85* 2.18  
 5  Spleen 20 0.87 47* 1.53  
 5  Spleen 20 0.77 80* 2.32  
Total   61  375 (212*)  2.54 
Tg-C 2  IPP 63 1.68 250 5.07  
 2  IPP 12 0.32 40 0.84  
 2  Spleen 34 1.67 111 3.98  
 2  Spleen 25 0.75 102 2.38  
 5  Spleen 52 1.56 136 2.98  
 5  Spleen 25 0.69 95 3.10  
Total   211  737  2.54 
Tg-G x Ung KO 2.5 IPP 18 0.74 72 2.04  
 2.5 IPP 131 2.56 333 4.49  
 2.5 IPP 125 2.38 422 5.56  
Total   274  827  2.08 
Tg-C x Ung KO 2 IPP 12 0.24 98 1.38  
 2 IPP 67 1.56 183 2.91  
 2 IPP 21 0.61 54 1.09  
Total   100  335  2.31 
 
 
 
 
 
 
 
 
 
 
 
 
!Table 2. Mutation distribution in various transgenic substrates. 
 
 
 
 
 
 
 
 
 
 
 
 
* Difference with Table 1 concerning total mutation numbers correspond to the elimination of mutations from clonally related sequences.  
 
 
 
 
 
 
 Tg-noC / Tg-noG  Tg-G / Tg-C  Tg-G / Tg-C x Ung KO 
 Tg-noC Tg-noG Tg-noC Tg-noG  Tg-C Tg-G Tg-C Tg-G  Tg-C Tg-G Tg-C Tg-G 
 all all 1-3 mut 1-3 mut  all all 1-3 mut 1-3 mut  all all 1-3 mut 1-3 mut 
A to G 68 185 34 110  239 109 55 48  93 171 45 26 
A to T 57 148 30 77  177 96 58 53  62 155 16 29 
A to C 34 84 17 48  118 46 33 21  39 107 16 18 
Total A mutations 159 417 81 235  534 251 146 122  194 433 77 73 
               
T to C 17 71 4 38  61 44 11 15  35 95 12 15 
T to A 14 48 7 28  69 33 18 11  41 76 10 14 
T to G 10 36 5 18  41 22 9 11  14 53 6 7 
Total T mutations 41 155 16 84  171 99 38 37  90 224 28 36 
               
C to T / G to A      11 8 4 6  32 49 20 12 
C to A / G to T      5 5 2 8  0 0 0 0 
C to G / G to C      13 9 0 6  0 2 0 1 
Total C/G mutations      29 22 6 20  32 51 20 13 
               
Total mutations* 200 572 97 319  734 372 190 179  316 708 125 122 
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Discussion
PhDprojectI:Towhatextentdoescellcycle
governdifferentphasesofsomatic
hypermutation?
 
Cellcyclerestrictionmodel:advantages,alternativesand
drawbacks
Our “cell cycle restrictor” approach allowed us for the first time to confine the 
expression of factors directly implicated in somatic hypermutation (AID, Pol Ș) to defined 
periods in cell cycle (G1, S/G2/M) and to efficiently track the restriction of fluorescent fusion 
proteins by flow cytometry. To our knowledge, only Ugi protein, the highly specific inhibitor 
of uracil-N-glycosylase 2 was subjected to the cell cycle-driven degradation in order to 
observe the effects of phase-restricted inhibition of UNG on the somatic hypermutation 
(Sharbeen et al., 2012), a report published during the course of this study. A caveat of this 
indirect approach is the inherent inertia of a restricted Ugi system, potentially introducing a 
lag of undefined length between the onset of inhibitor degradation and the release of UNG 
from inhibition. Authors had to ensure as well whether the phase-restricted degradation of Ugi 
targeted the UNG trapped in the inhibitory complex with Ugi at the moment of degradation.  
The approach of directly fusing SHM key players to functional elements of timely 
degradation (degrons) alleviates these uncertainties. 
However, the system of cell cycle-regulated degradation based on “Fucci” degrons is 
not perfect when it comes to restricting the degradation/accumulation pattern to the entire 
length of a precise phase. No known degron can confine the expression of a fusion partner in 
S or G2 phase only. A fusion with Cdt1:30/120 degron has a marked lag in accumulating in 
G1 phase, as demonstrated by the portion of transduced cells in early G1 phase not expressing 
the fluorescent fusion with this degron (our own observations, (Sakaue-Sawano et al., 2008; 
Sharbeen et al., 2012)). This is probably compensated in the normal cell cycle by the timed 
release of Cdt1 from the inhibitory complex of Geminin due to Geminin degradation at the 
end of mitosis, this interaction being absent from the “Fucci” system. Finally, the  
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overlap in function of APC/C and Skp2/SCF ubiquitin ligases in late G1/early S does not 
allow us to finely dissect any changes in mutation pattern that can be decisively introduced 
during this time frame.  Finally, care must be taken not to overexpress a fluorescent fusion 
with a degrons (a common issue when using systems with retroviral gene expression...) since 
the degradation machinery can easily get saturated, causing “leakage” of fluorescent reporter 
to distant phases and general deregulation of phase-restricted expression. This may be the 
reason for observing G2/M GFP+mCherry+ cells in hCDT1:30/120-governed expression in 
different cell lines. 
Not every protein can be the fusion partner of “Fucci” degrons, be it the fluorescent 
protein or the effector protein. Fluorescent protein is shown to be required as a “buffer zone” 
between the effector and the degron, since direct degron fusions with Ugi protein were 
ineffective (Sharbeen et al., 2012). The following fluorescent reporters were shown to 
function properly as cell cycle probes in fusion with Cdt1 degron: mCherry (reported here and 
(Abe et al., 2013)), mKO2 (Sakaue-Sawano et al., 2008), and GFP (Sharbeen et al., 2012) and 
with Geminin degron: mCherry (reported here), mAG and mKO2 (Sakaue-Sawano et al., 
2008) and mVenus (Abe et al., 2013).  
Other precautions must be taken into account when choosing the effector partner. 
Basic fusion of degron and fluorescent protein confers nuclear localization to the fluorescent 
fusion (Sakaue-Sawano et al., 2008); localization signal sequences of exclusively cytoplasmic 
proteins may interfere with the ones of the Fucci degrons. Interference of degradation-
signaling motifs between the effector partner (e.g. UNG) and degron must be considered 
when searching the candidate lists. Furthermore, degrons will confer cell-cycle regulated 
degradation only if its N-terminus is fused to its partners: can the effector protein stand this 
strict fusion directionality? We have chosen the configuration where both fluorescent reporter 
and degrons are fused to the C-terminus of our effector proteins. This fusion design was 
approved for AID protein in many instances; furthermore, we introduced the flexible hinge 
linker domain between AID and the fluorescent marker, ensuring that AID C-terminal signal 
sequences are exposed to the AID partners and do not interfere with degron targeting. This 
might be the reason of our success in restricting AID expression, since similar attempts with 
AID of other groups failed (D. Schatz, personal communication).  
 On the contrary, Pol Ș is mainly fused via its N-terminus in many studies (with 
exception to S.cerevisiae RAD30 gene product which supports well the C-terminal fusions 
(Skoneczna et al., 2007)). We provided evidence that C-terminal fusion of Pol Ș without 
flexible linker did not impair its in vitro recruitment to UV-induced foci and can fairly carry 
out UV-lesion bypass in deficient cells, independently of the cell cycle context. Our 
systematic usage of mutant degrons as a control of the putative alteration of the function of 
the fusion proteins is extremely important in this context to discriminate between phenotypes  
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caused by cell-cycle regulation or by side-effects of the fluorescent protein and/or degron 
peptide. 
 In contrast with results in cell lines, Pol Ș C-terminal fusion with Geminin:1/110ǻ 
motif showed compromised mutagenic activity in somatic hypermutation, although the 
recruitment to UV-foci proved positive. One interpretation of this failure is a hindered 
interaction with unidentified partner necessary to recruit Pol Ș downstream of non-canonical 
MMR, owing to the architecture of the fusion with Geminin:1/110ǻ motif. Another one, 
confirmed by fluorescence expression levels, is a much lower expression of Pol K in 
lymphocytes derived from transduced HSC than in the fibroblasts in which its 
complementation capacity was tested.  
Other cell cycle control systems can be applied to fluorescent markers in order to 
create cell cycle sensors, and many of them are in their turn theoretical candidates for cell 
cycle “restrictors” of effector proteins. Different promoters govern cell cycle-dependent 
expressions of proteins known to participate in limited periods, e.g. human S-complex cyclin 
A promoter that induces expression at the G1/S transition or promoters containing FoxM1 
binding sites that govern the expression during G2/M (Henderson et al., 2013). However, the 
choice of time frames for restriction by cell cycle-dependent promoters is quite finite; 
moreover, this form of cycle-regulated expression is known for its inherent inertia and 
difficult-to-modulate dynamics.  
Other peptides can confer phase-specific localization or pattern to the fusion partner, 
e.g. if PSLD peptide (phosphorylated subcellular localization domain), C-terminal portion of 
human DNA helicase B (HDHB) is fused to GFP, it concentrates green fluorescence in 
nucleus in G1 and swiftly translocates it to cytoplasm in post-G1 period (Gu et al., 2004). As 
Pol eta can only synthesize DNA when it is present in the nucleus, its activity would be 
restricted to the G1 phase when fused to EGFP-PSLD. The theoretical advantage of this 
shuttling system is the permanent stability of the protein throughout the cell cycle, which 
means potentially more molecules immediately available at the beginning of the G1 phase and 
a higher accumulation throughout G1 phase. However, it remains to be proven that some 
degradation of EGFP-PSLD does not accompany its nuclear export. 
Other proteins can confer focal organization to the fusion partner in different intervals 
of S/G2 phases (PCNA: early and mid S-phase, Dnmt1: mid S to late G2, DNA ligase 1: mid 
S-phase), while they adopt diffuse pattern in cytoplasm outside of these intervals (Kurzawa 
and Morris, 2010). This form of local activity restriction dependent on the cell cycle phase is 
applicable to Pol Ș, while it might severely interfere with AID shuttling necessary for 
deamination in SHM. Moreover, assessing cell cycle-regulated restriction of activity by 
microscopy is less straightforward than by flow cytometry. 
Lastly, other degrons exist that can govern cell cycle-dependent expression and they 
are integral part of proteins normally degraded in a specific phase: last 491-527 amino-acids  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zivojnovic Marija –L’hypermutation somatique des gènes des immunoglobulines -2013 
249 | P a g e  
 
confer S/G2/M-specific degradation to RAG2 protein, while destruction box (D-box) motif of 
M complex cyclin B confines its expression from late G2 to anaphase (Chapter III.2). While 
both degrons worked well within fusion with Ugi-GFP, our own experiments with AID-GFP-
RAG2:491/527aa fusion did not provide satisfactory G1-restricted expression of AID.   
 
AspectsofthebonemarrowǦtransplantedretrogenicmice
modelinSHM:usefulnessanddownsides
To date, germinal center reaction in not reproduced in vitro; the only insight is gained 
through mouse, human and chicken B-cell lines immortalized or transformed at different 
stages of B-cell activation. These B-cell lines either constitutively perpetuate somatic 
hypermutation at low rate (human Ramos, mouse 18-81, chicken DT40) or have inducible 
AID expression (human Burkitt lymphoma BL2, mouse A20, mouse CH12F3). However, the 
pattern of in vivo somatic hypermutation is not fully reproduced in these cell lines, most of 
them having intensified mutation bias at G:C over A:T basepairs. Unbalanced mutagenesis 
may reflect a downregulation of A:T mutagenic factors due to the transformed or 
immortalized status of the activated B-cell in spite of a proficient MMR pathway in many of 
these cell lines. 
Another plausible model consists in culturing ex vivo naive B-cells and triggering their 
activation. Although these cells readily switch in culture when supplemented with the right 
cytokine combination and are easy to transduce, they accumulate mutations only in S-regions 
and spare V(D)J region, although AID is confirmed to be properly induced in these cells. This 
differential targeting could reflect the huge amount of AID hotspots in S regions relative to 
that of the variable region of Ig genes; however, this phenomenon cannot be accounted for by 
this simple explanation. Although they upregulate AID expression upon stimulation, ex vivo 
mouse B cells can not mimic real germinal center B cells, as they for example fail to induce 
Bcl-6 expression (the master gene of the germinal center transcriptional program); they may 
therefore be short of unknown factor(s) required for proper targeting of AID to V(D)J regions. 
Thus, mice models remain the only reliable playground for studying somatic 
hypermutation and reporting effects that are closest to the physiological situation. Several in 
vivo models were available at the time we started this study. The most obvious and most 
frequently practiced in the lab is the knock-in; it guarantees the physiological expression of 
Pol Ș and AID-fusions from the endogenous promoter and surrounding regulatory elements. 
However, generating 8 knock-in lines simultaneously (AID-G1, Pol Ș-G1, AID-S/G2/M, Pol 
Ș-S/G2/M and respective mutants) was somewhat daunting, ever for our expertise in knock-
in/knockout mice generation... So we reached out for alternative mice models that will allow 
us to express our manipulated SHM factors more quickly but reliably: 
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Adoptive transfer of transduced HSC in irradiated immunocompromised host. This 
first method of choice is well-known for its success in another Necker team (Lagresle-Peyrou 
et al., 2006; Yates et al., 2002). A thing to keep in mind is that this model worked well for 
protein factors that conferred selective advantage to transduced cells in the host environment 
and served as a proof-of-concept for gene therapy approach. This was certainly not the case 
for highly mutagenic AID or low-fidelity polymerase Ș, which could in contrast contribute to 
the counter-selection of cells overexpressing them. In order to transduce hematopoietic stem 
cells with a B2-class insert in a P2 facility (the only one available at Necker/Broussais), we 
had to use retroviral vectors suited for expression in murine stem cells, such as derivatives of 
MSCV virus (pMIG, pMigR1) (Haas et al., 2003; Van Parijs et al., 1999; Pear et al., 1998; 
Robbins et al., 1998). Retroviral transduction implicated inducing HSC to proliferate while 
minimizing the odds for engaging into further differentiation steps. In order to avoid more 
perturbations, post-transduction HSC were not selected or sorted; they were injected with the 
total isolated Lin- population, allowing the pool of short-term progenitor cells in this subset to 
exert a radioprotective function during the establishment of long-term blood cell lineages 
(Olivier Albagli-Curiel, personal communication). Another prerequisite for successful 
reconstitution of adaptive immune network of cells in immunocompromised hosts is the 
minimum number of total Lin- cells injected, irrespective of the transduction rate: this 
threshold number ensured the survival of transduced progenitors which could in turn give rise 
to a large number of founder B-cells participating in an anti-SRBC immune response.   
By retroviral gene expression in adoptive germinal center B-cell from SWHEL 
Rag1-/-donor. SWHEL Rag1-/-donor provides for B-cells which express the same BCR 
against HEL-antigen due to knock-in of HEL-specific rearranged BCR heavy chain in IgH 
locus and stable ectopic expression of the low-copy HEL BCR light chain (Phan et al., 2005; 
Sharbeen et al., 2010). SWHEL Rag1-/- splenic B-cells are transduced ex vivo and delivered 
into HEL antigen-primed receiver simultaneously with a novel HEL immunization. Only 6 
days post-transfer, GC B-cells differentiated from these transduced cells can be isolated 
owing to fluorescent HEL binding and expression of the fluorescence marker. These cells 
undergo class switch recombination and accumulate mutations within the physiological 
context of cognate antigen encounter and GC reaction. Thus, although this system is 
extremely faster and directs expression only in the B cell lineage, its application to the type of 
questions that we asked remains complex: since our donor cells had to be either Aicda-/- or 
Polh
-/-, we should have first established mouse strains bearing at least 6 different mutant 
alleles (i.e. Aicda-/-SW HEL IgHKI/wtIgLtgRag1-/-). 
Adoptive transfer of ex vivo transduced fetal liver pre-B cells. Authors of  (Rolink et 
al., 2004) studied transferred these B progenitors into Rag-deficient mice along with normal 
T-cells in order to restore the fully effective adaptive immune response. This rather 
complicated procedure can be simplified if the transduced pre-B cells are transferred to µMT  
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mice, which have fully developed T-cell subsets but lack the entire B-cell lineage (Kitamura 
et al., 1991). Consequently, expression of AID and Pol Ș fusions would be strictly limited to 
the B-cell lineage, which is a great advantage compared to transduced bone marrow 
transplantation. Moreover, isolated pre-B cells can be transduced far more efficiently (and 
effortlessly...) than hematopoietic stem cell and are less sensitive to manipulation (can be 
frozen/thawed, kept for longer times in culture and subsequently selected). Unfortunately, our 
attempts indicated that, in our hands, this system works occasionally, but not reproducibly for 
reasons that have not been identified so far  [Sebastien Storck and Amélie Julé, unpublished 
results]. 
After checking all available options, we set up and successfully carried out HSC 
transductions with all 8 retroviral constructs, while transplantation worked well for 6 
transduction groups (exceptions being Pol Ș-G1 and Pol Ș-G1-Mut). This procedure can be 
completed in about 3 months for a mouse cohort reconstituted by one retroviral vector, in 
contrast to 1 year for the knock-in. Interestingly, this system can be easily applied to knock-
down studies using retroviral vectors coding shRNA against a given target. 
In order to transduce cells like HSC that are known for being refractory to retroviral 
infections, we used the retronectin technology to boost the AID or Pol Ș fusions delivery. This 
approach, although costly and time-consuming (4 hours for virus attachment, 4 hours for 
transduction), allowed us to attain 50% of the HSC transduction rate in a single infection 
cycle. Recently, a new technique was reported using the HIV peptide nanofibrils to bring into 
proximity a target cell and the viral particle (Yolamanova et al., 2013) in a 5 minute-long 
procedure, reproducing the efficiency of retronectin-mediated transductions. 
However, these highly efficient gene delivery methods were a double-sword in our 
study: higher numbers of transduced HSC would allow us to sort more GFP+ GC B-cells 
(which was the limiting step for the subsequent PCR amplification) if we managed to avoid 
high multiplicity of infection due to multiple integration sites and LTR promoter-driven 
overexpression (hampering the successful phase-restricted expression or even being toxic for 
the cell). This mouse model was already used to ectopically express different mutated forms 
of AID, leading to B and T cell tumors (Komeno et al., 2010). It is therefore essential for this 
procedure to find appropriate transduction conditions that provide the best balance between 
the percentage of transduced cells and the level of expression.  
Additionally, one must take into account the regulatory systems specific for the 
effector partner and the particular cell type that may impact the overall level of the retrovirally 
expressed fusion in the cell. This argument may account for the in vivo inefficiency of Pol Ș-
S/G2/M-Mut in B-cells, while high levels of this fusion in the MEF culture were sufficient to exert 
classical Pol Ș activity in UV-repair. 
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Differentmodesofmutationprofileanalysis
Amplification of hypermutating regions by PCR became the dominant approach in the 
analysis of the diversification by somatic hypermutation. However, during the bulk genomic 
DNA amplification of small GC B-cell sample, one must anticipate the artifacts linked to this 
technique due to elevated number of amplification cycles, thermostable polymerase 
misincorporation (minor but not to be ignored if overall mutation frequency is low) and 
crossovers-like events among related PCR products (Honjo and Alt, 1995). All these events 
lead to increased extent of clonal relatedness in mutating pools based on the small number of 
founder cells (defined as a GC B-cell with unique V(D)J junction). A mandatory step in our 
analyses is purging doubled sequences, followed by the manual rectification of dynastically 
related ones: if two or more sequences with the identical junction contain different mutations 
in JH4 intron, shared mutations are counted only once while independently acquired mutations 
are scored separately.  
This analysis mode allows scoring for many shared mutations that arise as the 
consequence of mutating a confirmed RGYW or WA hotspot in JH4 intron in vivo, a 
parameter which is largely neglected by traditional analysis with SHM tool software 
(MacCarthy et al., 2009). This tool scores as one all mutations of the same type found at an 
individual nucleotide position, attenuating the accumulating effect of hotspots and 
underestimating the mutational load of clonally related datasets (Rada et al., 2004). 
In a more stringent analysis mode, we applied another criterion concerning clonality of 
mutations: if two or more sequences have unrelated junctions but share two of more identical 
mutations, these mutations are considered as PCR crossovers and are counted only one per 
position. Most importantly, all three analysis modes gave comparable results when applied to 
mutation profiles of GFP+ GC B-cells from reconstituted hosts, notably concerning the A/T 
over G/C ratio of mutations. 
 
NewSHMmodelfromcombineddata
Data from diverse studies associated UNG activity to the S phase in cell cycle, 
revealing S-phase expression peak or colocalization with nuclear replication foci in S phase 
cells (Chapter III.3). UNG was found to interact with PCNA via its PIP domain (Moldovan et 
al., 2007; Otterlei et al., 1999), which can be easily explained by the need to have UNG 
somewhere near the replication fork in case of dUTP misincorporation. More intriguingly, 
UNG association with RPA protein is greatly enhanced upon UNG phosphorylation away 
from the residues in phosphodegron, while the same UNG phosphorform showed increased 
catalytic turnover on the single-stranded uracil in vitro (Hagen et al., 2008). While waiting for 
the validation in other in vitro and in vivo models, this last piece of puzzle fits well multi- 
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facetted action of UNG in somatic hypermutation: an activated UNG phosphoform could 
preferentially attack uracils in single-stranded DNA prior to the passage of replication fork 
and give rise to mutagenic translesion, justifying its S phase-associated action in our cell 
cycle hypothesis.  
However, many uncertainties linger about UNG-expression in GC B-cells: apart from 
being upregulated 6 to 20 times upon activation (Di Noia et al., 2006), not much is known 
about the timing or outcomes of pre-replicative, mid-S phase or post-replicative UNG-
mediated recognition of uracils. The last question is indirectly tackled by restricting 
expression of the UNG inhibitor Ugi to the different parts of the B-cell cycle by fusing it to 
different degrons and expressing it in adoptive GC SWHEL Rag1-/- B-cell model (Sharbeen et 
al., 2012). All outcomes of UNG intervention in SHM were inhibited if the UNG inhibitor 
was restricted to G1 phase. No U:G handling, error-prone or error-free, was observed in other 
phases.  
This study predicted in a way the crash of our “SHM-per-cell cycle phase” hypothesis, 
since AID expressed in S/G2/M yielded almost no mutation. This absence of mutations in 
S/G2/M in our restriction model can be accounted for in several ways: x by inefficiency of AIDS/G2/M fusion to mutate the Ig locus. Following arguments are 
against this proposition: firstly, AID fusion with the mutated counterpart successfully 
induced mutations, both in vivo and in NTZ 3T3 cell line (not shown). Secondly, 
constraining AID to S/G2/M period of NTZ 3T3 cell cycle also yielded a fair number 
of mutations (0.2% total mutation frequency) and GFP-reversion (up to 0.77% of living 
cells). As in the case of Pol ȘS/G2/M-Mut, this in vitro efficiency of AIDS/G2/M fusion might 
be due to overexpression in the cell line. In order to test AIDS/G2/M efficiency in vivo, 
one would have to express this fusion against Aicda-/- Ung-/- Msh2 -/- background, a 
mouse line whose breeding is underway.  x by the impossibility of S/G2/M-restricted AID to access the Ig locus and perform 
deaminations: it is plausible that AID may be sequestered away from the Ig locus or 
even from the nucleus by cytoplasmic retention during this period of the cell cycle. 
Other possibility is that S/G2/M passage triggers increased AID instability in the 
nucleus, as already showed for the DT40 chicken cell line. x by a novel hypothesis that places all SHM mutagenic actors downstream of AID in a 
common time frame, starting from the beginning of the G1 phase to the late G1/early S 
phase (Figure D32). This hypothesis assumes another important point, yet to be proved: 
due to its high transcription rate associated with somatic hypermutation, the Ig locus is 
susceptible to be early replicating. These premises might explain why most uracils 
generated in S/G2/M were not further diversified or not even replicated: all events 
contributing to mutagenesis had already taken place by the time AIDS/G2/M arrived on the 
scene. AIDS/G2/M-generated uracils could be repaired error-free throughout  
G1
S
G2
M
error-free
repair
error-prone
repair
no repair ?
Fixation of the 
mutation (early S)
 
Figure D1. New somatic hypermutation model based on combined data 
from our study and (Sharbeen, 2012). More details in the text. 
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S/G2/M; however, this options is contradicted by data from (Sharbeen et al., 2012) in 
which S/G2/M-restricted inhibition of UNG did not contribute to an increased 
mutation load in HEL Ig genes. Error-free repair of uracils in S/G2/M can nevertheless 
be compatible with the observation of (Sharbeen et al., 2012), if one assumes, in their 
configuration, that S/G2/M-introduced uracils will persist unrepaired up to the next G1 
phase where UNG within BER will repair them error-free. 
The coexistence of these three different outcomes within the same time frame  (repair 
i.e. UĺC reversion/G:C transversions/G:C transitions) having UNG as a denominator can be 
simply explained by lapses between following decisive events: AID deamination, uracil 
recognition and abasic site creation (Figure D1). If uracil is introduced early in the G1 phase, 
its most certain fate is repair by UNG and downstream BER components. The later in G1 it is 
introduced, the bigger the probability that UNG will manage to generate an abasic site 
thereafter occupied by early S phase progressing replication fork. This late G1/early S phase 
configuration of abasic site prevents the recruitment of other BER factors, but promotes 
involvement of translesional polymerases and generates G:C transversions (and transitions). 
However, a portion of late G1 uracils ignored by UNG can also persist into early S phase and 
be replicated, fixing G:C transitions. If events such as mid- or late S-phase AID deaminations 
exist, these uracils will remain in double-stranded configuration of freshly replicated Ig locus 
and await next G1 phase until they are handled error-free, or be readily repaired when 
occurring at a stage of strong Ung activity. Our observation that expression of AID in S/G2/M 
does not sustain SHM is in accordance with this model. 
The contribution of our study to this model is positioning the origins of A:T 
mutagenesis in the G1 phase as well, since AID-mediated deaminations in G1/early S phase 
were able to induce mutations at both A:T and G:C basepairs (Figure D1). Even though our 
approach did not directly imply the involvement of downstream MMR factors in generating 
A:T mutations in G1, other groups already tracked the activity of non-canonical MMR outside 
of its conventional post-replication scope and possibly in G1 and early S (Peña-Diaz et al., 
2012; Zlatanou et al., 2011). However, results of our study increase the stakes for G1-
restricted Pol Ș: will the G1 restriction allows Pol Ș to restore the 50% of A:T mutations in 
transduced PolȘ-deficient B-cells? An improved reconstitution of new Rag2-/- mice cohort 
with Pol Ș-G1-Mut HSC is underway and will allow us to refine and potentially re-apply our 
G1-restricted approach to Pol Ș as well. 
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PhDprojectII:Doestheuracilorientation
governthePolɄsynthesisinSHM,orisit
directedbythesingleǦstrandednickposition?
 Unfortunately, we realized that the initial question that animated the design of the 
A/T-rich hypermutation substrate knock-in was not to be answered by this study: control A/T 
substrates that lacked core G/C entry sites for AID were heavily mutated and reproduced the 
mutation pattern of G/C-containing A/T-rich substrates. Recruitment of the error-prone repair 
to the flanking sequences of highly targeted JH4 intron portion seemed to literally submerge 
any positional effect of core cytosines on the mutation pattern even in the central parts of the 
substrate considered “more protected”. However, our control hypermutating substrates 
combined with their highly targeted proximal environment turned out to be an extremely 
useful model in the following aspects: x directly assessing polymerase Ș activity in vivo on undamaged DNA template with 
controlled sequence context (symmetrical distribution of WA and TW motifs of knock-
in substrate) and in ideal conditions of unaltered SHM targeting to Ig locus;  x estimating the length of gap-filling activity of Pol Ș in vivo: our control substrates are 
targeted exclusively on the top strand and extended over the whole length (90 bp) from 
the patch initiated within the 5’ flank. This specific targeting pattern was deduced from 
the distribution of A/T mutation ratio in the body of the TgNoG substrate and probably 
results from the specific location and base content of control substrates; x providing the first in vivo simulation of scenario described in (Schanz et al., 2009) 
where UNG and mismatch repair collaborate in somatic hypermutation with the latter 
taking advantage the introduced single stranded break, initiated by the former; x tweaking the exaggerated A:T mutation bias at the substrate sequence owing to 
preferential guidance of intrinsically unbiased Msh2/Msh6 recruiter complex to the top 
strand. On Ung-deficient background, this bias is reversed to the physiological value, 
candidating UNG as the primary actor of strand directionality associated with A:T 
mutagenesis in hypermutating substrates. 
Some groups consider the absence of MutLĮ complex as a necessity for error-prone 
MMR to take place (Chahwan et al., 2011). However, EXO-1 entry in error-prone MMR can 
be provided by the very same MutLĮ complex if PMS2 cryptic endonuclease activity is 
induced (Kadyrov et al., 2006). Although the PMS2 mutant form lacking endonuclease 
activity did not seem to alter SHM (Oers et al., 2010), the effect of PMS2 absence in that case 
may be compensated by other “nicking” scenarios, and A:T bias of hypermutating substrates 
in Ung-deficient knock-in mice strongly suggest Ung as the next one in the waiting list  
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Figure D2. The mechanistic model combining different nicking scenarios inferred from 
the analysis of AT-rich hypermutating substrates in Ung-proficient and Ung-deficient 
background. 
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(Figure D33). Indeed, the marked A:T bias of hypermutating control substrates closely 
resembles the one of Pms2-/- mice. Further crossing of individual genetic knock-outs could 
help us to discern the exact hierarchy of nick generation mechanism and narrow down the 
candidates for a third, alternative mechanism, possibly mobilizing additional glycosylases. 
Our transduction strategy appears as an ideal tool to interrogate these additional partners by 
shRNA inhibition in Ung-/-Pms2-/- HSC. 
We might think at some point that we had identified all the key players of somatic 
hypermutation on the basis of our knowledge from phenotypes of knock-in or knock-out 
mice.  Nevertheless, one should always be cautious when bringing up such reductionist 
conclusions because as many other cellular processes, somatic hypermutation will have an ace 
up its sleeve if the physiological pipeline is altered: as soon as one predominantly recruited 
effector is removed, there always seems to be another one backing it up.  In a B-cell world 
where the competition is so harsh that no place for jammed molecular machineries, 
redundancy will confer selective advantage. It is therefore not striking to observe no marked 
phenotype in somatic hypermutation for Pms2-/- mice if UNG is capable to complement the 
requirements of mutagenic mismatch repair. This seemingly “non-canonical” mismatch repair 
which is thought to rely solely on MSH2-MSH6 complex according to the knock-out studies 
is finally not so different from the conventional one in terms of recruiting MutLĮ and 
reaching out for a free 3’ end.   
In conclusion, we are not yet done with short-listing for somatic hypermutation 
factors. Moreover, the greater challenges lie ahead as identifying interactions between them 
calls out for more wit and imagination in devising the new integrative models compared with 
the small puzzle pieces that the classical methods have to offer.   
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ANNEXE1: ABBREVIATIONS  
AP site abasic site  
AID activation-induced cytidine deaminase 
APC/C anaphase-promoting complex or cyclosome 
APC antigen presenting cell 
BAFF B-cell activating factor 
BCR B-cell receptor 
BER base excision repair 
CIP Cdk-inhibitory proteins 
CDR      complementary determining region 
CSF colon-stimulating factor 
CSR class-switch recombination 
Cdk cyclin-dependent kinases 
CPDs cyclo-butane pyrimidine dimer 
DSB double strand break 
Fucci. fluorescent ubiquitination-based cell cycle indicator 
GC germinal center 
HEL hen egg lysosyme  
HEV high-endothelial venules 
HSC hematopoietic stem cell 
HDHB human DNA helicase B 
Ig immunoglobulin 
IPP Ileal Peyer's Patches 
kb kilobase 
Lin- lineage negative cells 
LTR long terminal repeat  
MEF mouse  embryonic fibroblasts 
MHC major histocompatibility complex 
mKO2 monomeric Kusabira Orange protein 2 
MMR mismatch-repair 
MSCV     mouse stem cell virus 
MSH MutS homologs 
MLH MutL homolog 
NHEJ non-homologous end-joining pathway 
PAMPs. pathogen-associated molecular pattern 
PCNA proliferative cell nuclear antigen 
PIP PCNA-binding peptide domain 
PALS periarterioral lymphoid sheath 
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PMS2 post-meiotic segregation increased protein 2 
PNA peanut agglutinin 
Pol polymerase  
PAD polymerase-associated domain 
PSLD  phosphorylated subcellular localization domain 
RAG recombination-activated genes 
RFC replication factor C 
SCF stem cell factor 
SCF SKP1-CUL1-F box protein complex 
SHM somatic hypermutation 
SMUG single-strand selective monofunctional uracil-DNA glycosylase 
SRBC sheep red blood cells 
SSB  single strand break 
TCR T-cell receptor 
TDG thymidine-DNA glycosylase 
Tg transgene 
TLR-4  Toll-like receptors 
TLS  translesion synthesis 
Ub  ubiquitin 
UNG uracil-N-glycosylase 
WT wild type 
XPV xeroderma pigmentosum variant 
YFP yellow fluorescent protein 

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